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Abstract: Cancer is a heterogeneous disease, showing intra- and inter-tumor genetic and phenotypic
variability [1]. This variability translates to differential radiosensitivity and in consequence differential
response to radiotherapy. Head and neck squamous cell carcinoma (HNSCC) accounts for around 5-10%
of new cancer cases in developed countries [2]. It shows a heterogeneous response to radiochemotherapy
with loco-regional control and 5 years overall survival ranging from below 50% to 80%. Few molecular
factors were linked to outcome prognosis in HNSCC, for example human papilloma virus (HPV) infection.
However, tissue-based biomarkers from tumor biopsies may not account for intra-tumor heterogeneity [3,
4]. This PhD project aims to identify new tumor phenotypes in HNSCC related to worse prognosis of
treatment outcome using medical imaging techniques, which provides a 3D surrogate of tumor biology.
Tumor density, metabolism and perfusion were studied in respect to different HNSCC subtypes and
radiochemotherapy outcome. A quantitative and comprehensive image analysis method, radiomics, was
used to link intra-tumor heterogeneity and treatment outcome. Radiomics comprises four types of de-
scriptors: shape, intensity, texture and filter-based. It not only quantifies general properties of a tumor,
for example higher metabolic activity, but also provides information about the intra-tumor heterogeneity.
In the first subproject, I have analyzed tumor perfusion, metabolism and their correlation in subgroups
of HNSCC based on: tumor subtype (oropharynx, hypopharynx, larynx and oral cavity), tumor stage
(T1/T2 vs T3/T4) and HPV status. Computed tomography perfusion (CTP) and 18F-fludeoxyglucose
positron emission tomography (18F-FDG PET), from 41 HNSCC patients were analyzed. Three perfu-
sion parameters: blood volume (BV), blood flow (BF) and mean transit time (MTT), were computed.
Difference in perfusion parameters between the gross tumor volume (GTV) and its surrounding tissue
were investigated. Tumor subgroups related to worse prognosis (T3/T4 and HPV negative) showed in-
creased BV and MTT in comparison to surrounding healthy tissue. Additionally, I have shown that
the correlation of FDG uptake and perfusion is tumor subgroup dependent. I have observed positive
correlation only for HPV positive (r = 0.86, p = 0.04) and oropharyngeal (r=0.63, p = 0.05) cancer.
CTP consists of repeated CT scans and is thus dose intensive. I have performed a separate study using
Alderson phantom to adapt our clinical CTP head and neck protocol. The endpoint was a decrease in
delivered dose and maintenance of image quality. Our standard protocol on GE revolution CT is 100 kV,
80 mAs, 5 mm slice thickness and filtered back projection algorithm. I have adapted the percentage of an
adaptive statistical iterative reconstruction (ASiR), slice thickness, tube current and voltage. The signal
to noise ratio was measured in 7 predefined regions of interest and the effective dose was estimated using
thermoluminescent dosimeters. The optimized protocol used 80 kV, a tube current adapted based on
anatomy from 15 to 80 mAs, 2.5 mm slice thickness and 50% of ASiR reconstruction. The effective dose
was decreased by factor of 2 whereas the image quality was maintained. In the second part of the thesis,
I have investigated radiomics for its ability to predict treatment outcome and its correlation to tumor
biology. An in-house radiomics software implementation was developed in Python programing language
(v 2.7). Most of the radiomics studies are performed using in-house implementations or open source
codes and the implemented workflows are currently not fully standardized. Therefore, I have validated
my implementation against implementation from MAASTRO clinic, Maastricht, the Netherlands. I have
also used both implementations to train local tumor control models based on 18F-FDG PET imaging
3 months post-radiochemotherapy (128 patients). Only 80 out of 649 radiomic features, available in
both implementations and based on the same mathematical definition, were reproducible between the
implementations (intraclass correlation coefficient ICC > 0.8). In the univariate Cox regression feature’s
prognostic power depended strongly on used implementation. The main causes of irreproducibility were
differences in contour mask creation, translation of bin size to filtered images, and type of the used
transform decimated vs undecimated wavelet transform. In another radiomics robustness study I have
investigated the stability of radiomic features in respect to different CTP calculation factors. Some of the
CTP calculation factors are difficult to standardize (arterial input function definition and noise threshold
in the calculation) and thus should be considered before linking CTP radiomics with clinical outcome.
I have analyzed CTP scans in lung (n = 11) and head and neck cancer (n = 11). 255 out of 945 CTP
radiomic features were stable in both tumor sites in respect to artery contouring and noise threshold.
Among them, I have identified 10 groups of radiomic features, after the correction for inter-features cor-
relations and correlation to tumor volume. These features should be further tested for their prognostic
power. In the prognostic modeling, I have investigated the link between local tumor control and radiomics
in HNSCC based on contrast-enhanced CT and 18F-FDG PET pre-treatment imaging. I have used two
cohorts of patients: retrospective for models training (n > 90 patients) and prospective cohort from in-
stitutional phase II study with a standardized imaging protocol for models validation (n > 50 patients).
I have observed that tumors more heterogeneous in CT density were at higher risk for tumor recurrence.
This model had a higher prognostic power than model incorporating clinical prognostic factors (tumor
stage, volume and HPV status) or combination of CT radiomics and clinical factors, concordance index
(CI) in the validation cohort CIradiomics = 0.78, CIclinical = 0.73 and CIcombination = 0.76. In a
follow-up study, I have investigated whether the inclusion of metabolic information can further improve
radiomics-based local tumor control modeling. I have observed that round tumors (based on 18-FDG
PET autosegmentation) with a focused region of high FDG uptake surrounded by a rim of low FDG
uptake were linked with better prognosis. However, this model did not outperform the CT based model.
In the validation cohort evaluated in this study, both models achieved CI around 0.7. Also the com-
bination of PET and CT radiomics did not improve the predictions. Nevertheless, the PET radiomics
model showed a better calibration, which may be linked to the presence of metal artifacts in CT in head
and neck region. To link the abstract radiomic features with tumor biology, I have correlated CT ra-
diomics with HPV status. I have observed that tumors more homogenous in CT density tend to be HPV
positive. Although, this signature (set of radiomic features) has a similar interpretation to local tumor
control signature, it comprised different features and the signatures were not correlated with each other.
For example local tumor control CT radiomics model was also prognostic in HPV negative subgroup
of patients. In summary, I have shown that biological information can be recovered even from simple
morphological imaging (CT). Additionally, I have identified imaging signatures, based on differences in
perfusion between tumor and its surrounding as well as CT and PET radiomics, which were linked with
worse outcome prognosis. These signatures need to be further validated in an external cohort of patients
and treatment intensification options for worse prognosis groups have to be defined.
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Abstract 
Cancer is a heterogeneous disease, showing intra- and inter-tumor genetic and phenotypic variability 
[1]. This variability translates to differential radiosensitivity and in consequence differential response 
to radiotherapy. Head and neck squamous cell carcinoma (HNSCC) accounts for around 5-10% of new 
cancer cases in developed countries [2]. It shows a heterogeneous response to radiochemotherapy 
with loco-regional control and 5 years overall survival ranging from below 50% to 80%. Few molecular 
factors were linked to outcome prognosis in HNSCC, for example human papilloma virus (HPV) 
infection. However, tissue-based biomarkers from tumor biopsies may not account for intra-tumor 
heterogeneity [3, 4]. This PhD project aims to identify new tumor phenotypes in HNSCC related to 
worse prognosis of treatment outcome using medical imaging techniques, which provides a 3D 
surrogate of tumor biology. Tumor density, metabolism and perfusion were studied in respect to 
different HNSCC subtypes and radiochemotherapy outcome. A quantitative and comprehensive image 
analysis method, radiomics, was used to link intra-tumor heterogeneity and treatment outcome. 
Radiomics comprises four types of descriptors: shape, intensity, texture and filter-based. It not only 
quantifies general properties of a tumor, for example higher metabolic activity, but also provides 
information about the intra-tumor heterogeneity. 
In the first subproject, I have analyzed tumor perfusion, metabolism and their correlation in subgroups 
of HNSCC based on: tumor subtype (oropharynx, hypopharynx, larynx and oral cavity), tumor stage 
(T1/T2 vs T3/T4) and HPV status. Computed tomography perfusion (CTP) and 18F-fludeoxyglucose 
positron emission tomography (18F-FDG PET), from 41 HNSCC patients were analyzed. Three perfusion 
parameters: blood volume (BV), blood flow (BF) and mean transit time (MTT), were computed. 
Difference in perfusion parameters between the gross tumor volume (GTV) and its surrounding tissue 
were investigated. Tumor subgroups related to worse prognosis (T3/T4 and HPV negative) showed 
increased BV and MTT in comparison to surrounding healthy tissue. Additionally, I have shown that 
the correlation of FDG uptake and perfusion is tumor subgroup dependent. I have observed positive 
correlation only for HPV positive (r = 0.86, p = 0.04) and oropharyngeal (r=0.63, p = 0.05) cancer.  
CTP consists of repeated CT scans and is thus dose intensive. I have performed a separate study using 
Alderson phantom to adapt our clinical CTP head and neck protocol. The endpoint was a decrease in 
delivered dose and maintenance of image quality. Our standard protocol on GE revolution CT is 100 kV, 
80 mAs, 5 mm slice thickness and filtered back projection algorithm. I have adapted the percentage of 
an adaptive statistical iterative reconstruction (ASiR), slice thickness, tube current and voltage. The 
signal to noise ratio was measured in 7 predefined regions of interest and the effective dose was 
estimated using thermoluminescent dosimeters. The optimized protocol used 80 kV, a tube current 
adapted based on anatomy from 15 to 80 mAs, 2.5 mm slice thickness and 50% of ASiR reconstruction. 
The effective dose was decreased by factor of 2 whereas the image quality was maintained. 
In the second part of the thesis, I have investigated radiomics for its ability to predict treatment 
outcome and its correlation to tumor biology. An in-house radiomics software implementation was 
developed in Python programing language (v 2.7). Most of the radiomics studies are performed using 
in-house implementations or open source codes and the implemented workflows are currently not 
fully standardized. Therefore, I have validated my implementation against implementation from 
MAASTRO clinic, Maastricht, the Netherlands. I have also used both implementations to train local 
  
 
tumor control models based on 18F-FDG PET imaging 3 months post-radiochemotherapy (128 
patients). Only 80 out of 649 radiomic features, available in both implementations and based on the 
same mathematical definition, were reproducible between the implementations (intraclass correlation 
coefficient ICC > 0.8). In the univariate Cox regression feature’s prognostic power depended strongly 
on used implementation. The main causes of irreproducibility were differences in contour mask 
creation, translation of bin size to filtered images, and type of the used transform decimated vs 
undecimated wavelet transform.  
In another radiomics robustness study I have investigated the stability of radiomic features in respect 
to different CTP calculation factors. Some of the CTP calculation factors are difficult to standardize 
(arterial input function definition and noise threshold in the calculation) and thus should be considered 
before linking CTP radiomics with clinical outcome. I have analyzed CTP scans in lung (n = 11) and head 
and neck cancer (n = 11). 255 out of 945 CTP radiomic features were stable in both tumor sites in 
respect to artery contouring and noise threshold. Among them, I have identified 10 groups of radiomic 
features, after the correction for inter-features correlations and correlation to tumor volume. These 
features should be further tested for their prognostic power. 
In the prognostic modeling, I have investigated the link between local tumor control and radiomics in 
HNSCC based on contrast-enhanced CT and 18F-FDG PET pre-treatment imaging. I have used two 
cohorts of patients: retrospective for models training (n > 90 patients) and prospective cohort from 
institutional phase II study with a standardized imaging protocol for models validation (n > 50 patients). 
I have observed that tumors more heterogeneous in CT density were at higher risk for tumor 
recurrence. This model had a higher prognostic power than model incorporating clinical prognostic 
factors (tumor stage, volume and HPV status) or combination of CT radiomics and clinical factors, 
concordance index (CI) in the validation cohort CIradiomics = 0.78, CIclinical = 0.73 and CIcombination = 0.76. In a 
follow-up study, I have investigated whether the inclusion of metabolic information can further 
improve radiomics-based local tumor control modeling. I have observed that round tumors (based on 
18-FDG PET autosegmentation) with a focused region of high FDG uptake surrounded by a rim of low 
FDG uptake were linked with better prognosis. However, this model did not outperform the CT based 
model. In the validation cohort evaluated in this study, both models achieved CI around 0.7. Also the 
combination of PET and CT radiomics did not improve the predictions. Nevertheless, the PET radiomics 
model showed a better calibration, which may be linked to the presence of metal artifacts in CT in 
head and neck region. 
To link the abstract radiomic features with tumor biology, I have correlated CT radiomics with HPV 
status. I have observed that tumors more homogenous in CT density tend to be HPV positive. Although, 
this signature (set of radiomic features) has a similar interpretation to local tumor control signature, it 
comprised different features and the signatures were not correlated with each other. For example 
local tumor control CT radiomics model was also prognostic in HPV negative subgroup of patients. 
In summary, I have shown that biological information can be recovered even from simple 
morphological imaging (CT). Additionally, I have identified imaging signatures, based on differences in 
perfusion between tumor and its surrounding as well as CT and PET radiomics, which were linked with 
worse outcome prognosis. These signatures need to be further validated in an external cohort of 
patients and treatment intensification options for worse prognosis groups have to be defined.
  
 
 
Zusammenfassung 
Krebs ist eine heterogene Erkrankung, die sich durch ihre genetische und phänotypische Variabilität 
auszeichnet [1]. Diese Heterogenität führt zu einer differentiellen Radiosensitivität und in der Folge zu 
einem sehr unterschiedlichen Behandlungserfolg der Strahlentherapie. Etwa 5-10% aller 
Krebserkrankungen in den Industrieländern werden durch das Plattenepithelkarzinom im Kopf-Hals-
Bereiches (HNSCC) verursacht. Bei dieser Tumorart ist der Behandlungserfolg auf eine Radio-
Chemotherapie sehr heterogen mit lokoregionären Kontrolle und 5-Jahres Überlebungsraten zwischen 
unter 50% bis 80%. Es konnten bisher nur wenige molekulare Faktoren festgestellt werden wie 
beispielsweise eine Infektion mit dem humanen Papillomavirus (HPV) die einen Einfluss auf die 
Prognose beim HNSCC haben. Jedoch können viele der Gewebe-basierte Biomarker aus Tumorbiopsien 
die intra-tumorale Heterogenität nicht richtig erfassen. Das Ziel dieser Doktorarbeit war es neue 
Tumor-Phänotypen für das HNSCC zu identifizieren, welche mit einer guten bzw schlechten Prognose 
assoziiert sind. Dazu wurden medizinischen Bildgebungsverfahren als 3D Surrogat für die 
Tumorbiologie verwendet. Tumordichte, Metabolismus sowie Perfusion wurden unter 
Berücksichtigung der unterschiedlichen HNSCC Subgruppen und Radio-Chemotherapie Ergebnissen 
untersucht. Die Heterogenität im Tumor wurde mit dem Behandlungsergebnis korreliert mit Hilfe einer 
quantitativen mathematischen Bildanalyse-Technik genannt Radiomics. In Radiomics Analysen werden 
vier Arten von Deskriptoren bestimmt: Form, Intensität, Textur sowie filter-basierte Features. Zum 
einen quantifiziert Radiomics die allgemeinen Eigenschaften des Tumors, wie zum Beispiel die erhöhte 
metabolische Aktivität, zum anderen liefert es Informationen zur Heterogenität im Tumor. 
Im ersten Teilprojekt wurde Tumor Perfusion und Metabolismus zu folgenden Tumoreigenschaften 
beim HNSCC korreliert: Tumorsubarten (Oropharynx, Hypopharynx, Kehlkopf und Mundhöhle), 
Tumorstadium (T1/T2 versus T3/T4) und dem HPV Status. Dabei wurden Perfusions-
Computertomographie (CTP) und 18F-Fludeoxyglucose Positronen-Emissions-Tomographie (18F-FDG 
PET) Aufnahmen von 41 HNSCC-Patienten analysiert. Drei Perfusionsmerkmale wurden ermittelt: das 
Blutvolumen (BV), der Blutfluss (BF) und die mittlere Durchflussgeschwindigkeit (MTT). Des Weiteren 
wurden Unterschiede in den Perfusionsmerkmalen zwischen dem Gross-Tumor-Volumen (GTV) und 
dessen Gewebeumgebung untersucht. Tumoreigenschaften, welche mit einer schlechten Prognose 
assoziiert sind (T3/T4 und HPV negativ), haben einen erhöhten BV-Wert sowie einen erhöhten MTT-
Wert im Vergleich zum umgebenden gesunden Gewebe. Zudem wurde gezeigt, dass die Korrelation 
zwischen der FDG-Aufnahme und der Perfusion abhängig von den Tumoreigenschaften ist. Eine 
positive Korrelation wurde lediglich für den HPV-positiven (r = 0.86, p = 0.04) und oropharyngealen (r 
= 0.63, p = 0.05) Tumore beobachtet. 
CTP Aufnahmen bestehen aus wiederholten CT-Scans und sind deshalb dosisintensiv. Wir haben eine 
separate Studie mit dem Alderson Phantom durchgeführt, um unser klinisches CTP-Kopf-Hals-Protokoll 
anzupassen. Der Endpunkt der Studie war eine Reduzierung der deponierten Dosis bei 
gleichbleibender Bildqualität. Unser Standardprotokoll für CTP Aufnahmen am GE Revolution CT war 
100 kV, 80 mAs, 5 mm Schichtdicke und gefilterter Rückprojektionsalgorithmus. Wir haben den 
Prozentsatz der adaptiven statistischen iterativen Rekonstruktion (ASiR), Schichtdicke, Röhrenstrom 
und -spannung angepasst. Das Signal-Rausch-Verhältnis wurde in 7 vordefinierten Regionen gemessen 
und die effektive Dosis wurde unter Verwendung von Thermolumineszenz-Dosimetern abgeschätzt. 
Das optimierte Protokoll verwendet nun 80 kV, einen auf die Anatomie adaptierten Röhrenstrom von 
  
 
15 bis 80 mAs, 2.5 mm Schichtdicke und 50% der ASiR-Rekonstruktion. Die effektive Dosis wurde um 
den Faktor 2 verringert, während die Bildqualität beibehalten wurde. 
Im zweiten Teil der Doktorarbeit wurde die Radiomics Methodik verwendet, um den 
Behandlungserfolg und deren Korrelation zur Tumorbiologie zu untersuchen. Eine eigene Radiomics-
Softwarelösung wurde in der Programmiersprache Python (Version 2.7) implementiert. In den meisten 
Radiomics-Studien werden Eigenentwicklungen oder Open-Source Lösungen verwendet, wobei die 
implementierten Berechnungsprozesse derzeit nicht vollständig standardisiert sind. Aus diesem 
Grund, haben wir unsere eigene Software-Lösung mit derjenigen der MAASTRO-Klinik (Maastricht, 
Niederlande) verglichen. mit beiden Software Lösungen haben wir ein Modell zur Prognose der lokale 
Tumorkontroll-Modelle erstellt. Die Radiomics Parameter wurden auf 18F-FDG PET Scans berechnet, 
welche 3 Monate nach Radio-Chemotherapie aufgenommen wurden (n = 128 Patienten). 649 
Radiomics Feature waren in beiden Implementationen mit gleicher mathematischer Definition 
vorhanden, nur 80 davon konnten zwischen den Implementationen reproduziert werden (Intra-
Klassen Koeffizient ICC > 0.8). In der univariaten Cox-Regressions-Analyse wurde gezeigt, dass die 
Aussagekraft der Radiomics Features stark von der verwendeten Implementierung abhängt. Die 
Hauptursachen dafür, dass viele Features nicht reproduzierbar waren können auf Unterschiede in der 
Maskenerzeugung, der Verwendung der Bin-Grösse in den gefilterten Bildern und dem Typ der 
verwendeten transformierten stationären versus nicht-stationären Wavelet-Transformation 
zurückgeführt werden.  
In einer weiteren Radiomics Stabilitätsstudie wurde die Reproduzierbarkeit der Radiomic Features 
bezüglich verschiedener CTP Berechnungsfaktoren untersucht. Einige dieser Berechnungsfaktoren 
können nicht standardisiert werden (arterielle Eingangsfunktionsdefinition und Rausch-Level in der 
Berechnung) und Radiomics Parameter die nicht reproduzierbar sind unter Variation dieser Faktoren 
sollten nicht mit den klinischen Ergebnissen verknüpft wird. Es wurden CTP Scans von Lungen- (n = 11) 
und Kopf-Hals-Karzinome (n = 11) untersucht. 255 der 945 CTP Radiomic Features waren in beiden 
Tumorarten stabil bezüglich der Konturierung der Arterien sowie des Rausch-Levels. Nach Korrektur 
der Inter-Feature-Korrelation sowie der Korrelation der Features zum Tumorvolumen, konnten unter 
den untersuchten Features 10 Gruppen identifiziert werden. Weitere Untersuchungen werden 
benötigt, um die prognostische Aussagekraft jener Features zu testen. 
Es wurden verschiedene Modelle gebildet um die Beziehung zwischen der lokalen Tumorkontrolle und 
den Radiomics Features in HNSCC zu untersuchen. Diese basierten auf CTs mit Kontrastmittel und 18F-
FDG PETs, welche vor der Behandlung akquiriert wurden. Dabei wurden zwei Patienten-Kohorten 
verwendet: eine retrospektive Kohorte um das Modell zu bilden (n > 90 Patienten) und eine 
prospektive Kohorte aus einer Phase-2 Studie (durchgeführt in unserem Institut mit standardisierten 
Bildgebungs-Protokoll) für die Validierung des Modells (n > 50 Patienten). Tumore, welche heterogener 
in der CT Dichte waren, zeichneten sich durch ein erhöhtes Risiko für Tumorrezidiv aus. Dieses Modell 
erwies eine grössere Aussagekraft als ein Model basierend auf klinischen prognostischen Faktoren 
(Tumorstadium, Volumen und HPV-Status) - Konkordanzindex (CI) im der Validierungskohorte CIradiomics 
= 0.78 and CIclinical = 0.73. Auch im Vergleich zur Kombination aus CT Radiomics Parametern und 
klinischen Faktoren besass das Modell alleinig aus CT Radiomics eine grössere Aussagekraft (CIcombination 
= 0.76). In der Folgestudie, wurde untersucht, ob das Hinzufügen von metabolischen Informationen 
das Radiomics basierte lokale Tumorkontroll-Modell verbessert. Es wurde beobachtet, dass runde 
Tumore (basierend auf 18-FDG PET Autosegmentierung) mit einer fokussierten Region aus hoher FDG-
Aufnahme, umgeben von einem Rand mit niedriger FDG-Aufnahme, eine bessere Prognose hatten. 
  
 
Dieses Modell war jedoch nicht besser als das CT-basierte Modell. In der Validierungskohorte 
erreichten beide Modelle einen CI-Wert von ungefähr 0.7. Auch die Kombination von PET und CT 
Radiomics konnte die Vorhersagkraft nicht verbessern. Jedoch zeigte das PET-Radiomics-Modell eine 
bessere Kalibrierung, welche mit der Präsenz von Metallartefakten im CT im Kopf- und Halsbereich in 
Verbindung gebracht werden kann. 
Um die abstrakten Radiomic Features mit der Tumorbiologie zu verknüpfen, haben wir die CT basierten 
Radiomics Parameter mit dem HPV-Status korreliert. Dabei wurde beobachtet, dass HPV positive 
Tumore eine homogenere CT -Dichte aufweisen. Obwohl das Set von Radiomic Features das den HPV 
Status beschreibt eine ähnliche Interpretation zu den Parametern, die lokalen Tumorkontrolle 
charakterisieren, aufweist, umfasst sie verschiedene Merkmale und die Parameter waren nicht 
miteinander korreliert. Zum Beispiel war das lokale Tumorkontroll-CT-Radiomics Modell auch in der 
HPV-negativen Untergruppe von Patienten prognostisch. 
Zusammenfassend haben wir gezeigt, dass biologische Informationen auch aus der einfachen 
morphologischen Bildgebung (CT) wiederhergestellt werden können. Zusätzlich haben wir 
bildgebenden Eigenschaften basierend auf Perfusionsunterschieden zwischen dem Tumor und seiner 
Umgebung sowie CT- und PET-basierenden Radiomics identifiziert, die mit einer schlechteren 
Prognose assoziiert waren. Diese Signaturen sollten in einer externen Kohorte von Patienten weiter 
validiert werden. Zudem müssen Optionen zur Intensivierung der Behandlung für schlechtere 
Prognosegruppen definiert werden. 
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Chapter 1 Introduction: Cancer 
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Chapter 1 
Introduction 
 
 
1.1 Cancer  
 
1.1.1    Epidemiology of cancer 
Almost 4 million new patients are diagnosed with cancer each year in Europe [5]. Yearly it causes 
around 20% of deaths [5].  Globally, the number of new cases is expected to rise by about 70% over 
the next 2 decades [6]. The rate of 5-year overall survival greatly varies between tumor sites, stages 
and subtypes [3, 4, 7]. It ranges from less than 10% in pancreatic cancer to more than 90% in prostate 
cancer in the USA [7]. 
Three factors can lead to induction of mutations and consequently carcinogenesis: physical, chemical 
and biological factors [5]. Ionizing radiation is an example of a physical factor. Chemical factors 
comprise: asbestos, tobacco smoke, aflatoxin and arsenic. Biological factors are connected to 
infections from viruses, bacteria or parasites. Therefore, the common cancer risk factors include: 
smoking, unhealthy diet, alcohol abuse, HPV-infection, infection by hepatitis, overweight, lack of 
physical activity, exposure to ionizing and ultraviolet radiation as well as urban air pollution. 
 
1.1.2 Hallmarks of cancer 
Cells in a multicellular organism function as a society and are committed to collaborate with each other 
[8]. They send and receive signals, which coordinate their resting, growing, dividing, differentiating and 
eventually dying. Mutations can influence those control mechanisms. Carcinogenesis is a multistep 
process, when a cell accumulates mutations, which enable an increase of division rate and survival in 
a hostile environment. This selective advantage promotes survival of that cell at the expense of its 
neighbors. All cancer cells share common traits (hallmarks) that enable tumor growth and metastatic 
dissemination [9]. They are summarized in the Figure 1. They can be divided into eight biological 
capabilities and two enabling characteristics.  
Cancer cells can both sustain proliferative signaling and evade growth suppressors [9]. Unlike the 
normal cells, cancer cells do not follow a normal regulatory mechanism where cells control the 
production and release of growth-promoting signals. Therefore, they escape the maintenance of cell 
number and tissue architecture. Additionally, they are blocking pathways preventing cells from 
proliferating. Moreover, cancer cells have the capability to resist cell death. They are resistant to 
extracellular and intracellular signals inducing apoptosis. Normal cells are programmed to a limited 
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number of divisions. However, cancer cells present replicative immortality. The rapid proliferation and 
high cellular concentration would not be possible without a supply in oxygen and nutrition. Therefore, 
cancer cells need to develop the capability to form their own vasculature and to induce angiogenesis. 
This process is rarely switched on in the normal tissue (for example during a wound healing), but is 
almost constantly on in tumors. The high nutrition supply is essential for the reprogramed energy 
metabolism. Cancer cells were shown to metabolize glucose in the glycolic process even in the 
presence of oxygen, so called aerobic glycolysis. The aerobic glycolysis is known to be less efficient but 
a faster process than conversion to pyruvate and carbon dioxide. Cancer cells can recruit more glucose 
and compensate for the aerobic glycolysis inefficiency [10]. A rapidly growing tumor needs more 
nutrition and more space. Cancer cells are able to alter their shape as well as the attachment to other 
cells and extracellular matrix via the epithelial-mesenchymal transition, which enables them an active 
invasion and development of metastasis [9]. The last biological capability of cancer cells is the avoiding 
of immune destruction. 
The two enabling characteristics support the acquiry of aforementioned distinct biological capabilities 
[9].  A transition from normal to cancerous cell requires multiple steps and multiple mutations. Cells, 
which inherits an impaired DNA repair mechanism or resistance to cell death are more prone to 
genomic instability and further mutations. Additionally, the inflammatory state in the tumor 
microenvironment enhances the infiltration, carcinogenesis and progression, by for example suppling 
the tumor microenvironment in growth or proangiogenic factors.  
Although common cancer traits exist, they can be caused by a wide range of mutations and 
consequently by alteration of different regulatory pathways. It results in a high intra- and inter-tumor 
heterogeneity.  
 
Figure 1. The summary of hallmarks of cancer adapted from [9]. 
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1.1.3 Heterogeneity of cancer 
Cancer is a heterogeneous disease, showing intra- and inter-patient genetic and phenotypic variation. 
Tumor cells show a differential gene expression due to genetic and epigenetic heterogeneity [1]. It can 
further correspond to differences in the cell proliferation rate, tumor aggressiveness and its level of 
hypoxia. Currently, a comprehensive explanation for translation of the genomic instability to intra-
tumor heterogeneity and sub-clonal architecture is lacking.  In addition, the fluctuations in tumor 
microenvironment and exposure to a treatment may contribute to intra-tumor heterogeneity. Tumor 
biopsy, functional imaging and blood or other body fluids analysis can quantify the biochemical or 
molecular genetic substances (biomarkers) corresponding to disease phenotype [11]. Different 
phenotypes may lead to differential response to a treatment and thus in-depth understanding of 
cancer heterogeneity is crucial for the development of new treatment strategies as well as the choice 
of the right treatment.
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1.2 Radiotherapy  
 
1.2.1 Principle 
Radiotherapy is one of the main treatment options in cancer, next to surgery, chemotherapy, targeted 
therapy and immunotherapy. The aim of radiotherapy is to deliver the prescribed dose of ionizing 
radiation (energy deposited per mass) to a target volume (for example tumor) with minimal damage 
to surrounding healthy tissues. To achieve that, it is crucial to understand how radiation interacts with 
matter and how it influences function of a living organism. 
Ionizing radiation is any type of radiation that carries energy high enough to liberate electrons from 
the atoms and thus create ions. The most common type of ionizing radiation used in radiotherapy are 
photons. Photons transfer their energy to atoms in an absorber, which leads to the creation of a 
secondary radiation and further ionization of the material. There are three main types of photon 
interactions with matter: photoelectric effect, Compton scattering and pair production. Their 
probability (cross section) depends on the photon’s energy and composition of the medium.  In the 
photoelectric effect, a photon transfers its energy to an electron bound in an atom. The part of the 
energy is used for breaking a bond between the electron and the atom, and the rest is transformed to 
the electron’s kinetic energy. Compton scattering is an inelastic scattering of a photon on a free 
electron. The photon transfers a part of its energy to the electron, which results in change of the 
photon’s travel direction. Pair production occurs for photons with energy higher than 1.02 MeV. In the 
presence of a third body (electron or nucleus) a photon can disappear and reappear as a pair of 
electron and positron. The particles are emitted in the opposite directions and energy of each of the 
particles equals half the energy of the photon minus the electron rest mass.  
Most of the patients are treated using linear accelerators. In the linear accelerator electrons are 
accelerated to energies from 4 to 18 MeV. To produce photons a target made from a material with 
high atomic number is placed on the path of electrons [12]. In the interaction of electrons with target 
photons are produced via bremsstrahlung. Photon energy spectrum from a linear accelerator is 
heterogeneous and its maximal energy is equal to maximal energy of the used electron beam. The 
Compton effect is a dominant interaction in this photon energy range and soft tissue medium (Figure 
2). Free electrons produced in the photon interactions ionize other molecules. At the end of their path, 
they create clusters of ionizations. If they occur in the region of DNA they are potentially lethal. 
On a time scale, three phases of interaction of ionizing radiation with a cell are distinguished [13]. First, 
ions (free radicals) are produced in the physical phase. The stable equilibrium is lost. Free radicals are 
highly reactive. They interact with other molecules disrupting their structures e.g. create single- and 
double-strand breaks in DNA (chemical phase). The second phase lasts few seconds. The third, 
biological, phase is the longest and ranges from seconds to years. It includes all the reactions of the 
organism on the damage, from repair processes, early and late side effects, to possible secondary 
carcinogenesis. This last phase is the field of studies in radiobiology.  
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Figure 2. Regions of relative predominance of the three main forms of photon interaction with matter. 
The Compton scattering is predominant interaction in water for photons in the therapeutic energy 
range [12]. 
 
 
1.2.2 Radiobiology 
Radiobiology studies response mechanisms of a living organism to the damage caused by ionizing 
radiation. Not every irradiated cell will die. On average, the dose of 1Gy will kill only around 30% of the 
cells [13]. The 5Rs of radiobiology (repair, redistribution, reoxygenation, repopulation, and intrinsic 
radiosensitivity) summarize factors influencing cytotoxicity of ionization radiation.  
Cells have the capacity to repair DNA damage and thus not every ionization in the DNA base region is 
lethal. The examples of DNA repair mechanisms in response to irradiation are: base excision repair, 
single-strand break repair, non-homologous end joining, and homologous recombination  [8]. The 
majority of breaks are repaired within the first few hours after the irradiation. A sensor group of 
proteins searches through the genome for a damage and signal it to three main effector pathways: 
checkpoint, repair and death. Some of the checkpoints may be disabled in a cancer cell, causing cell 
replication in the presence of DNA damage. Consequently, it may increase genomic instability [13]. 
Repair mechanism depends on the cell cycle phase. For example, homologous recombination uses the 
sister DNA strand as a template for repair. The sister DNA strand is available in S and G2 phases and 
cells in these cycle phases are known to be more resistant to radiation damage.   
A consequence of differential repair efficacy through the cell cycle is redistribution. As the cells in the 
S phase are the least radiosensitive, the majority of surviving cells were in the S phase in the moment 
of irradiation. This causes a synchronization in the cell cycle of the tumor cells. However, it is lost after 
some time and thus cannot be exploited as a target for radiosensitization (for example irradiation at 
the time points when most of the cells are in the most radiosensitive cell cycle phase). It seems that 
the cancer cells proceed through the cell cycle with heterogeneous speed. 
Oxygen concentration in the cell also influences the radiosensitivity. Free radicals (R●) produced by the 
ionizations are highly reactive and contributes greatly to the DNA damage caused by irradiation. In the 
presence of oxygen they produce RO2●, which ultimately results in a stable change in a target (ROOH). 
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In the absence of oxygen, they have a longer half-life and can react with H+ ions to restore its original 
form. In this case they do not contribute to DNA damage. In consequence, the well-oxygenated cells 
are more radiosensitive and thus are primarily killed. It causes the reoxygenation of hypoxic cells as 
they have a better access to blood supply. Hypoxia-modifying agents are promising tools for 
radiosensitization [14].  
Decrease in cancer cell numbers also has a negative effect, as it induces repopulation [13]. It can be 
related to increased access to nutrition or a regenerative response. The doubling time shortly after 
irradiation exceeds doubling time of non-irradiated cells. A rapid repopulation is observed after around 
3 weeks of fractionated therapy, which can be an effect of increased proliferation or decreased cell 
loss. As a consequence of repopulation, higher cumulative dose has to be delivered to kill the tumor. 
Evidence from studies in cell lines, animal tumor models and clinical samples shows a wide variation 
in intrinsic tumor radiosensitivity. Tumors of similar origin and histological subtype show a differential 
response to irradiation. The intrinsic tumor radiosensitivity is defined as an in-vitro cell survival fraction 
of cells from individual tumor after 2Gy irradiation. It is was shown to correlate with treatment 
outcome [15]. In the correlation with gene expression it was linked to genes responsible for regulation 
of DNA damage response, histone deacetylation, cell-cycle, apoptosis and proliferation. 
The 5R’s of radiobiology points out the tumor characteristics, which are linked to higher 
radioresistance. Targeting these characteristics could help to improve treatment outcome
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1.3 Medical imaging in radiotherapy 
 
1.3.1   Basics of morphological, functional and molecular imaging  
Medical imaging plays an important role in the management of cancer. It has a wide range of 
applications from screening and diagnosis to tailoring treatment decision [16]. In radiation oncology 
each treatment plan is based on the individual patient anatomy and tumor localization, which is 
assessed by medical imaging. Three types of imaging can be distinguished: morphological, functional 
and molecular [17]. This section gives a short introduction to the basics of medical imaging techniques 
studied in this PhD project: computed tomography, computed tomography perfusion and positron 
emission tomography.  
 
Computed tomography 
The common and most often used example of morphological imaging is computed tomography (CT) 
[18]. It is based on the analysis of X-ray attenuation in different tissues. The energy range used in CT 
imaging is in order of 100 kV. The photoelectric effect is the dominant interaction in this energy range. 
Its mass attenuation coefficient is proportional to atomic number (Z) to the power of 3, therefore the 
photon absorption is higher in tissues with high Z. The Hounsfield scale relates a tissue linear 
attenuation coefficient (𝜇), the direct measure in CT, to linear attenuation coefficients of water 
(𝜇𝑤𝑎𝑡𝑒𝑟) and air (𝜇𝑎𝑖𝑟):  
(1) 
𝐻𝑈 =  1000
𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟 − 𝜇𝑎𝑖𝑟
 
It gives a relative measure of number of photos passing through a tissue, which is also called 
radiodensity. This property is used in the radiotherapy planning process to calculate delivered dose. 
 
Computed tomography perfusion 
A repeated contrast-enhanced CT scan can also provide functional information. Capillary level 
hemodynamic information, mainly blood flow (BF), blood volume (BV) and mean transit time (MTT), 
can be derived from repeated CT scans of the same region of interest, which shows the time-
dependent distribution of intravascular iodine contrast agent [19]. A theoretical physiological model 
of tissue perfusion is used to estimate the perfusion parameters [20]: 
(2) 
𝐶𝑣(𝑡) =  ∫ 𝐶𝑎(𝜏)𝑅(𝑡 − 𝜏)𝑑𝜏
𝑡
0
 
where: Cv – concentration of contrast agent in the voxel, Ca – concentration of the contrast agent in 
the supplying artery, R – residue function describing the amount of contrast still present in the voxel 
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at time τ. Knowing the time-dependent concentration in the voxel and in the supplying artery the 
deconvolution can be performed to solve the equation 3 for R(t). The perfusion descriptors are 
consecutively defined as: 
 (3) 
𝐵𝐹 = max(𝑅(𝑡)) 
(4) 
𝑀𝑇𝑇 =  
1
𝑚𝑎𝑥(𝑅(𝑡))
 ∫ 𝑅(𝑡)𝑑𝑡
∞
0
 
(5) 
𝐵𝑉 =  𝐵𝐹 ∙  𝑀𝑇𝑇 
The equation (5) is a consequence of the central volume theorem [21].  
 
Positron emission tomography 
The positron emission tomography (PET) is an example of molecular imaging, where the observed 
process depends on a compound administered to the patient (radiopharmaceutical) [22]. The 
radiopharmaceutical (tracer) consists of a 𝛽+ radioisotope and a ligand – biochemical substance of a 
receptor system. The positron emitted in 𝛽+ decay travels on a short distance until it loses the kinetic 
energy and meets an electron, which results in an annihilation process. Two photons of energy of 511 
keV are emitted in opposite directions. The coincident detection of those photons by a detector ring 
is used to define the emission point and thus the distribution of the radiopharmaceutical in the body. 
The example of PET radiopharmaceutical widely used in oncology is 18F-fludeoxyglucose (18F-FDG) 
the analog of glucose labeled with radioactive 18F. It helps to identify regions of increased metabolism 
in the body. The activity measured by the PET scanner depends on patient size and the injected 18F-
FDG activity. The standardized uptake value (SUV) was defined to account for these factors and 
increase the comparability between the measurements [23]: 
(5) 
𝑆𝑈𝑉 =
𝐴𝑣
𝐴𝑖
𝑤  
where: Av – measured activity in a voxel, w – body weight, Ai – injected activity corrected for decays 
during the uptake time.  
 
1.3.2  Staging and target definition 
The well-established staging system in cancer - TNM (tumor-node-metastasis) scores the primary 
tumor size, its invasion of the adjacent structures, the involvement involved lymph nodes and their 
distribution as well as the presence and location of distant metastasis [24]. Cancer diagnosis requires 
the pathological examination, whereas imaging is crucial for disease extent assessment. The right 
choice of treatment depends on the correct TNM classification. The addition of functional imaging 
(18F-FDG PET/CT) to anatomical imaging improved TNM staging and consecutively treatment outcome 
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[24, 25]. The 18F-FDG-PET imaging is especially useful in detection of suspicious lymph nodes and 
asymptomatic distant metastasis.  
The introduction of CT imaging in 1980s triggered a change in target definition in radiotherapy [22]. In 
1993, the International Commission of Radiation Units and Measurements released a report with 
definition of volumes, which need to be considered in the external radiotherapy [26]: 
 the Gross Tumor Volume (GTV) - the gross palpable or visible/demonstrable extent and location 
of the malignant growth. The demonstrable extent can be visualized using different medical 
imaging techniques (e.g. computed tomography, magnetic resonance, positron emission 
tomography, mammography and ultrasound).  
 the Clinical Target Volume (CTV) contains the GTV and subclinical microscopic malignant disease.  
 the Planning Target Volume (PTV) is created to compensate for uncertainties of the tumor position 
caused by patient set-up errors, patient movement during treatment fraction or due to internal 
organs movements. In the 1999 revision, the PTV was separated into two components: the Internal 
Target Volume (ITV) as a margin around CTV to account for variation in CTV size and location (due 
to the motion of adjacent organs); and PTV as a margin to account for set-up uncertainties [27]. 
 the Treated Volume is defined by the isodose corresponding to the dose appropriate to achieve 
the tumor eradication. 
 the Irradiated Volume is the volume, which receives a significant dose in relation to normal tissue 
tolerance. 
 organs at risk are all healthy tissues which would affect the treatment planning process. 
Over the years, development in medical imaging techniques allowed for more precise target and 
organs at risk definition. Together with technical developments in radiotherapy, such as the 
introduction of the intensity modulated treatment, it resulted with a higher personalization of 
treatment plans, dose intensification and lower rate of side effects [22]. The exact definition of tumor 
borders is challenging and often depends on the experience of radiation oncologist. The use of 
additional functional information from 18F-FDG PET was shown to reduce the interobserver variability 
in different tumor types [28-30]. In the case of tumors originating from organs with high natural 
concertation of glucose, other PET traces are available, for example amino acids for brain and choline 
for prostate [22]. Additionally, the molecular imaging can be used to define radioresistant subregions 
of tumor (concept of biological target volume [31]), such as regions with increased metabolism or 
hypoxia, to deliver a higher radiation dose in a dose painting approach [32-34]. Precise tumor 
localization may also be challenging due to its inter- and intra-fraction motion caused by differential 
organ filling or respiratory motion. The introduction of cone-beam CT and 4D-CT helped to reduce the 
associated uncertainty.   
 
1.3.3 Response assessment 
Tumor response is an important endpoint in further disease management as well as the design of 
prospective clinical trials [35]. The reduction of tumor burden can be one of the indicator of tumor 
response. Response Evaluation Criteria in Solid Tumors (RECIST) defines the methodology for 
measurements of tumor shrinkage or progression. It points out medical imaging (computed 
tomography, magnetic resonance and ultrasound) as an important component of that process. The 
follow-up FDG-PET imaging shows a high sensitivity in detection of recurrences [36]. However, false 
positive findings can be observed due to the post-radiotherapy inflammatory processes [37].                 
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The 3'-deoxy-3'[(18)F]-fluorothymidine (FLT), marker for cell proliferation, presented a good 
differentiation between post-treatment necrosis and tumor recurrence in glioblastoma [38].  
Imaging can also be performed in the interim of treatment to assess if further intensification is needed. 
A prospective phase II study showed that the continuation of preoperative chemotherapy in 
esophageal cancer for patients, who did not show early 18F-FDG uptake decrease was not beneficial 
[39]. However, definition of pathologic complete response using imaging after neoadjuvant treatment, 
to avoid unnecessary surgery, remains challenging [40, 41]. 
 
1.3.4 Imaging tumor biology  
Functional imaging serves as a 3D surrogate of tumor biology and this contributes to its wide 
applicability in radiation oncology, from target definition and treatment adaption to response 
assessment. The two tumor characteristics studied in the largest extent are metabolism and 
oxygenation.  
The 18F-FDG PET is a widely used imagining modality for tumor metabolism quantification [22]. 
However, a high natural glucose accumulation in some organs triggered a research in the field of 
tracers for tumor-specific metabolism unrelated to glycolysis. The 11C-Acetate is linked to metabolism 
and has no urinary excretion, thus can be used for imaging of prostate and other urological diseases. 
The 11C-Choline or amino acids analogs (for example 18F-DOPA) enable visualization of brain tumors. 
Not only PET tracers can be used to detect tumor metabolites. The magnetic resonance spectroscopy 
can track similar processes as described above. A detection of substances such as choline and lactate 
(product of glycolysis) is possible. 
Several PET tracers related to hypoxia are currently available in the clinics. The 18-fluoromisonidazole 
(18F-FMISO) is a widely studied tracer, which was validated for different tumor sites and its correlation 
with regional partial oxygen pressure was confirmed [42]. Further, a newer generation tracers 18F-
FAZA and 18F-HX4 are promising hypoxia markers with a superior pharmacokinetics [22, 43]. In the 
field of magnetic resonance (MR) imaging, it was observed that deoxygenated hemoglobin has 
paramagnetic properties and thus causes magnetic field inhomogeneity. This effect can be measured 
by a blood oxygen level dependent (BOLD) MR sequence. However, in most cases the results are only 
qualitative and quantitative comparison is impossible [22]. The CTP allows for a quantitative 
measurement and blood volume was shown to correlate with microvessel density in colorectal cancer 
[44]. 
Tumor biology influences its response to radiotherapy. Pretreatment imaging can serve as a surrogate 
of tumor phenotype. Therefore, a large effort is made to predict treatment outcome based on the 
pretreatment imaging characteristics. Few examples are mentioned in Chapter 1.5.2. 
Chapter 1 Introduction: Precision medicine 
11 
 
 
1.4 Precision medicine 
 
Precision medicine aims to tailor treatment to intra-disease specific traits. An old example of precision 
medicine is blood transfusion, which has been guided by blood types since decades [45]. Precision 
medicine in cancer is a rapidly growing field of research with genomics, proteomics, metabolomics and 
studies of cellular assays being major drivers in understanding the complexity of the disease. 
Additionally, development of advanced computational tools is crucial to extract the relevant 
information from large databases. Targeted therapies acting on a specific molecular target are under 
development [46, 47]. It also changes the design of clinical trials, from large, population-based studies 
to prove treatment efficacy to a targeted approach [48]. 
The choice of the right treatment depends largely on the development of biomarkers, measurable 
indicators of some biological state or condition [49]. Two types of biomarkers can be distinguished: 
prognostic and predictive [50]. Prognostic biomarker gives information about overall risk of recurrence 
of disease after a treatment, whereas the predictive biomarker indicates a benefit of a given treatment 
for a subgroup of patients. For example, prostate-specific antigen level correlates with patient 
response to prostate cancer therapy, thus it is a prognostic biomarker [51]. On the other hand, 
treatment with Trastuzumab provides benefit only for HER2 overexpressing breast and 
gastric/gastroesophageal cancer, thus HER2 expression is a predictive biomarker [52]. 
Cancer is a dynamic disease, which exhibits clonal evolution, intra- and inter-tumor heterogeneity as 
well as varied mechanisms of drug resistance. Therefore, an ideal cancer biomarker should allow for 
spatial tumor analysis and be non-invasive to assure repeated tumor monitoring. This is a major 
challenge in cancer biomarker development. Promising candidates are the imaging-based biomarkers 
[53]. 
 
Chapter 1 Introduction: Head and neck cancer 
12 
 
 
 
1.5 Head and neck cancer 
 
1.5.1 Overview 
Head and neck cancer is originating from: lip, oral cavity, nasopharynx, oropharynx, hypopharynx, 
larynx or trachea. Head and neck cancer accounts for around 5-10% of new cancer cases in developed 
countries [2]. The 5-year overall survival rate depends on the tumor site. It is more than 90% in the 
case of lip cancer, but less than 40% in hypopharyngeal carcinoma [54]. However, over the last few 
decades the prognosis for most of the head and neck caner subtypes improved. The introduction of 
concurrent radiochemotherapy was shown to improve overall survival in comparison to radiotherapy 
alone [55]. Moreover, in recent years the incidence of human papillomavirus (HPV) related tumors, 
showing a better response to a therapy, is increasing [54].  
The major risk factors include: tobacco use (also chewing tobacco), alcohol consumption, HPV  
infection, male gender and betel quid chewing [56]. The combination of alcohol and tobacco abuse 
was observed to have a large impact than alcohol only. The HPV infection, as a cause of head and neck 
cancer, was mainly linked to the oropharyngeal carcinoma. The geographical variation in the incidence 
of head and neck cancer depends on the habits of tobacco and alcohol abuse, which contributes to the 
development of around 80% of new cases diagnosed globally. In recent years, head and neck cancer 
rate has been decreasing for the alcohol consumption related cases, but has been increasing for the 
HPV-related ones [56].  
The recommended treatment depends on the primary tumor location and extension [57]. In early stage 
tumors (I-II) a similar rate of loco-regional control can be achieved by conservative surgery or 
radiotherapy. In the locally advanced stage III and IV tumors surgery combined with postoperative 
radiotherapy or chemoradiotherapy is an option. In the case of non-resectable tumors or patients with 
contradiction for surgical treatment, combined concomitant chemoradiotherapy is offered. This 
treatment option is also offered in resectable patients with an anticipated poor functional outcome. 
In comparison to surgery it is an organ preservation treatment option with a similar treatment 
outcome [58]. Although the introduction of advanced radiotherapy techniques, such as intensity 
modulated radiotherapy, increased treatment conformity, the toxicity rate is still high [59, 60].  The 
common toxicities comprise: mucositis, dermasitis, dysphagia and xerostomia. Several clinical studies 
are currently investigating different treatment protocols to decrease the toxicity and increase 
treatment efficacy [61]. The exemplary concepts include: adaptive radiotherapy, altered 
fractionations, reduction of high dose target volume (dose painting) for selected patients, or de-
escalation of dose for HPV positive oropharyngeal carcinoma.  
 
1.5.2 Prognostic factors and imaging biomarkers in head and neck cancer 
Head and neck cancer squamous cell carcinoma (HNSCC) shows a heterogeneous response to 
radiochemotherapy with loco-regional control and 5 years overall survival ranging from below 50% to 
80% [3, 4]. The human papilloma virus (HPV) is a well-established prognostic factor in the subgroup of 
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oropharyngeal carcinoma. The HPV infection corresponds to a favorable radiotherapy treatment 
outcome [3, 4]. The overexpression of epidermal growth factor receptor (EGFR) generally relates to 
poor prognosis, however those tumors show a better response to hyperfractionated and accelerated 
radiotherapy in comparison to a standard one [62]. Tumor hypoxia (largely mediated by HIF-1) makes 
it more resistant to radiotherapy [63]. In terms of chemotherapy, the overexpression of cyclin D1 was 
shown to cause cisplatin resistance. 
Several groups have investigated pretreatment medical imaging as a biomarker in head and neck 
cancer. Mixed results have been reported in respect to prognostic power of 18F-FDG maximum SUV 
[64]. However, other 18F-FDG measures: metabolic tumor volume (MTV) and tumor lesion glycolysis, 
were found to be prognostic in meta-analysis for adverse events and overall survival [65]. Few studies 
have shown that, the uptake of PET hypoxia tracers (18F-FMISO and 18F-FAZA) correlates with disease 
free survival [64]. Further, tumors with higher cell density, quantified by increased apparent diffusion 
coefficient in MR, were linked to worse prognosis [66]. Recently, a single center study investigated 
multiparametric imaging 18F-FDG and 18F-FMISO. It showed that the slope of voxelwise correlation 
between the uptakes of those two tracers is prognostic for tumor recurrence [67].  
 
Medical imaging enables to capture the 3D complexity of a tumor. Recent studies try to correlate 
tumor heterogeneity with treatment outcome. Those efforts are described in Chapter 1.6.  
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1.6 Radiomics 
 
1.6.1  Principle of radiomics 
Radiomics aims for a quantitative and comprehensive description of a medical image [17]. The 
quantitative analysis is assured by the use of well-described mathematical definitions to extract 
features such as contrast or heterogeneity [68]. In comparison to traditional image assessment, 
radiomics is observer independent. The comprehensive description is achieved by the extraction of 
hundreds of features from the region of interest (ROI). This high-throughput analysis allows for 
studying differences between the ROIs on different scales and using different characteristics. Four 
main radiomic features characteristics are distinguished: shape-, intensity-, texture- and filter-based 
features (Figure 3).  
The shape-based features describe the properties of the ROI outline. Among others, they provide 
information about the ROI’s volume, surface, sphericity and compactness [69]. They do not contain 
any information about image intensities.  
The intensity-based features (also known as first-order texture features) provides global description of 
image intensities in the ROI. They comprised well-known histogram descriptors such as: mean value, 
minimum value, maximum value, skewness and kurtosis [69]. They ignore the relationship between 
the adjacent voxels. 
The texture-based features focus on the intensity changes between the adjacent voxels. Examples of 
texture features are contrast, homogeneity, directionality and coarseness [69]. Texture features are 
calculated in two steps. First, a matrix describing dependencies between the voxels is defined. 
Depending on the number of voxels taken into account in the calculation we distinguish second-order 
texture features (two voxels) and higher-order texture features (three and more voxels). An example 
of second-order matrix is the Gray Level Co-occurrence Matrix (GLCM), which describes intensity 
changes between two voxels in a defined distance and direction [70]. One way to calculate the higher-
order texture features is to compute the Gray Level Size Zone Matrix, which contains information about 
the number of homogenous regions of a given size and intensity level [71]. In the second step, these 
matrices are used to compute the texture characteristics. 
The filter-based features allow for analysis of the image in different scales and in the frequency 
domain. The most popular filters are wavelets and Laplacian of Gaussian (LoG) [72, 73]. The wavelet 
transform enhances the information about low and high frequencies in the image. The LoG filter 
enables detection of edges. After the image filtering, the intensity- and texture-based features are 
computed on the new images. Altogether, filter-based features allow for in-depth analysis of image 
heterogeneity.  
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Figure 3. Scheme of radiomics analysis. Depending on the studied question, different input data 
(image modalities) can be used. 
 
1.6.2 Radiomics prognostic signatures  
The potential of radiomics to predict treatment outcome has been recognized for many tumor types 
and using different imaging modalities [69, 74-85].  In addition, multiple endpoints were studied, 
ranging from loco-regional control to development of new metastases. One of the first, large radiomics 
studies has shown that CT radiomics is prognostic for patient overall survival in lung cancer after 
curative radiotherapy or chemoradiotherapy [69]. The same signature was further validated for head 
and neck cancer and its prognostic power was also proven in the presence of CT artifacts [69, 79]. 
Although there seems to be a general radiological phenotype associated with worse prognosis, more 
recent study showed that some of the radiomic features are prognostic only for certain tumor types 
[80].  
Clinical relevance of radiomics is under investigation. Radiomic features were found to significantly 
improve models based on clinical parameters. The addition of previously mentioned radiomic 
signature to the tumor volume and the TNM stage increased the model prognostic power in both lung 
and head and neck cancer [69]. More recently it was shown, that the inclusion of another CT radiomic 
signature to a clinicopathological nomogram (tumor stage, histologic grade, gender, age) improves 
prediction of disease free survival in patients with early stage lung cancer after surgical resection [76]. 
Another example for clinical relevance of radiomics is the identification of new non-invasive 
biomarkers for certain treatment options. In recurrent glioblastoma, a group of patients who may 
potentially gain the most benefit from antiangiogenic therapy was identified using MR radiomics [77, 
85]. In the locally advanced rectal cancer, the MR defined tumor compactness allowed for better 
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identification of patients with and without complete pathological response after the preoperative 
concurrent chemoradiotherapy [86]. Similarly, in breast cancer, FDG-PET radiomics was associated 
with pathological complete response after neoadjuvant chemotherapy [75].  
 
1.6.3 Radiomics link to tumor biology 
The complex nature of radiomic signatures and the fact that radiomic features often outreach human 
visual perception is a motivation for studies relating radiomics to tumor biology. The histopathology 
or genetic profiles are used to better interpret radiomic signatures. In lung cancer, CT radiomic features 
corresponding to tumor heterogeneity were found to correlate with cell cycling pathways [69]. Further, 
the influence of two important biomarkers: epidermal growth factor receptor gene (EGFR) and KRAS 
protein, on radiomic phenotype was investigated. Both PET and CT radiomics were shown to 
successfully distinguish the EGFR+ and EGFR- lung tumors [87, 88]. On the other hand, the KRAS status 
did not influence FDG-PET tumor phenotype and the changes in CT phenotype were found to be 
moderate.  
Similar studies were performed for other tumor types. In glioblastoma, both IDH1 and EGFR status 
were shown to influence the tumor MR phenotype [89, 90]. The metabolic patterns, quantified by    
18F-FDG-PET radiomics, in breast cancer were correlated with the Ki67 expression, a molecular 
biomarker for cell proliferation [75].  
The correlation of radiomics with tumor biology may be challenging as it requires a large number of 
both imaging and molecular data. An analysis of preclinical data could be a solution to that problem. 
Significant changes in CT phenotype were observed in tumor xenografts with differential hypoxic 
fraction [91]. 
 
1.6.4 Radiomics challenges 
Radiomics is a relatively new discipline. The major challenges in radiomics come from missing 
standardization of: image acquisition parameters, definitions of radiomic features, normalization 
methods and reporting of results and methods. Radiomic features need to be validated against image 
acquisition and post-processing protocols [92-95]. Results of some of the stability studies, such as voxel 
size influence on texture, can be translated between image modalities. Nevertheless, most of the 
factors are modality-specific and warrant separate investigation. It was recently shown that even the 
best method for image discretization is modality dependent [92]. Additionally, little is known about 
the translation of stability results from one tumor site to another.  
Several radiomics implementations are currently available. Most of them are an open source or in-
house developed codes. Although they are based on the same mathematical definitions, the freedom 
in their implementation is a big challenge in the field [93, 96]. Studies aiming for workflow 
standardization should be encouraged [68]. 
 
The challenges in radiomics in the context of robustness studies performed within this PhD project are 
further addressed in Chapter 4.3. 
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This PhD project aims to investigate imaging phenotypes in head and neck squamous cell carcinoma 
(HNSCC) related to outcome prognosis in radiotherapy. It consist of two main parts: the investigation 
of the influence of tumor subtype on functional imaging phenotype and the study of imaging 
phenotypes related to prognosis and tumor biology by means of radiomics. 
In the first part, we hypothesize that HNSCC tumor imaging phenotype, in particular the metabolism 
and perfusion, depends on tumor subtype, stage and HPV status (Chapter 3.1). Previous studies found 
that, the HPV infection interfere with the tumor microenvironment, for example HPV positive tumors 
show more rapid decrease in their hypoxic fraction after irradiation [97]. Additionally, head and neck 
cancers grow from differentially vascularized tissues, which may subsequently influence 
vascularization of a tumor [98]. Changes in the vasculature may interfere with glucose transport and 
glucose metabolism. I have assessed tumor metabolism using 18F-FDG PET and perfusion using CT 
perfusion (CTP). I have studied the differences in perfusion parameters between tumor and the 
surrounding healthy tissue, the differences in perfusion and metabolism for HNSCC subgroups as well 
as correlation of perfusion and metabolism for the HNSCC subgroups. The CTP is a dose intense 
examination. Therefore, I have further investigated dose reduction methods (iterative reconstruction 
and tube current and voltage adaptation) for a head and neck CTP protocol (Chapter 3.2). This 
subproject aimed to define a new CTP protocol with a similar image quality, improved resolution and 
lowered dose. 
In the second part of the thesis, I have exploited radiomics (advanced image analysis technique) to 
capture comprehensive tumor imaging subtypes.  This PhD project contributes to the field of radiomics 
by evaluation of its robustness as well as by its correlation to treatment outcome and tumor biology. 
The first two studies are focused on the radiomics standardization and robustness. Majority of 
radiomics studies are conducted using open source or in-house developed implementations. A 
standard guideline for radiomics implementation is not yet defined (detailed description of my 
implementation can be found in Chapter 3.3 and Chapter 4.2). Therefore, I have investigated the 
influence of independent radiomics implementation on the prognostic power of radiomic features 
(Chapter 3.3). The two studied implementations were based on the same mathematical definitions. I 
have compared the local tumor control predictions between the implementations as well as tried to 
identify differences in the radiomics workflow that contribute to the errors in those predictions. The 
other source of errors in radiomics-based predictions is image quality. Image quality in CTP can be 
influenced by multiple factors as it is a computationally complex technique. Some of the computation 
steps are difficult to standardize, for example artery contouring or noise threshold. Therefore, the 
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second study was focused on the stability of radiomics features in CTP maps. We hypothesize that CTP 
computation steps influence the stability of radiomic features thus reducing the set of the features, 
which can be used for prognostic modeling (Chapter 3.4). I have evaluated this hypothesis for lung and 
head and neck perfusion scans. 
Finally, I have performed two studies to link radiomic signatures (set of radiomic features) with tumor 
biology and local tumor control prediction to provide better understanding of imaging phenotypes. 
Some exploratory studies have already indicated a relationship between HPV infection and the 
heterogeneity of imaging-based tumor density [99, 100]. However, they were performed on small 
cohorts of patients with no validation. In this project, I have used CT data from 149 patients divided 
into two separate cohorts to investigate the link between HPV status and CT radiomics (Chapter 3.5). 
In the outcome modeling, most of the radiomics-based studies uses the overall survival as an endpoint 
[101]. Whilst it is important from the clinical point of view, it is also influenced by other non-tumor-
related factors [102]. I have therefore decided to study local tumor control as our endpoint. First, I 
have investigated the added value of a CT radiomics signature for local tumor control to the clinically 
relevant prognostic factors: tumor volume, tumor stage and HPV status (Chapter 3.5). In the second 
step, I have evaluated whether tumor metabolic information improves tumor control predictions in 
comparison to CT radiomics (Chapter 3.6). Conflicting results have been published on the role of 
pretreatment 18F-FDG PET (mean and maximum FDG uptake) for prediction of treatment outcome in 
head and neck cancer [103]. I have therefore quantified tumor metabolism using PET radiomics and 
subsequently correlated it with treatment outcome and compared it with predictions based on CT 
radiomics. 
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3.1 Tumor stage, tumor site and HPV dependent correlation 
of perfusion CT parameters and [18F]-FDG uptake in head and 
neck squamous cell carcinoma. 
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Background and purpose: This study investigated whether tumor perfusion, FDG uptake and their corre-
lation depend on tumor stage, site and HPV in head and neck cancer.
Material and methods: 41/55 eligible patients with integrated FDG-PET/perfusion CT from 2 prospective
studies were assessed. A GTVCT and GTVPET were created. Perfusion maps were calculated using singular
value decomposition method. Blood volume (BV), blood flow (BF), mean transit time (MTT) and standard-
ized uptake value (SUV) in the tumor were compared to the surrounding tissue using Wilcoxon test and
Spearman correlation of perfusion and SUVmean in the tumor was studied (p = 0.05).
Results: Perfusion parameters were significantly increased in the GTVCT of advanced tumors in compar-
ison to the surrounding soft tissue (p < 0.01). Oral cavity and oropharyngeal cancer showed a higher BF
than laryngeal cancer (p < 0.04). No correlation between perfusion and SUVmean was found, however
SUVmean correlated significantly with BF for the HPV-positive tumors (r = 0.86, p = 0.04) and with BV
for the oropharyngeal cancer (r = 0.63, p = 0.05).
Conclusion: Tumor stage, site and HPV are associated with different perfusion or combined perfusion/SUV
signatures. Further studies are needed to investigate if these signatures co-determine clinical outcome.
 2015 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 117 (2015) 125–131
The response of human head and neck squamous cell carcinoma
(HNSCC) to radiotherapy depends not only on tumor size but also
on tumor site and biology [1,2]. Results from clinical trials indicate
that patients with oropharyngeal carcinoma (OPC) have the
highest loco-regional control rate followed by laryngeal, hypopha-
ryngeal and oral cavity cancers [3,4]. Part of this differential
outcome is explained by the high rate of human papilloma virus
(HPV)-induced OPC. Since the knowledge about HPV as prognostic
and predictive marker is rather new we are only beginning to
understand the biology of HPV associated cancers. Recent studies
using in vivo tumor models suggest that HPV increases radiosensi-
tivity [7] and may also interfere with the tumor microenvironment,
e.g. HPV was associated with a more rapidly decreasing hypoxic
fraction in HPV-positive HNSCC xenografts in comparison to
HPV-negative tumors [8] and xenografts formed by HPV-positive
cells had fewer hypoxic areas and displayed a lower hypoxic signa-
ture [9].
In addition to HPV infection tumor size and tumor site specific
anatomy might co-determine tumor physiology as well. For exam-
ple large tumors might be more heterogenous with regard to vas-
cularization than smaller tumors due to necrotic areas. In addition,
cancers of the tongue and floor of mouth grow in an anatomical
region with abundant normal vasculature and therefore might dis-
play increased angiogenesis [10] in comparison to cancers of the
larynx.
A surrogate marker for tumor angiogenesis is tumor perfusion
assessed by computed tomography perfusion (CTP) [11–13]. Perfu-
sion is mainly described by three parameters: blood flow (BF),
blood volume (BV) and mean transit time (MTT) [14]. BF is defined
as the rate of blood supplying a particular area. BV represents the
volume of blood within the vasculature. The average time taken by
blood to travel from the arterial to the venous end is called MTT. All
three parameters might be differentially expressed due to a tumor
http://dx.doi.org/10.1016/j.radonc.2015.09.026
0167-8140/ 2015 Elsevier Ireland Ltd. All rights reserved.
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biology and site-specific vascularity and functionality of the
vasculature.
In the clinic, the most important functional imaging parameter
used in the diagnostic workup of HNSCC patients so far is
18F-fluorodeoxyglucose ([18F]-FDG) PET. [18F]-FDG uptake in the
tumor is a balanced signal of tumor cell metabolism, hypoxia,
perfusion and aggressiveness [15,16]. On the other hand, tumor
vasculature is known to be disorganized, tortuous and leaky and
thereby largely ineffective [17]. Here we hypothesized that tumor
perfusion, [18F]-FDG uptake and their correlation differ dependent
on tumor stage, site and HPV status.
Materials and methods
Study population
55 patients, who had a pre-treatment [18F]-FDG-PET with inte-
grated perfusion CT in 2 separate prospective studies between
2008 and 2014, were pooled and assessed. Both studies had ethical
approval. The patients had suspicion for head and neck cancer and
were scanned before histological verification by panendoscopy. 14
patients had to be excluded from our analysis due to only inflam-
mation present in the PET/CT scan (n = 7), non-squamous cell car-
cinoma (n = 3), no primary tumor inside the limited region of the
CTP (n = 2), spine deformation (n = 1) or stenosis of carotid arteries
(n = 1). Finally, 41 patients with HNSCC were enrolled (Table 1).
HPV status was determined by p16 analysis (n = 36).
[18F]-FDG PET/CT and CT perfusion imaging
All images were acquired with a combined PET/CT scanner
(Discovery VCT, GE Healthcare, Milwaukee, WI, USA). The imaging
procedure is described in the Supplement. The region for the CTP
examination was defined based on the [18F]-FDG uptake. The
obtained images had the following characteristics: PET in-plane
pixel size of 5.08 mm and slice thickness of 3.27 mm; CTP temporal
resolution of 1 s (45 scans), in-plane pixel size of 0.7 mm, slice
thickness of 5 mm and cranial-caudal coverage of 4 cm. As the
PET and CTP images were taken consecutively no additional regis-
tration was performed.
Volumes contouring
The GTVCT of the primary tumor was contoured on the perfusion
CT, and all contours were checked by an experienced senior
radiation oncologist. Auto-segmentation of the PET signal in the
tumor (GTVPET) was performed. A gradient-based segmentation
method was chosen, as it better estimates a true tumor volume
than a threshold approach in the case of laryngeal cancer [19]
and performs equally good for other head and neck tumors [20].
PET images were pre-processed and segmented as described by
Geets et al. [19] using the Python programming language (version
2.7.6).
Quantitative image comparison and statistical methods
An in-house software for perfusion maps determination and
image comparisons was developed. Perfusion calculations were
based on the singular value decomposition method [21]. The final
results were normalized to the perfusion in the carotid artery. The
details of the perfusion parameter calculation are described in
the Supplement. A window of 20 to 180 HU was used to exclude
the bone, air and metal artifacts from the analysis. CTP image res-
olution was adjusted to the resolution of the PET image by signal
averaging. The analysis was comprised of the following parts:
The GTVCT and the GTVPET were compared using Dice’s coefficient
[22] and Hausdorff distance [23]. The mean perfusion parameters
(blood volume BV, blood flow BF and mean transit time MTT) were
determined inside the tumor and its surrounding tissue and their
differences were examined using paired-samples Wilcoxon
Signed-Rank test: the PET non-active part of the GTVCT was com-
pared to the active GTVPET and the whole GTVCT was compared
to its surrounding normal tissue, which was a 10 mm ring struc-
ture around the tumor (ring structure M). Mean perfusion param-
eters and [18F]-FDG uptake values inside the GTVCT were
compared between tumor stage, site and HPV status using Krus-
kal–Wallis and Mann–Whitney tests. For each patient, standard
deviations of the standardized uptake values (SUV) and the
perfusion parameters in the different GTVsCT were calculated and
normalized (nSD) to the mean value in this region to analyze the
homogeneity inside the GTVsCT. The SUVmean and mean CTP signals
inside the GTVPET and the whole GTVCT were correlated by
Spearman correlation.
The analysis was performed for the whole patient population
and subsequently for subgroups based on stratification into tumor
stage, site and HPV status. For each of the subgroups the multiple
testing correction was performed using Holm–Bonferroni method
[24] with family-wise error rate of 0.05. Corrected p-values are
denoted in this paper as pc. The uncorrected strikingly low p-
values were also mentioned (p < 0.05) as a hint for the future stud-
ies [25]. The statistical analysis was performed using Python
library SciPy.
Results
GTVCT and GTVPET volumes’ comparison
The mean GTVCT and GTVPET were 20.5 cm3 (range
0.4–91.9 cm3) and 14.2 cm3 (0.5–67.9 cm3), respectively. In one
case the segmentation was not possible due to the low PET signal
in the tumor (oropharynx T1 HPV-negative). The CT scan before the
PET acquisition and perfusion CT were rigidly registered in the
commercial software Eclipse (v. 11, Varian Medical Systems, Palo
Alto, California, USA) to evaluate potential patient movement.
The mean motion was 4.9 mm, which is smaller than the image
resolution. One patient (hypopharynx T3 HPV negative) was
excluded due to large motion (16.1 mm). An example of perfusion
and SUV maps together with contours is presented in Fig. 1. The
mean Dice’s coefficient for GTVCT and GTVPET was 0.63 (range
0.23–0.84), whereas the mean Hausdorff distance was 23 mm
Table 1
Patients included into the study.
Group Number of patients
All patients 41
Tumor stage T1/T2 12
T3/T4 29
Tumor site Oropharynx 17
Hypopharynx 8
Larynx 8
Oral cavity 8
HPV status Positive 9
Negative 27
N stage N0 12
N1/N2/N3 29
Gender Female 7
Male 34
Age Mean 60 years (43–79 years) 41
GTV volume Mean 20.2 cm3 (0.4–91.9 cm3) 41
Study 2008–2010 27
2012–2014 14
126 Correlation of CTP and FDG in HNSCC
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(range 10–60 mm) indicating substantial heterogeneity and
variability between the two volumes.
Perfusion parameters in the GTVCT and GTVPET in comparison to the
surrounding normal tissue
BV and MTT perfusion parameters were significantly increased
in the GTVCT compared to the 1 cm ring structure M (BV differ-
ence = 26%, pc < 0.01; MTT difference = 16%, pc < 0.01). An increased
tumor perfusion in comparison to the surrounding soft tissue was
found for stages T3/T4 (BV difference = 31%, pc < 0.01; MTT differ-
ence = 21%, pc < 0.01; BF difference = 19%, pc = 0.01) but not for
T1/T2. Regarding HPV status increased perfusion in the GTVCT
was observed for the HPV negative (BV difference = 21%,
pc < 0.006: MTT difference = 16%, pc = 0.02), but not for positive
tumors. With regard to the [18F]-FDG-active (GTVPET) and non-
active parts of the GTVCT, no difference of the perfusion parameters
was found (Table 2).
Perfusion parameters and standardized uptake value dependent on
tumor site, stage and HPV
Kruskal–Wallis test showed strikingly low p-values without
multiple testing for the BF in the GTVPET in different tumor sites
(p = 0.02). Larynx tumors were characterized with lower BF in
comparison to OPC (p = 0.04) and oral cavity (p < 0.01) tumors
(Fig. 2). The higher BF was observed in the GTVPET in HPV negative
tumors (p = 0.03). These results were not significant after multiple
corrections. All other parameters including SUVmean did not differ
according to tumor site and HPV status. With regard to tumor stage
SUVmean was higher for stages T3/T4 (GTVPET pc = 0.02; GTVCT
pc = 0.01), while no difference was observed in the perfusion.
Inhomogeneity of CTP and PET parameters
The mean values of the nSDs were calculated to represent the
inhomogeneity for the whole population. The largest inhomogene-
ity was found for BV (nSD = 71%) and the smallest for MTT
(nSD = 34%). For BF and SUV nSD of 53% was found.
Correlation of mean perfusion parameters with SUV for the whole
population
The correlations of MTT and SUVmean had strikingly low
p-values (GTVPET r = 0.40, p = 0.02 and GTVCT r = 0.35, p = 0.04).
However after correcting for multiple testing, these correlations
were not significant anymore. No other statistically significant cor-
relation was found (Table 3).
Correlation of mean perfusion parameters with SUV dependent on
tumor stage, tumor site and HPV
Significant correlation was found after multiple testing regard-
ing the HPV status and tumor site (Table 3). The SUVmean correlated
in the GTVPET with BF for HPV positive tumors (r = 0.86, pc = 0.04)
and in the GTVCT with BV for OPC (r = 0.63, pc = 0.05). In addition,
several in part differential correlations with strikingly low
p-values without multiple testing were observed. The SUVmean cor-
related with BV for the larynx (GTVPET r = 0.83, p = 0.04), stage T3/
T4 (GTVPET r = 0.42, p = 0.05) and HPV negative (GTVPET r = 0.44;
p = 0.05; GTVCT r = 0.51, p = 0.01) tumors. The HPV negative tumors
showed also a correlation of SUVmean with MTT (GTVPET r = 0.46,
p = 0.04). The negative correlation of SUVmean and BF was found
for the laryngeal cancer (GTVCT r = 0.75, 0.05).
Discussion
Using an integrated PET/CT scanner this study analyzed tumor
stage, tumor site and HPV dependent tumor perfusion and [18F]-
FDG activity as well as the correlation of these parameters. Our
results show that perfusion in the tumor is significantly different
in comparison to the surrounding soft tissue. This difference was
highly significant for advanced tumors (T3/T4) but not for small
tumors (T1/T2). With regard to tumor site, only BF differed with
laryngeal cancer having a lower BF compared to OPC and oral cav-
ity cancer. Mean BF was also decreased in the HPV-negative
tumors in comparison to the positive ones. In addition, we did
not find significant correlation of perfusion parameters and
[18F]-FDG uptake for the whole population, however we observed
significant correlation dependent on tumor site and HPV status.
The prognosis of HNSCC differs according to tumor site. In a
recent phase III randomized trial, which compared different frac-
tionation regimens, patients with OPC had a LCR of 88% after
5 years in comparison to only 49% for oral cavity carcinoma [3].
In this trial, patients with HPV-negative OPC had a LCR of 74%,
which was still significantly better in comparison to oral cavity
cancers, which are HPV-negative in 90–95% of cases. The reason
why HPV-positive cancers respond better is not yet completely
understood and has been linked to differential intrinsic radiosensi-
tivity [7] as well as to altered amount and behavior of tumor
hypoxia during radiotherapy in experimental models [9,8]. In addi-
tion to HPV status, factors related to the anatomical site co-
determine treatment outcome, e.g. tumor physiological factors
such as the possibility to recruit blood vessels for regional or dis-
tant spread of tumor cells or, on the contrary, a lack of regional
blood supply resulting in tumor hypoxia. This is supported, for
example, by anatomical studies showing a high vascular supply
to cancers of the tongue [10].
It is well known that vasculature differs between tumor and
healthy tissue, e.g. inside solid tumors angiogenesis is increased,
but on the other hand tumor vasculature is disorganized, tortuous
and leaky [17]. Increased tumor perfusion indicates increased
angiogenesis. This is supported by clinical studies in patients with
prostate and colorectal cancer as well as preclinical studies using
VX2 lung tumors implanted in mice showing a correlation between
perfusion parameters and microvessel density [11–13]. The
Fig. 1. Example of perfusion and standardized uptake value (SUV) maps for one of
the patients. The red line corresponds to GTVPET and black one to GTVCT. The white
pixels in the perfusion maps refer to the pixels with HU values outside the defined
range. BV – blood volume, BF – blood flow, MTT – mean transit time.
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increased BV in the tumor shown by us is consistent with other
studies [18,26]. However, whereas all other studies compared per-
fusion in the tumor with either muscle or contra-lateral healthy
tissue, we took the immediate surrounding soft tissue for compar-
ison. The rationale for using the surrounding soft tissue was the
limited scan region of 4 cm, which precludes comparison of tumors
in different sites with the same reference muscle. In addition the
comparison of tumor tissue with the normal soft tissue fromwhere
the tumor originated eliminates the influence of differential
vascularization in different anatomical regions. A counter argu-
ment for our approach would be that angiogenesis might also be
increased in the immediate surroundings of the tumor due to
microscopic tumor extension. Mean pathologic extension in
HNSCC was shown to be below 5 mm in a pathological study
[27]. The use of different normal tissue regions for comparison of
perfusion values is one possible explanation why, in contrast to
Table 2
Median differences of mean perfusion parameters for the FDG-active (GTVPET) and non-active parts of the tumor (GTVCT – GTVPET) as well as the GTVCT and its margin. BV – blood
volume, BF – blood flow, MTT – mean transit time, M – 10 mm ring structure around GTVCT, d – difference of relative perfusion parameters normalized to the GTVCT, p –
significance level, pc – significance level corrected for the multiple testing. Differences with strikingly low p-values (p < 0.05) are underlined and statistically significant values
(pc < 0.05) are in bold.
Tumor subgroup Comparison Perfusion parameters
Structure 1 Structure 2 BV MTT BF
All
n = 39
GTVPET GTVCT – GTVPET d = 7.0%
p = 0.62
pc = 1.25
d = 3.9%
p = 0.393
pc = 1.18
d = 3.4%
p = 0.67
pc = 0.67
GTVCT M d = 26%
p < 0.01
pc < 0.01
d = 16%
p < 0.01
pc < 0.01
d = 16%
p = 0.02
pc = 0.07
T1/T2
n = 11
GTVPET GTVCT – GTVPET d = 2.0%
p = 0.96
pc = 1.92
d = 8.5%
p = 0.40
pc = 1.99
d = 3.8%
p = 0.61
pc = 1.84
GTVCT M d = 18%
p = 0.05
pc = 0.30
d = 3.8%
p = 0.58
pc = 2.30
d = 0.80%
p = 1.00
pc = 1.00
T3/T4
n = 28
GTVPET GTVCT – GTVPET d = 9.4%
p = 0.49
pc = 0.97
d = 3.9%
p = 0.61
pc = 0.61
d = 7.6%
p = 0.48
pc = 1.43
GTVCT M d = 31%
p < 0.01
pc < 0.01
d = 21%
p < 0.01
pc < 0.01
d = 19%
p < 0.01
pc = 0.01
Oropharynx
n = 16
GTVPET GTVCT – GTVPET d = 1.3%
p = 0.78
pc = 0.78
d = 3.6%
p = 0.45
pc = 0.89
d = 5.8%
p = 0.29
pc = 1.43
GTVCT M d = 23%
p = 0.02
pc = 0.09
d = 5.5%
p = 0.31
pc = 1.26
d = 3.6%
p = 0.44
pc = 1.32
Hypopharynx
n = 7
GTVPET GTVCT – GTVPET d = 21%
p = 0.50
pc = 1.50
d = 4.6%
p = 0.50
pc = 0.50
d = 17%
p = 0.50
pc = 1.00
GTVCT M d = 28%
p = 0.12
pc = 0.46
d = 21%
p = 0.08
pc = 0.40
d = 14%
p = 0.08
pc = 0.48
Larynx
n = 8
GTVPET GTVCT – GTVPET d = 7.0%
p = 0.35
pc = 1.04
d = 8.9%
p = 0.35
pc = 0.69
d = 5.0%
p = 0.46
pc = 0.46
GTVCT M d = 31%
p = 0.02
pc = 0.11
d = 28%
p = 0.04
pc = 0.17
d = 19%
p = 0.04
pc = 0.22
Oral cavity
n = 8
GTVPET GTVCT – GTVPET d = 24%
p = 0.24
pc = 0.47
d = 5.7%
p = 0.13
pc = 0.38
d = 11%
p = 0.13
pc = 0.51
GTVCT M d = 29%
p = 0.03
pc = 0.17
d = 14%
p = 0.05
pc = 0.23
d = 1.9%
p = 0.92
pc = 0.92
HPV-positive
n = 9
GTVPET GTVCT – GTVPET d = 8.2%
p = 0.40
pc = 1.20
d = 1.3%
p = 0.89
pc = 0.89
d = 5.8%
p = 0.26
pc = 1.05
GTVCT M d = 29%
p = 0.02
pc = 0.10
d = 0.72%
p = 0.69
pc = 1.37
d = 21%
p = 0.04
pc = 0.22
HPV-negative
n = 26
GTVPET GTVCT – GTVPET d = 7.0%
p = 0.60
pc = 0.60
d = 4.4%
p = 0.26
pc = 1.02
d = 9.2%
p = 0.47
pc = 0.94
GTVCT M d = 21%
p < 0.01
pc < 0.01
d = 16%
p < 0.01
pc = 0.02
d = 2.4%
p = 0.31
pc = 0.92
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our observation of increased MTT, other investigators found
decreased MTT in the tumor [11,18].
Interestingly, we did not find significant differences in mean
perfusion parameters of large versus small tumors. It would be
interesting to perform heterogeneity analyses in future studies
based on the assumption of higher probability of tumor necrosis
and hypoxia in larger tumors.
We showed significant correlation of tumor metabolism and
perfusion. This is expected from the existing literature investigating
the underlying biology of tumor metabolism and [18F]-FDG uptake
[15,16]. Several studies in head and neck, lung, breast and rectal
cancers investigated correlation of [18F]-FDG and CT perfusion
parameters [28–33]. These studies used different perfusion models
and parameters. So far only few studies investigated the correlation
between CT perfusion and [18F]-FDG metabolism in head and neck
cancer: a summary of the correlations between perfusion and SUV
parameters found by us and in other studies of HNSCC is presented
in Table 4. The overview is limited to the perfusion parameters
studied by us. Patient numbers in these studies were small, no clin-
ically relevant subgroup analyses were made and the results pre-
sented are inconclusive. Our subgroup analysis in terms of tumor
HPV status provides an additional explanation to contradictory
results of previously published studies regarding SUV correlations
with BF [18,26,34]. We did not observe a correlation for the whole
patient cohort, but we found a significant correlation for the HPV
positive tumors.
Strikingly low p-values, however not significant after multiple
testing corrections, were shown for the correlations of the BV
and SUVmean in the case of HPV negative tumors as well as T3/T4
stages. Also the differences in the BV and MTT between the GTVCT
and its 1 cm margin were statistically significant for the T3/T4 and
HPV-negative subgroups. As these groups are associated with
impaired prognosis it might be a signature for a high risk tumor
physiology, e.g. pro-angiogenic, ineffective vasculature and pro-
metastatic tumor bed conditions. In this study the size of these
subgroups was larger in comparison to T1/T2 and HPV-positive
subgroups, which could also influence the obtained results. Further
studies on larger, equally stratified patient cohorts are needed to
validate these correlations as well as studies in form of correlations
Fig. 2. Boxplots showing the mean values of the blood flow inside the GTVPET for
different tumor sites and tumor stages.
Table 3
Spearman correlation of perfusion parameters and SUVmean according to tumor stage, tumor site and HPV status. BV – blood volume, BF – blood flow, MTT – mean transit time,
GTVPET – GTV auto-segmented based on the PET signal, r – correlation coefficient, p – significance level, pc – significance level corrected for the multiple testing. Correlations with
strikingly low p-values (p < 0.05) are underlined and statistically significant values (pc < 0.05) are in bold.
Tumor subgroup Correlation of Perfusion Parameters and SUVmean
BV BF MTT
GTVPET GTVCT GTVPET GTVCT GTVPET GTVCT
All r = 0.29 r = 0.29 r = 0.34 r = 0.21 r = 0.40 r = 0.35
p = 0.09 p = 0.08 p = 0.05 p = 0.22 p = 0.02 p = 0.04
pc = 0.17 pc = 0.25 pc = 0.21 pc = 0.22 pc = 0.12 pc = 0.19
T1/T2 r = 0.02 r = 0.53 r = 0.38 r = 0.49 r = 0.27 r = 0.47
p = 0.96 p = 0.08 p = 0.31 p = 0.13 p = 0.49 p = 0.14
pc = 0.96 pc = 0.45 pc = 0.96 pc = 0.63 pc = 0.98 pc = 0.57
T3/T4 r = 0.42 r = 0.20 r = 0.30 r = 0.17 r = 0.38 r = 0.28
p = 0.05 p = 0.34 p = 0.16 p = 0.45 p = 0.07 p = 0.20
pc = 0.29 pc = 0.69 pc = 0.64 pc = 0.45 pc = 0.37 pc = 0.60
Oropharynx r = 0.31 r = 0.63 r = 0.45 r = 0.48 r = 0.32 r = 0.37
p = 0.26 p = 0.01 p = 0.12 p = 0.08 p = 0.29 p = 0.20
pc = 0.52 pc = 0.05 pc = 0.49 pc = 0.42 pc = 0.29 pc = 0.590
Hypopharynx r = 0.60 r = 0.66 r = 0.26 r = 0.37 r = 0.43 r = 0.03
p = 0.21 p = 0.16 p = 0.62 p = 0.47 p = 0.40 p = 0.96
pc = 1.04 pc = 0.94 pc = 1.25 pc = 1.41 pc = 1.59 pc = 0.96
Larynx r = 0.83 r = 0.36 r = 0.54 r = -0.75 r = 0.71 r = 0.32
p = 0.04 p = 0.43 p = 0.27 p = 0.05 p = 0.11 p = 0.48
pc = 0.25 pc = 0.86 pc = 0.80 pc = 0.26 pc = 0.44 pc = 0.48
Oral cavity r = -0.36 r = 0.21 r = 0.07 r = 0.071 r = 0.46 r = 0.50
p = 0.43 p = 0.64 p = 0.88 p = 0.88 p = 0.29 p = 0.25
pc = 1.73 pc = 1.93 pc = 1.76 pc = 0.88 pc = 1.47 pc = 1.52
HPV-positive r = 0.48 r = 0.19 r = 0.86 r = 0.33 r = 0.10 r = 0.02
p = 0.23 p = 0.65 p = 0.01 p = 0.42 p = 0.82 p = 0.96
pc = 1.17 pc = 1.95 pc = 0.04 pc = 1.68 pc = 1.65 pc = 0.96
HPV-negative r = 0.44 r = 0.51 r = 0.33 r = 0.19 r = 0.46 r = 0.41
p = 0.05 p = 0.01 p = 0.16 p = 0.40 p = 0.04 p = 0.06
pc = 0.18 pc = 0.08 pc = 0.31 pc = 0.40 pc = 0.20 pc = 0.19
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of tissue and imaging markers to provide a better understanding of
the perfusion parameters on the biological level.
In contrast to tumor biopsies that only provide a snapshot of a
small tumor area, functional imaging allows delineating tumor
biology and physiology with spatial resolution. This is the prereq-
uisite for the development of dose painting, i.e. the distribution of
radiation dose within the tumor dependent on radiation sensitiv-
ity. Due to the broad availability of integrated PET/CT scanners
the combination of [18F]-FDG PET and functional CT is promising
for future clinical research in this direction.
There are also some limitations of the imaging procedures used
in our study. An important issue is patient fixation during imaging.
The large inhomogeneity of perfusion parameters and SUV in the
GTVCT suggest that future studies should best be performed by
voxel-wise correlations. However, this requires very stable patient
positioning with possible movement smaller than image resolu-
tion, which only can be achieved by use of a thermoplastic mask
during the 30 min lasting PET/CTP procedure.
The auto-segmented GTVPET was on average 65% overlapping
with the GTVCT contoured by the radiation oncologists, which is
in agreement with the published data [35]. This mismatch
is explained by the known fact that often only part of the tumor
is [18F]-FDG-active and by the motion of the patient.
In summary, we found different perfusion in the tumor in com-
parison to the surrounding soft tissue as well as differential corre-
lation of perfusion and PET parameters dependent on HPV status.
Further studies on tumor physiology in HNSCC should therefore
take into account the various subgroups. A significantly different
perfusion or combined perfusion/SUV signature dependent on
the subgroup might predict outcome in HNSCC. Further studies
are needed with outcome analyses of large cohorts as well as stud-
ies that correlate perfusion parameters with immunohistochemical
markers. In addition, the inhomogeneity of tumors in terms of vas-
cularity and metabolism requires voxel-wise correlation studies
with proper patient fixation during the imaging procedure. In the
long-term this research points to a better understanding of differ-
ential tumor response of HNSCC.
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[18F]-FDG PET/CT and CT perfusion imaging 
After the measurement of blood sugar level, an activity of 270-410 MBq of [18F]-FDG was injected 
intravenously. The administered activity depended on the patient’s weight. The imaging procedure 
started 60 minutes after [18F]-FDG injection with a CT examination for attenuation correction using the 
following scanning parameters: 80 mA, 140 kV, 0.5 s tube rotation and 4.25 mm slice thickness. In the 
next step the PET acquisition was performed for 2 minutes with a 15 cm axial field-of-view at each bed 
position. Total acquisition time of the PET was 12-16 min. Images were reconstructed with a 3D iterative 
algorithm with an in-plane pixel size and the slice thickness of the PET/CT images of 5.08 mm and 3.27 
mm, respectively. The region for further CTP examination was defined based on the      [18F]- FDG 
uptake. 
The CTP scanning protocol suggested by the vendor was used. 40 ml of contrast media (Ultravist 370, 
Bayer Schering Healthcare, Germany) was injected at a flow of 5 ml/s in a cubital vein. After a delay of 
5 s, the perfusion scans were acquired for 45 s (1 s rotation time with 1 image/s, 8 slices, 5 mm slice 
thickness, 80 mA, 100 kV) [1]. It enabled an anatomical cranial-caudal coverage of 4 cm of the target 
lesion. CT images were reconstructed using filtered back projection with an in-plane pixel size of the of 
0.7 mm and the slice thickness of 5 mm. 
 
 
Perfusion maps calculations 
An in-house software for perfusion maps determination and image comparisons was developed in the 
Python programming language (version 2.7.6). To calculate perfusion maps the baseline image, arterial 
input function (AIF) and concentration of contrast agent in each voxel Cv were defined. 
Based on the signal enhancement in an artery the time point of contrast arrival to the scanned region  t0 
was defined individually for each patient. The baseline image was calculated as an average of images 
before t0. Concentration of the contrast agent in each voxel as a function of the time Cv(t) was calculated 
by subtracting the baseline image from the image at a certain time point. 
For defining the AIF it is important to reduce partial volume effect. It was performed by choosing the 
artery with the biggest diameter - carotid artery. As the signal enhancement in the artery Ca did not differ 
throughout the scanned region, it was sufficient to contour a region of interest inside the artery in 2 to 3 
slices. For the final AIF definition, the gamma function was fitted to the mean Ca(t). The onset  for 
recirculation was defined, by fitting the function only to the first pass of the bolus. 
To speed up the calculations and reduce the noise, the resolution of perfusion maps was set to 2.8  mm 
by grouping the 4x4 pixels. A threshold of -20 to 180 Hounsfield units was defined, to exclude the bone, 
air, large vessels and metal artifacts from the analysis. 
Blood volume was calculated as the total enhancement in the voxel Cv divided by the total enhancement 
in the artery Ca [2]: 
 
 
𝐵𝑉 = 
 
∫
∞ 
𝐶𝑣(𝑡)𝑑𝑡 
∫
∞ 
𝐶𝑎(𝑡)𝑑𝑡 
(1) 
 
 
 
 
To obtain BF and MTT maps a deconvolution was performed using singular value decomposition (SVD) 
method [3]. The threshold of 20% of the maximum singular value in the matrix was introduced  to reduce 
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the influence of noise on the final results [4]. The adapted BF and MTT definitions were used, to account 
for the delayed arrival of the contrast at a certain voxel in comparison to the artery  [4]: 
(2) 
𝐵𝐹 = max(𝑘(𝑡)) 
𝑀𝑇𝑇 =  
1
𝑚𝑎𝑥(𝑘(𝑡))
 ∫ 𝑘(𝑡)𝑑𝑡
∞
0
 
 
where: k(t) is the flow scaled residual function. 
All parameters were normalized to the mean values in the carotid artery. 
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Abstract: Perfusion computed tomography (CTP) images 
tumor angiogenesis and can assess tumor aggressiveness. 
However, the CTP examinations are dose intensive. This 
study aimed to optimize a routinely used CTP protocol for  
the head and neck region in oncology in order to reduce the 
effective dose to the patient and simultaneously achieve the 
same image quality. 
The Alderson phantom was scanned on a GE Revolution 
CT scanner. A scan with our standard protocol for head and 
neck cancer patients was used (100kV, 80mAs, 5mm slice 
thickness and backprojection algorithm) and in seven 
predefined regions (ROI) the signal to noise ratio (SNR) was 
measured. For the dose optimized protocol, the tube voltage 
was lowered and the mAs adaptation protocol was used. To 
improve image quality different percentage of an adaptive 
statistical iterative reconstruction (ASiR) was applied. For a 
better resolution we set the slice thickness to 2.5 mm. The 
mAs adaption range and the percentage of the ASiR 
reconstruction were varied until we found a combination with 
the same median SNR in the seven defined ROIs as for our 
old protocol. For the old and the optimized protocol dose 
measurements were performed using 25 LiF-TLDs. Organ 
doses were calculated and the effective dose was determined 
based on the weighting factors of ICRP103. 
The optimized scanning protocol used a voltage of 80kV, 
a mAs range between 15 and 80, a noise level of 10%, and 
50% ASiR reconstruction. The median SNR ratio was  
slightly better (14% better SNR) with the new protocol. An 
effective  dose  of  8  mSv  was  measured  with  the  original 
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protocol and 4 mSv with the optimized scanning protocol. 
For organs in the scanning field the dose was reduced by a 
factor of 2 and outside the field by a factor of  2.2. 
Advanced reconstruction algorithms allow a significant 
dose reduction and an improvement of image resolution, 
while maintaining the image quality. 
Keywords: Perfusion CT imaging, head and neck cancer, 
effective dose 
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1 Introduction 
Perfusion computed tomography (CTP) is a non invasive 
functional imaging technique to assess the tissue blood 
circulation, which is associated with tumor angiogenesis. In 
head and neck tumors CTP imaging has been shown to be a 
promising tool for treatment prognosis, differentiation of 
different tumor histologies and differentiation between 
malignant and benign tumors. [1-4] 
The number of CT examinations is continuously increasing, 
and the average lifetime cancer risk due to medical radiation 
exposure has been estimated to be as high as 2% [5]. It might 
be even higher for patients receiving CTP, which consists of 
repetitive CT scans. Therefore, dose reduction is an  
important topic, especially for patients with benign tumors 
and long term survivors. 
The current CT technology implements several dose 
reduction methods, such as automated tube  current 
modulation and iterative reconstruction. These methods have 
successfully been applied to conventional CT imaging [6] as 
well as for CTP imaging in the brain region [7]. However 
their potential to reduce dose for CTP imaging of head and 
neck cancer has not yet been investigated. 
This study was performed to optimize a routinely used 
CTP protocol for the head and neck region in order to reduce 
the effective dose to the patient and simultaneously achieve 
an equal image quality. New iterative reconstruction 
technology  and  automated  tube  current  modulation    were 
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evaluated for dose reduction. The effective dose was 
estimated based on  TLD measurements. 
 
 
2 Materials and methods 
 
2.1 Scanning protocols and dose 
optimization 
A routinely used protocol suggested by the vendor   (Protocol 
R) was the starting point for our dose optimization process 
(see Table 1). For dose reduction the tube voltage was 
lowered from 100 to 80 kVp. The milliampere-second (mAs) 
was adapted based on the attenuation of the body region that 
was analysed in the scout. The level of adaptation depends  
on the set noise index, i.e. image noise which influences 
image quality. We set the noise index to 10%, which was a 
comparable noise to the images from Protocol R. Such a dose 
reduction results in a worse image quality. To compensate for 
that an adaptive statistical iterative reconstruction algorithm 
(ASiR), provided from GE, was applied. The percentage of 
ASiR was varied until an optimal setting was found. 
Additionally, for a better resolution we set the slice thickness 
to 2.5 mm. 
 
 
2.2 Image quality measurements 
To compare the image quality we measured the signal to 
noise ratio (SNR) in seven predefined regions (ROI 1-7). The 
images were registered in the MIMVISTA (MIM Software 
Inc., Cleveland, OH, USA), which is a registration and 
contouring tool. The ROIs were drawn as circles of 2 cm 
diameter, equally distributed over the head and neck region. 
The ROIs were propagated from CTP of Protocol R to CTP  
of Protocol O (see Figure 1). 
 
 
Figure 1: Location of 7 regions of interest (ROI) that were 
used to evaluate the image quality in the two CTP of 
protocols: R - routine and O - optimized. 
 
 
 
2.3 Dose measurements and effective 
dose calculation 
A tissue equivalent anthropomorphic phantom (Alderson 
Rando Phantom, Radiology Support Devices, CA, USA) was 
scanned on a GE Revolution CT scanner (GE Healthcare 
Technologies, Waukesha, Wisconsin, USA) with both 
protocols (Protocol R and Protocol O). Dose measurements 
were performed with LiF-TLD. For each scan, 25 TLDs  
were distributed over the multiple slices of the phantom 
inside and outside the scanning field (see Figure 2). The 
allocation of the TLDs was chosen to measure the 
corresponding organ doses necessary for the effective dose 
calculation. Additionally, the dose to the eye lenses, a 
radiation sensitive organ in the scanning field, was measured. 
The dose to organs in the scanning field was measured using 
two TLDs, whereas the dose to organs outside of the field  
was measured with a single TLD. Moreover, for organs 
located partially in the scanning field (i.e. for brain, 
oesophagus, skin, bone), the final dose was a result of a 
weighted average from corresponding TLDs placed in and  
out of the field. 
33  
 
 
 
 
 
Figure 2: Alderson Phantom with TLDs in the corresponding slice 
(25 TLDs in total). The red rectangle marks the scanning field with 
a size of 16 cm. 
 
In the effective dose calculation the weighting factors given 
by ICRP103 [8] were applied. The fraction of bone marrow 
distribution inside and outside of the scanning region was 
estimated based on Cristy et al. [9]. 
Additionally, the TLD-based effective dose was 
compared with the effective dose based on the scanner 
estimation of CTDIvol. Dose length product (DLP) was 
calculated and the effective dose was estimated according to 
the AAPM 96 [10] using a conversion factor of 0.0031 (for 
adults for head and neck). 
 
 
3 Results 
The 50% of ASiR was found to provide as good image 
quality as the Protocol R and consecutively was used in the 
new optimized protocol (Protocol O) (see Table 1). 
 
 Protocol R Protocol O 
scan length [cm] 16 16 
number of scans 45 (1/s) 45 (1/s) 
kV 100 80 
mAs 80 ---- 
mAs adaptation [mAs] ---- 15-80 
noise [%] ---- 10 
slice thickness [mm] 5 2.5 
iterative recon ASiR [%] 0 50 
 
Table 1: CTP parameters for the optimized scanning protocol 
(Protocol O) and the old in our clinic routinely used protocol 
(Protocol R). 
 
 
The median SNR ratio (over all 7 segments) was slightly 
better (14% better SNR) with the new protocol (see Figure  
3). ROI 1 shows the largest improvement with 2.5  times 
better SNR. The Wilcoxon rank sum test showed no 
significant difference between the two protocols (p>0.1). 
 
 
 
Figure 3: Boxplot of the SNR measurements for the ROI 1 – 7 for 
both protocols. 
 
The measured organ doses, the effective dose based on the 
TLD measurements and based on the DLP are shown in 
Figure 4 for both protocols (Protocol R, Protocol O). The 
effective dose decreased with the new protocol. For organs in 
the scanning field the median dose was reduced by a factor of 
2 and outside the field by a factor of 2.2. Additionally, the 
dose to the eye lenses was reduced by a factor of 1.6. Based 
on TLD measurements, the Protocol R delivered 8 mSv, 
whereas the Protocol O delivered only 4 mSv. The effective 
dose calculated out of DLP was 9 mSv and 5 mSv for the 
protocol R and protocol O, respectively. 
 
 
Figure 4: Organ doses, effective doses based on TLD 
measurements and based on the DLP calculation for protocol R 
and protocol O. 
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4 Discussion 
In this study we showed that the decreased tube voltage and 
tube current in combination with iterative reconstruction 
allowed for an effective dose reduction by a factor of 2 and 
the preservation of the image quality in the CTP head and 
neck scan. Additionally, our new protocol improved the out- 
plane resolution by a factor of 2. 
The organ dose comparison showed a dose reduction of 
43% to 61% with the new protocol. This is in agreement with 
the study published by Niesten et al [7], which showed a 50% 
dose reduction for cerebral brain perfusion imaging. In our 
study, exceptions were colon and bladder, where the dose  
was equal. However, these organs were far off the scanning 
field and the delivered doses were minimal. Generally, for 
organs in the scanning field the median dose was reduced by 
a factor of 2 and outside field by a factor of 2.2. 
The use of the iterative algorithm ASiR allowed not only 
the maintenance of image quality but also a slight 
improvement of the median SNR as well as an improvement 
in the out-plane resolution. The median SNR decreased by 
14% over all the analyzed ROIs. The slice thickness was 
reduced from 5 mm to 2.5 mm. 
The effective dose to the patient was measured using 
TLD measurements and we additionally calculated the dose 
based on the DLP given by the scanner. The effective dose 
estimated from the DLP was slightly higher compared to our 
TLD measurements. This is in agreement with the study of 
Bauhs et al [11], who showed that CTDI overestimates the 
dose in perfusion CT imaging up to 50%, but contradicts 
studies on conventional CT, which often show that the DLP 
based method underestimates the effective dose [12]. The 
TLD measurements enabled us to give an organ specific 
estimation of the doses. 
A limitation of the study is that we assumed an equal 
image quality in the phantom without contrast agent will 
result in a similar quality of the calculated perfusion 
parameters and that no perfusion parameters were calculated 
in the frame of this study. 
 
 
5 Conclusion 
 
Iterative reconstruction algorithms such as ASiR allow a 
significant dose reduction while maintaining the image 
quality. Therefore CTP protocols should be adapted if 
iterative reconstruction algorithms are available. The 
optimized scanning protocol used a voltage of 80kV, a   mAs 
range between 15 and 80 with a noise level of 10%, and 50% 
ASiR reconstruction. 
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Abstract 
Purpose 
This study investigated an association of post-radiochemotherapy (RCT) PET radiomics with local tumor 
control in head and neck squamous cell carcinoma (HNSCC) and evaluated the models against two 
radiomics software implementations. 
Materials and methods 
649 features, available in two radiomics implementations and based on the same definitions, were 
extracted from HNSCC primary tumor region in 18F-FDG PET scans 3 months post definitive RCT (training 
cohort n=128, validation cohort n=50) and compared using the intraclass correlation coefficient (ICC). Local 
recurrence models were trained, separately for both implementations, using principal component analysis 
(PCA) and the least absolute shrinkage and selection operator. The reproducibility of the concordance 
indexes (CI) in univariable Cox regression for features preselected in PCA and the final multivariable models 
was investigated using respective features from the other implementation.   
Results  
Only 80 PET radiomic features yielded ICC>0.8 in the comparison between the implementations. The 
change of implementation caused high variability of CI in the univariable analysis. Both final models 
performed equally well in the training and validation cohorts (CI>0.7) independent of radiomics 
implementation.  
Conclusion 
The two post-RCT PET radiomic models, based on two different software implementations, were 
prognostic for local tumor control in HNSCC. However, 88% of the features was not reproducible between 
the implementations. 
 
Keywords: post-radiochemotherapy 18F-FDG PET, radiomics, local tumor control modelling, software 
implementation, reproducibility 
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide with 
tobacco and alcohol consumption as well as HPV infection being the important risk factors. The standard 
of care for patients with locally advanced HNSCC is definitive radiochemotherapy (RCT). The locoregional 
recurrence rate is high, exceeding 50% in HPV negative oropharyngeal carcinoma and non-oropharyngeal 
cancers [1, 2]. A meta-analysis of post-RCT 18F-fluorodeoxyglucose positron emission tomography (18F-
FDG PET) studies reported sensitivity and specificity of around 80% in respect to detection of local tumor 
recurrence or persistence in HNSCC [3]. Additionally, post-RCT FDG PET has been shown to correlate with 
overall survival [4]. 
Radiomics, a high throughput method for quantification of medical images, has been shown a promising 
input for treatment response modelling [5-11]. It is based on a comprehensive and quantitative analysis 
of a region of interest performed on different levels: shape, intensity, texture and filter-based analysis. 
Radiomics is a rapidly growing field of research. However, the studies have been predominantly performed 
in independent single-institution settings and consequently, the importance of workflow standardization 
has been indicated [5, 6]. 
Radiomics analysis requires several image pre-processing steps such as region of interest segmentation 
and extraction as well as image interpolation and discretization. These steps together with image 
acquisition and reconstruction parameters may influence radiomic features and therefore 
interchangeability of derived models (i.e. radiomic signatures) [12, 13]. Many institutions use different 
software packages for the analysis, which are often in-house developed. Although the implementations 
are based on the same mathematical definitions, it is likely that they will produce different results due to 
differences in implementation of algorithms as well as pre-processing [13].  
To base clinical decisions on a prognostic model, its validation is required [14, 15]. Several strategies, 
characterized by different strength, can be used. A cross-validation is often implemented as a first step, 
followed by temporal validation using data from the same institution but from a different period. Finally, 
to achieve an unbiased validation, an external validation in an independent dataset should be performed 
[16]. Most of the radiomics studies have used cross-validation to quantify model performance and so far 
only one model has been validated in an external and independent dataset [17, 18]. Validation is usually 
performed by the same research group, using the same tools and methodology. However, radiomic 
features have been shown to vary with image acquisition parameters, pre-processing and contouring [5, 
6, 12] and (to our knowledge) none of the previously published studies investigated the reproducibility of 
a radiomics-based prognostic model in terms of radiomics software implementation. 
This study hypothesize that the prognostic value of radiomic features is software implementation 
dependent.  First, we investigated whether the 3 months post-RCT follow-up 18F-FDG PET radiomics is 
prognostic for tumor recurrence in HNSCC. Two independent models were trained using two independent 
radiomics implementations and their performance was validated in a separate dataset. Subsequently, the 
reproducibility of these models was evaluated when their respective radiomic features were calculated 
with an independent software implementation.  
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Materials and methods 
Imaging protocol and studied population 
This retrospective analysis was approved by the local ethical commission. HNSCC patients treated with 
definitive radiochemotherapy were enrolled in the study (128 patients in the training and 50 patients in 
the validation cohort). The validation cohort consisted of patients treated in an institutional phase II 
prospective study (NCT01435252) with a standardized imaging protocol (the same slice thickness and 
reconstruction algorithm). Surgery or induction chemotherapy were exclusion criteria (biopsy allowed). 
The characteristic of the studied cohorts is presented in the Table 1. All patients underwent 18F-FDG 
PET/CT imaging prior to the treatment and 3 months after the end of the treatment as a standard follow-
up examination. Depending on patient’s body weight, an activity of 170-470 MBq of 18F-FDG was injected 
intravenously after the measurement of blood sugar level. The PET acquisition was preformed 60 minutes 
after 18F-FDG injection with a 3 minutes scanning time and 15 cm axial field-of-view at each bed position. 
Total acquisition time of the PET was 12-18 min. Images were reconstructed with an iterative algorithm 
(2D or 3D reconstruction in the training cohort and 3D reconstruction in the validation cohort) with an in-
plane pixel size and the slice thickness of 2.73 – 5.47 mm and 3.27 – 4.25 mm, respectively. All data was 
acquired in the same center.  
  Training cohort Validation cohort 
 Total number of patients 128 50 
 Median follow-up (months) 46 (3-156) 16 (3-28) 
 Number of local recurrences 38 (30%) 13 (26%) 
T1/T2 43 (34%) 6 (12%) 
T3/T4 85 (66%) 44 (88%) 
Positive 31 (24%) 22 (44%) 
Negative 36 (28%) 28 (66%) 
Unknown 61 (48%) 0 
Oropharynx 91 (71%) 29 (58%) 
Hypopharynx 22 (17%) 7 (14%) 
Larynx 11 (9%) 7 (14%) 
Oral cavity 4 (3%) 7 (14%) 
Treatment Radiotherapy on average 70 Gy  
(68 – 72 Gy) 
70 Gy 
 Chemotherapy Cisplatin (40 mg/m2, up to 
7 cycles) or cetuximab 
(loading dose 400 mg/m2 
followed by 250 mg/m2 
weekly) 
Cisplatin/cetuximab 
(weekly same doses as in 
training cohort) with or 
without consolidation 
cetuximab (500 mg/m2 
biweekly x 6) 
PET 
scanners 
GE Discovery STE 
GE Discovery 690 
GE Discovery RX 
GE Discovery HR 
GE Discovery LS 
64 (50%) 
10 (8%) 
23 (18%) 
15 (12%) 
16 (12%) 
39 (78%) 
6 (12%) 
5 (10%) 
Table 1. Detailed characteristic of studied cohorts. 
40 
 
Image pre-processing and radiomics analysis 
Tumors were semi-automatically segmented in the pre-treatment PET scans using a gradient-based 
method implemented in MIMVISTA (MIM Software Inc., Cleveland, OH, USA). The pre-treatment and post-
treatment scans were rigidly registered and contours were transferred to post-treatment scans. To 
account for differences in image reconstruction grid all scans were rescaled to 5.5 mm cubic voxels using 
linear interpolation. This corresponds to the smallest resolution in the studied dataset. 
The pre-processed images were shared between the institutions. Post-RCT metabolic heterogeneity was 
studied in the region of the primary tumor (Figure 1). Two independent software implementations were 
used: implementation from the University Hospital Zurich (USZ) and the MAASTRO clinic (MAASTRO). In 
total 649 features, which were based on the same definition and available in both implementations, were 
extracted: 
 Shape (n = 8) 
 Intensity-based (n = 17) 
 Texture: the Gray Level Co-occurrence Matrix (GLCM; n = 24), the Neighborhood Gray Tone 
Difference Matrix (NGLTDM; n = 4), the Gray-Level Size Zone Matrix (GLSZM; n = 14), the Gray-
Level Run Length Matrix (GLRLM; n = 14). 
 Filter-based: Wavelet coiflet (n = 568). 
The full list of the extracted features is presented in the supplemental material. A bin size of 0.5 SUV was 
used for image intensity discretization. The consistency of radiomic features calculated in two different 
implementations was studied using the two-way mixed single measures intraclass correlation coefficient 
(ICC). 
 
Figure 1. Scheme of the reproducibility analysis of the local tumor control models using two independent radiomics 
implementation. 
 
Features preselection and comparison of the features’ prognostic power between the radiomics 
implementations 
The following feature selection procedure was used. First, a principal component analysis (PCA) was 
performed to account for inter-feature correlations. The number of retained components was adjusted to 
represent 95% of data variance. Next, for each principal component one feature was selected to represent 
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it. To that end we determined the feature that correlated the most (the largest Pearson correlation 
coefficient) with the principal component.  
The prognostic power of radiomic features selected in different implementations was investigated in an 
univariable Cox regression. The models were fitted separately for the USZ and MAASTRO implementations. 
To quantify the discriminative power of different models the concordance indexes (CI) were calculated 
and compared between the implementations. The p-value from Cox regression was corrected for the 
multiple testing using false discovery rate (FDR) < 10% and the number of features defined in the PCA. The 
statistical analysis was performed in R (v. 3.2.3). 
 
Prediction of local tumor recurrence and model reproducibility between the implementations 
To train a final model for the association of the radiomic features derived from post-RCT PET with the 
likelihood of tumor recurrence, the least absolute shrinkage and selection operator (LASSO) (100 times 5-
fold cross-validated) was used for variable selection in multivariable Cox regression. Only the features 
preselected in the PCA were used in the multivariable analysis. A random sampling with replacement was 
used to create a different training set in each of the LASSO iterations. In the final model we included only 
radiomic features with selection rate higher than 70% among all random training sets.  Patients were 
stratified into low- and high-risk of recurrence groups based on a threshold from the receiver operating 
characteristic curve for local recurrence at 18 months. The threshold was selected to equate the level of 
sensitivity and specificity. The groups were compared using G-rho test (p-value < 0.05). Two models were 
trained separately, one on the USZ and one on the MAASTRO feature set. Both models were validated in 
the independent cohort of patients.  
Each trained model, based on the features calculated in one implementation, was later evaluated by 
calculating its respective features with the other independent implementation (Figure 1). The regression 
coefficients of the Cox model and the stratification threshold were then fixed. Model performance was 
quantified using the concordance index (CI). Additionally, the calibration of the models was investigated 
by calculation of the calibration slope based on the prognostic index [19]. The calibration slope equals 1 
evidences the same level of discrimination in the training and validation datasets. Finally, the correlation 
of hazards obtained with two implementations and the reproducibility of the patients risk group 
assignments were investigated. 
 
Results  
Radiomic features reproducibility between the two implementations 
The intraclass correlation coefficient was used to investigate features reproducibility. Out of 649 features, 
46 and 80 were characterized by an ICC greater than 0.9 and 0.8, respectively. These were mostly 
histogram-based (92% of the features in the studied group based on the ICC > 0.8) and texture-based (68%) 
features calculated on the non-transformed images. The shape features showed intermediate 
reproducibility (50%), whereas the biggest discrepancy was observed for the wavelet features (supplement 
Figure 1S). The wavelet features where high-pass filter was applied more than once were the least 
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reproducible. A translation of the 0.5 SUV bin size to the wavelet coefficients was different between the 
implementations (see supplement section Wavelet).  It resulted in a different number of analyzed gray 
levels in the wavelet maps (supplement Figure 3S). Additionally, the MAASTRO implementation uses an 
undecimated transform, whereas the USZ implementation uses the decimated one. This influenced the 
resolution of the analyzed maps.  
 
Figure 2. Comparison of the features’ prognostic power in the univariable Cox regression between the radiomics 
implementations. The fit was considered non-significant if false discovery rate (FDR) > 10%. The concordance 
indexes for the same feature varied between the radiomics implementations and this effect did not depend on the 
feature’s intraclass correlation (ICC) from the implementations comparison. The LLL, LLH, LHL, LHH, HHH, HHL, HLH, 
HLL – denote the combination of wavelet filters in 3D (L – low-pass, H – high-pass). 
 
Comparison of the features’ prognostic power between the radiomics implementations 
In the principal component analysis, 31 and 33 components retained the 95% of data variance in the USZ 
and MAASTRO implementation, respectively. We found only 6 representative features based on the 
principal components analysis to be the same for both implementations. In a univariable Cox regression, 
9 features in USZ and 12 features in MAASTRO implementation yielded a FDR < 10%. Among those 
features, more than 50% was not significant in the univariable Cox regression when calculated with 
secondary implementation (Figure 2). Even if the feature was significant in both implementations, a 
substantial difference in CI was observed.  The features were grouped according to their FDR in the 
secondary implementation (FDR < 10% or FDR ≥ 10%). No significant difference in the ICC values between 
those groups was observed (Wilcoxon test p-value > 0.05). 
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Prediction of local tumor recurrence and comparison between the implementations 
In the multivariable analysis, GLCM difference entropy was found to be prognostic in the USZ 
implementation, whereas the histogram range was selected from the MAASTRO implementation. 
Radiomic features in the final local tumor recurrence models showed high level of reproducibility between 
the radiomics implementations (ICC > 0.9). A strong correlation (r > 0.9) between GLCM difference entropy 
and histogram range was observed independent of the implementation. There was a weak, significant 
correlation between selected radiomic features and tumor volume (r < 0.5). 
Both models showed similar prognostic power in the training (5-fold cross-validation) and validation 
cohorts with CI ranging between 0.70 and 0.76 (Table 2) and allowed for a significant risk group 
stratification (Figure 3). In the validation cohort, the calibration slope was not significantly different from 
1, indicating the preservation of model discriminative power (Table 2). Additionally, the models were 
prognostic in the group of HPV negative patients (supplement Figure 4S). In both models, tumors with 
higher risk of recurrence were characterized by a higher post-treatment metabolic heterogeneity 
(supplement Figure 5S).  
The main research question asked in this work was to investigate the model performance when an 
independent radiomics implementation was used to calculate the hazards. Also in this case, the studied 
PET radiomics models achieved a very similar performance in terms of the concordance index as well as 
similar calibration slope (Table 2). It showed that the general discriminative power of the models was not 
affected by the change of the implementation. On the patient level, a strong correlation was observed 
between patient rankings based on the features from both implementations (r > 0.9). Most of the patients 
(around 90%) were correctly classified into low- or high-risk of recurrence group when the independent 
implementation was used (Figure 4).  
 
 Model developed using radiomic features from 
 MAASTRO USZ 
Radiomic features Histogram range GLCM difference entropy 
Intraclass correlation 0.97 0.93 
Concordance Index 
training 0.76 0.75 
validation 0.73 0.73 
training 0.75 0.74 
validation 0.71 0.72 
Calibration slope 
MAASTRO features  1.20 (0.39 – 2.02)* 1.04 (0.27 – 1.95)* 
USZ features  1.13 (0.39 – 1.88)* 1.02 (0.20 - 1.83)* 
Table 2. Performance of PET radiomics models for prediction of local tumor control and the stability of radiomic 
features between two radiomics implementations (USZ and MAASTRO). Underlined values indicates results where 
the same implementation was used for the training of the model and model performance evaluation, * 95% 
confidence interval. 
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Figure 3. PET radiomics-based local tumor recurrence models: a) USZ implementation, b) MAASTRO 
implementation. Local control rate curves split significantly (G-rho test p-value < 0.05) in both training and 
validation cohorts based on the optimal sensitivity-specificity thresholds at 18 months. 
 
 
Figure 4. Local control rate curves for low- and high-risk of recurrence groups based on the two PET radiomic 
models. The curves split significantly independent of the implementation 
 (G-rho test p-value < 0.05). 
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Discussion 
This study investigated the prognostic value of post-RCT PET radiomics in head and neck squamous cell 
carcinoma and tested the reproducibility of prognostic models between independent radiomics 
implementations (USZ or MAASTRO). Independent of the radiomics implementation used for model 
training, the prognostic model for local tumor control showed a good discriminative power with a 
concordance index higher than 0.7 in both training and validation cohorts. Both models significantly 
stratified patients into low- and high-risk of recurrence groups. Furthermore, the validation of the models 
using an independent radiomics implementation resulted in a similar concordance indexes. However, it is 
important to note that the reproducibility of the models is a consequence of the high ICC between the 
implementations for the selected features. In the modelling process we have observed that the 
discriminative power of single radiomic features preselected for the multivariable analysis depended on 
the radiomics implementation.  
The value of post-treatment FDG-PET imaging for assessment of residual disease is currently unclear [3]. 
Recently, it has been shown in a prospective study that the positive findings on 3 months post-treatment 
FDG PET are a prognostic factor for overall survival and cancer-specific survival [4]. Additionally, our work 
shows that the heterogeneity of 3 months post-RCT FDG activity in the region of primary tumor is related 
to the risk of tumor recurrence. Higher histogram range (range of SUV in the region of primary tumor) and 
higher GLCM difference entropy corresponded to higher risk of tumor recurrence. We have further shown 
that these radiomics models can also significantly stratify the HPV negative patients, who belong  to a 
group with a generally bad prognosis.  Another study found that a pre-treatment FDG PET radiomics has a 
similar prognostic power to our post-treatment model [20]. 
Our prognostic models were trained on a heterogeneous dataset, different PET scanners and 
reconstruction algorithms were used. However, we were able to validate obtained results on a dataset 
with a standardized imaging protocol (the same slice thickness and reconstruction algorithm). Our findings 
should be further validated in datasets from other centers as the lack of calibration between different PET 
scanners can affect the performance of the models [21]. Additionally, we have defined our region on 
interest based on the pre-treatment PET images and propagated it to the post-treatment scan. The model 
reproducibility should be tested against different registration methods for propagation of the delineated 
tumor volume.  
The two radiomics implementations used in this study are based on the same mathematical definition of 
radiomic features. Additionally, the image pre-processing (image and region of interest resizing) was 
performed independent of the radiomics implementation and the same bin size was used for image 
discretization [22]. Nevertheless, a relevant variability in radiomic features value was observed, mostly for 
the shape and wavelet features. It was most probably caused by differences in mask construction and 
wavelet transform workflow: especially in the translation of the bin size to the wavelet transformed images 
and the type of transform (decimated vs undecimated). For more details see supplement sections 
Contours mapping and Wavelet.. Variations of contour masks constructed from the same DICOM files is 
also a well-known issue in different treatment planning systems [23]. The comparison of the number of 
analyzed voxels, as well as minimum, maximum and mean value in the GTV  between two radiomics 
implementations is shown in Figure 2S. The GTV constructed with USZ implementation was always larger 
then in MAASTRO implementation and consequently the minimum SUV in USZ implementation was always 
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lower. Regarding wavelet transform, the two implementations transferred differently the bin size of 0.5 
SUV into the wavelet coefficients space, which resulted in different number of analyzed gray levels (Figure 
S3). A separate study investigating a discriminative power of wavelet features obtained with the two gray 
level discretization methods could be conducted to clarify which method is more informative in the context 
of medical image analysis This study points out differences in radiomics workflow steps, which are rarely 
described in radiomics studies. Therefore, clear guidelines, such as the Image Biomarker Standardization 
Initiative [24], providing detailed description of radiomics workflow and implementation are needed. For 
a workflow comparison purpose, we are also open to share our source code upon request. Nonetheless, 
we showed that the majority of histogram and texture features was reproducible (i.e. high ICC values) 
despite the existing differences in contours mask construction. This result suggests that the mask creation 
is only a minor concern in the standardization aiming for the reproducibility of patients ranking and model 
prognostic power. 
Our final prognostic models for local tumor recurrence were reproducible when the features from the 
independent radiomics implementation were used, which can be explained by the fact that both models 
consisted of radiomic features with a high ICC in the comparison between the implementations (ICC > 0.9). 
Most of the available radiomic features showed a much lower agreement in this comparison. A large 
variation in concordance indexes was observed for the radiomic features preselected in the principal 
component analysis. Most of the features preselected in one implementation were not significantly 
associated with local tumor recurrence in the other implementation in the univariable analysis. This shows, 
for the first time on a clinically relevant model and dataset, that a model developed by one institution 
should not be directly transferred to another center, which uses a different radiomics implementation, 
without rigorous comparison. We recommend that each model, additionally to a detailed description of 
the radiomics implementation, should be published with a sample dataset and corresponding radiomics 
signature, such as a recently published digital phantom [25]. This will allow for a comparison of results 
obtained from a model, before it will be used in a prospective cohort.  
In conclusion, this study shows the potential of post-RCT FDG-PET radiomics for early identification of 
patients with a high risk of local tumor recurrence. It also raises an awareness of the impact of radiomics 
software implementation on model reproducibility.  
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Radiomics features 
The following approaches were used to determine radiomics: shape analysis, histogram of intensities 
analysis, texture analysis (the Gray Level Co-occurrence Matrix, the Neighborhood Gray Tone Difference 
Matrix, the Gray Level Size Zone Matrix and the Gray Level Run Length Matrix) and wavelet transform 
analysis. 
 
Contours mapping 
 
Both radiomics implementations are fully DICOM compatible. The contours used in the analysis were saved 
in the DICOM format. In the USZ implementation, the contour points were translated to the voxel 
coordinates of the analyzed image. Next, those voxels were used to find a contour polygon and points 
inside this polygon using the pointPolygonTest function from Python cv2 library (version 2.4.6). In the 
MAASTRO implementation an algorithm, which is equivalent to the standard mask construction algorithm 
available in Computational Environment for Radiotherapy Research (CERR), was used [1]. The contour 
points were used directly to construct contour polygon. Next, the image-specific coordinates of voxels inside 
this polygon were found. 
The difference in mask construction resulted in generally larger masks in USZ implementation in 
comparison to MAASTRO implementation (see Figure 2S). 
 
Discretization of image intensities 
Both radiomics implementations used in this study the fixed bin size discretization of image intensities, with 
the bin size of 0.5 SUV. The lower range of bin 1 was defined as the minimum value in the analyzed region 
of interest. However, two different discretization schemes were used in the transformed images (see the 
Wavelet transform section). 
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Shape 
 
In the USZ implementation: to calculate shape features contours were transformed onto 1 mm isotropic 
grid; the volume and surface estimation was done using marching cubes algorithm implemented in the VTK 
library [2]. In the MAASTRO implementation: shape features were calculated from the same resolution 
images as the texture features; surface area was calculated using the isosurface triangulation and volume 
was defined as the voxel’s volume times number of voxels in the region of interest. 
1) 𝑉 – volume 
2) 𝐴 – surface 
3) 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 1 =  
𝑉
(𝜋2𝐴)
3
2
 
4) 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 2 =  36𝜋
𝑉2
𝐴3
 
5) 𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑎𝑙 𝑑𝑖𝑠𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =  
𝐴
4𝜋𝑅2
 
where: 𝑅 is the radius of a sphere with the same volume as the tumor. 
6) 𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑖𝑡𝑦 =  
(36𝜋𝑉2)
1
3
𝐴
 
7) 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑜 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 =  
𝐴
𝑉
 
8) 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 3𝐷 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 - the largest pairwise Euclidian distance between voxels of the region of 
interest 
 
Histogram of intensities 
 
The parameters from the histogram of intensities were calculated on PET images before a discretization. 
Let 𝑋 denotes the intensities of the 3D image with 𝑁 voxels. ?̅? - mean of 𝑋, 𝑁𝑔 - number of gray levels in 
the image, 𝑝𝑖 - the occurrence probability of gray level 𝑖. 
 
9) 𝑚𝑒𝑎𝑛 =  
1
𝑁
∑ 𝑋𝑖
𝑁
𝑖=1  
10) 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑎𝑡𝑖𝑜𝑛 =  √
1
𝑁
∑ (𝑋𝑖 − ?̅?)2
𝑁
𝑖=1  
11) 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑁
∑ (𝑋𝑖 − ?̅?)
2𝑁
𝑖=1  
12) 𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 =
 
1
𝑁
∑ (𝑋𝑖−?̅?)
3𝑁
𝑖=1
(√
1
𝑁
∑ (𝑋𝑖−?̅?)
2𝑁
𝑖=1 )
3 
13) 𝑚𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
1
𝑁
∑ |𝑋𝑖 − ?̅?|
𝑁
𝑖=1  
14) 𝑟𝑜𝑏𝑢𝑠𝑡 𝑚𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
1
𝑁
∑ |𝑋10−90,𝑖 − ?̅?10−90|
𝑁10−90
𝑖=1  
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where: 𝑁10−90- number of voxel in the range from and 10
th percentile and 90th percentile, ?̅?10−90 - mean value of 
voxel in the range from 10th percentile and 90th percentile  
15) 𝑒𝑛𝑒𝑟𝑔𝑦 =  ∑ 𝑋𝑖
2𝑁
𝑖=1  
16) 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 =  − ∑ 𝑝𝑖
𝑁𝑔
𝑖=1
log2 𝑝𝑖  
17) 𝑟𝑜𝑜𝑡 𝑚𝑒𝑎𝑛 𝑠𝑞𝑢𝑎𝑟𝑒 =  √
𝑒𝑛𝑒𝑟𝑔𝑦
𝑁
 
18) 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  ∑ 𝑝𝑖
𝑁𝑔
𝑖=1
 
19) 𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒 = min(𝑋)  
20) 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒 = max(𝑋) 
21) 𝑚𝑒𝑑𝑖𝑎𝑛 –  the median value of 𝑋 
22) 10𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 – 10th percentile of 𝑋 
23) 90𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 – 90th percentile of 𝑋 
24) interqurtile range = 90𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 − 10𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒    
25) 𝑟𝑎𝑛𝑔𝑒 = max(𝑋) − min(𝑋)  
 
Texture 
 
The Gray Level Co-occurrence Matrix 
 
The parameters from the Gray Level Co-occurrence Matrix [3] were calculated in all 26 directions with a 
distance of one voxel. The final parameters were the average of all directions. If one of the voxels had a 
‘not a number’ value the pair was not taken into account in the calculations. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry 
in the Gray Level Co-occurrence Matrix, 𝑁𝑔 - number of gray tones in a studied structure, 𝑃𝑥𝑖 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
, 
𝑃𝑦𝑗 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
, 𝑃𝑥+𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1
, where 𝑘 = 𝑖 + 𝑗, 𝑃𝑥−𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1
, where 𝑘 =  |𝑖 − 𝑗|. 
 
26) 𝑒𝑛𝑒𝑟𝑔𝑦 =  ∑ ∑ 𝑃𝑖𝑗
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
27) 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 = ∑ ∑ (𝑖 − 𝑗)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
28) 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  
∑ ∑ 𝑖𝑗𝑃𝑖𝑗−𝜇𝑥𝜇𝑦
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
𝜎𝑥𝜎𝑦
 
where: 𝜇𝑥 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
, 𝜇𝑦 =  ∑ ∑ 𝑗𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
, 𝜎𝑥 =  ∑ ∑ 𝑃𝑖𝑗(𝑖 − 𝜇𝑥)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
, 𝜎𝑦 =  ∑ ∑ 𝑃𝑖𝑗(𝑗 − 𝜇𝑦)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
29) 𝑠𝑢𝑚 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 = ∑ ∑ (𝑖 − 𝜇)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
  
where 𝜇 – mean of 𝑃 
30) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 (ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦) = ∑ ∑
𝑃𝑖𝑗
1+(𝑖−𝑗)2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
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31) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃𝑖𝑗
1+
(𝑖−𝑗)2
𝑁𝑔
2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
32) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = ∑ ∑
𝑃𝑖𝑗
1+|𝑖−𝑗|
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
33) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃𝑖𝑗
1+
|𝑖−𝑗|
𝑁𝑔
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
34) 𝑠𝑢𝑚 𝑜𝑓 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ 𝑖 ∙  𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
 
35) 𝑠𝑢𝑚 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
log2 𝑃𝑥+𝑦(𝑖) 
36) 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
37) 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
log2 𝑃𝑥−𝑦(𝑖) 
38) 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 1 =  
− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
−(− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
)
𝑚𝑎𝑥{(− ∑ ∑ 𝑃𝑥𝑖 log2 𝑃𝑥𝑖
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
),(− ∑ ∑ 𝑃𝑦𝑗 log2 𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
)}
 
39) 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 2 =
 √1 − exp [−2 − (− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
) + ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
] 
40) 𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  √second largest eigenvalue of ∑
𝑃𝑖𝑘𝑃𝑗𝑘
𝑃𝑥𝑖𝑃𝑗𝑖
𝑁𝑔
𝑘=1   
41) 𝑗𝑜𝑖𝑛𝑡 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 = max (𝑃𝑖𝑗) 
42) 𝑗𝑜𝑖𝑛𝑡 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
43) 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ 𝑖𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
 
44) 𝑑𝑖𝑠𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 =  ∑ ∑ |𝑖 − 𝑗|
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
𝑃𝑖𝑗 
45) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 2 ∑ ∑
𝑃𝑖𝑗
(𝑖−𝑗)2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
46) 𝑎𝑢𝑡𝑜𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  ∑ ∑ 𝑖𝑗𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
47) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑡𝑒𝑛𝑑𝑒𝑛𝑐𝑦 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
2
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
48) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠ℎ𝑎𝑑𝑒 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
3
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
49) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑝𝑟𝑜𝑚𝑖𝑛𝑒𝑛𝑐𝑒 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
4
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
 
The Neighborhood Gray Tone Difference Matrix 
 
The Neighborhood Gray Tone Difference Matrix [4] was calculated based on 26 adjacent voxels. The voxels 
with ‘not a number’ value were excluded from the average over the neighborhood region. Let 𝑠𝑖 denotes 
the ith entry in the Neighborhood Gray Tone Difference Matrix, 𝑁𝑖 - the number of voxels having gray tone 
𝑖, 𝐺 - number of gray tones in a studied structure, 𝑛 - number of studied voxels. 
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50) 𝑐𝑜𝑎𝑟𝑠𝑒𝑛𝑒𝑠𝑠 =  [𝜖 + ∑
𝑁𝑖
𝑛
𝐺
𝑖=1 𝑠𝑖]
−1
 
where 𝜖 is a small number to prevent coarseness becoming infinite. 
51) 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  [
1
𝑁𝑔(𝑁𝑔−1)
∑ ∑
𝑁𝑖
𝑛
𝐺
𝑗=1
𝑁𝑗
𝑛
𝐺
𝑖=1 (𝑖 − 𝑗)
2] [
1
𝑛
∑ 𝑠𝑖
𝐺
𝑖=1 ] 
where 𝑁𝑔 is the total number of different gray levels present in the image. 
52) 𝑏𝑢𝑠𝑦𝑛𝑒𝑠𝑠 =  
∑
𝑁𝑖
𝑛
𝐺
𝑖=1 𝑠𝑖
∑ ∑ 𝑖
𝑁𝑖
𝑛
𝐺
𝑗=1 −𝑗
𝑁𝑗
𝑛
𝐺
𝑖=1
 
for 
𝑁𝑖
𝑛
≠ 0 and 
𝑁𝑗
𝑛
≠ 0 
53) 𝑐𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 =  ∑ ∑
|𝑖−𝑗|(
𝑁𝑖
𝑛
𝑠𝑖+
𝑁𝑗
𝑛
𝑠𝑗)
𝑁𝑖+𝑁𝑗
𝐺
𝑗=1
𝐺
𝑖=1  
for 𝑁𝑖 ≠ 0 and 𝑁𝑗 ≠ 0 
 
 
The Gray Level Size Zone Matrix 
 
In the Gray Level Size Zone Matrix [5] calculation the voxels with ‘not a number’ value were excluded from 
the analysis. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry in the Gray Level Size Zone Matrix, 𝑖 - gray value, 𝑗 - size, 𝑛𝑟 - 
number of homogeneous areas inside a studied structure and 𝑝𝑖𝑗 =  𝑃𝑖𝑗 𝑛𝑟⁄ , 𝜇𝑖 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1 , 𝜇𝑗 =
 ∑ ∑ 𝑖𝑃𝑖𝑗 .
𝑁
𝑗=1
𝑀
𝑖=1  
54) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑁
𝑗=1 )
2𝑀
𝑖=1  
55) 𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑀
𝑖=1 )
2𝑁
𝑗=1  
56) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
57) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑗
2𝑀
𝑖=1  
58) 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
59) ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1  
60) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2∙𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
61) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑖
2
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
62) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑗
2
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
63) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1 ∙ 𝑗
2 
64) 𝑠𝑖𝑧𝑒 𝑝𝑟𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
𝑛𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒
 
65) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑖 − 𝜇𝑖)
2𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
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66) 𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑗 − 𝜇𝑗)
2
𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
67) 𝑧𝑜𝑛𝑒 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗 log (𝑃𝑖𝑗)
𝑁
𝑗=1
𝑀
𝑖=1  
 
The Gray Level Run Length Matrix 
 
In the Gray Level Run Length Matrix [6] calculation the voxels with ‘not a number’ value were excluded from 
the analysis. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry in the Gray Level Run Length Matrix, 𝑖 - gray value, 𝑗 - size, 𝑛𝑟 
- number of homogeneous areas inside a studied structure and 𝑝𝑖𝑗 =  𝑃𝑖𝑗 𝑛𝑟⁄ , 𝜇𝑖 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1 , 𝜇𝑗 =
 ∑ ∑ 𝑖𝑃𝑖𝑗 .
𝑁
𝑗=1
𝑀
𝑖=1  
 
68) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑁
𝑗=1 )
2𝑀
𝑖=1  
69) 𝑟𝑢𝑛 𝑙𝑒𝑛𝑔𝑡ℎ 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑀
𝑖=1 )
2𝑁
𝑗=1  
70) 𝑠ℎ𝑜𝑟𝑡 𝑙𝑒𝑛𝑔𝑡ℎ 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
71) 𝑙𝑜𝑛𝑔 𝑙𝑒𝑛𝑔𝑡ℎ 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑗
2𝑀
𝑖=1  
72) 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑙𝑒𝑛𝑔𝑡ℎ 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
73) ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑙𝑒𝑛𝑔𝑡ℎ 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1  
74) 𝑠ℎ𝑜𝑟𝑡 𝑙𝑒𝑛𝑔𝑡ℎ 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2∙𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
75) 𝑠ℎ𝑜𝑟𝑡 𝑙𝑒𝑛𝑔𝑡ℎ ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑖
2
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
76) 𝑙𝑜𝑛𝑔 𝑙𝑒𝑛𝑔𝑡ℎ 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑗
2
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
77) 𝑙𝑜𝑛𝑔 𝑙𝑒𝑛𝑔𝑡ℎ ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1 ∙ 𝑗
2 
78) 𝑙𝑒𝑛𝑔𝑡ℎ 𝑝𝑟𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
𝑛𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒
 
79) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑖 − 𝜇𝑖)
2𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
80) 𝑟𝑢𝑛 𝑙𝑒𝑛𝑔𝑡ℎ 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑗 − 𝜇𝑗)
2
𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
81) 𝑟𝑢𝑛 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗 log (𝑃𝑖𝑗)
𝑁
𝑗=1
𝑀
𝑖=1  
 
Wavelet 
The coiflet wavelet of 1st order was used in the wavelet transform in both implementations [7].The decimated 
wavelet transform (with downsmaple factor of 2) was used by the USZ implementation, whereas the 
MAASTRO implemenatition used the undecimated one. It influenced resoltuion of analyzed images. In the 
MAASTRO implementation no contour adaptation was needed, because the wavelet decompositions are 
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of the same resolution as the original image. In the USZ implementation contours had to be resampled to 
the lower resolution grid.  
The two implementations differed also in terms of wavelet maps discretization. In the USZ implementation, 
the sum of energy in the wavelet maps was normalized to the energy of the original image. Next, the same 
bin size of 0.5 was used. In the MAASTRO implementation, the bin size in each of the wavelet maps was 
adapted to match the number of bins analyzed in the original image. In both cases the minimum value in a 
single wavelet map corresponded to the lower range of bin number 1. 
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Results 
 
 
Figure 1S. The reproducibly of radiomics features between the implementations. a) Histogram of 
reproducible radiomic features. The intensity and texture features showed a high level of agreement 
between the implementations. The irreproducibility of shape and wavelet features was caused by 
differences in mask extraction and wavelet maps normalization. b) Intraclass correlation coefficient for 
different features, H – high-pass filet, L – low-pass filter. The features where high-pass filter was applied 
more than once were the least reproducible. The difference between the implementation in wavelet maps 
normalization did not have a big influence on the low-pass filtered images.  
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Figure 2S. The comparison of mask extraction algorithms used by the different radiomics implementation. 
Each point corresponds to one patient in the training cohort. The masks extracted with USZ implementation 
were generally larger (larger number of analyzed voxels (a)). It also resulted in a lower minimum SUV (c) 
observed in USZ implementation, whereas the maximum (d) and mean SUV (b) were less affected. A 1:1 
line was plotted for the comparison. 
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Figure 3S. The comparison of the number of gray level used in the analysis by the two independent 
implementations (USZ and MAASTRO). Each point corresponds to one patient in the training cohort. 
Although, both implementations used the same bin size (0.5 SUV) its translation to the bin size in the 
wavelet transformed maps differed, resulting in different number of gray levels.  
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Figure 4S. PET radiomics-based local tumor recurrence models: a) USZ implementation, b) MAASTRO 
implementation. The models are prognostic not only in the validation cohort but also in the subgroup of 
HPV negative patients (CIUSZ  = 0.78, CIMAASTRO = 0.82). The local control curves split significantly (G-rho 
test p-value < 0.05) based on the optimal sensitivity-specificity thresholds at 18 months. 
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Figure 5S. Post-RCT PET radiomics signature prognostic for local tumor recurrence. In both 
implementations radiomic features selected in the final models were significantly different for patients with 
controlled tumors and with recurrences (* Wilcoxon rank-sum test p < 0.05).   
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Abstract 
This study aimed to identify a set of stable radiomic parameters in CT 
perfusion (CTP) maps with respect to CTP calculation factors and image 
discretization, as an input for future prognostic models for local tumor 
response to chemo-radiotherapy. 
Pre-treatment CTP images of eleven patients with oropharyngeal carcinoma 
and eleven patients with non-small cell lung cancer (NSCLC) were analyzed. 
315 radiomic parameters were studied per perfusion map (blood volume, blood 
flow and mean transit time). Radiomics robustness was investigated regarding 
the potentially standardizable (image discretization method, Hounsfield unit 
(HU) threshold, voxel size and temporal resolution) and non-standardizable 
(artery contouring and noise threshold) perfusion calculation factors using   
the intraclass correlation (ICC). To gain added value for our model radiomic 
parameters correlated with tumor volume, a well-known predictive factor for 
local tumor response to chemo-radiotherapy, were excluded from the analysis. 
The remaining stable radiomic parameters were grouped according to inter- 
parameter Spearman correlations and for each group the parameter with the 
highest ICC was included in the final set. The acceptance level was 0.9 and 0.7 
for the ICC and correlation, respectively. 
The image discretization method using fixed number of bins or fixed 
intervals gave a similar number of stable radiomic parameters (around 40%). 
The potentially standardizable factors introduced more variability into radiomic 
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parameters than the non-standardizable ones with 56–98% and 43–58% instability 
rates, respectively. The highest variability was observed for voxel size (instability 
rate >97% for both patient cohorts). Without standardization of CTP calculation 
factors none of the studied radiomic parameters were stable. After standardization 
with respect to non-standardizable factors ten radiomic parameters were stable 
for both patient cohorts after correction for inter-parameter correlations. 
Voxel size, image discretization, HU threshold and temporal resolution 
have to be standardized to build a reliable predictive model based on CTP 
radiomics analysis. 
 
Keywords: radiomics, CT perfusion, radiomic features  stability 
S Online supplementary data available from stacks.iop.org/PMB/61/8736/ 
mmedia 
(Some figures may appear in colour only in the online  journal) 
 
Introduction 
 
Cancer is a heterogeneous disease in regard to etiology, pathogenesis, therapy response and 
prognosis (Lamlertthon et al 2011). Tumor response to therapy varies not only among patients 
but also within the tumor itself. For optimizing treatment strategies, identification of biomark- 
ers may be essential. Imaging biomarkers are of special interest as they provide spatial infor- 
mation on tumor biology and are acquired non-invasively. 
Tumor perfusion assessed by computed tomography perfusion (CTP) is a surrogate marker 
for tumor angiogenesis (Goh et al 2008, Ling et al 2014, Luczynska et al 2014). Based on 
CTP images, blood in the vasculature can be described by three main parameters: blood vol- 
ume (BV), blood flow (BF) and mean transit time (MTT) (Lee et al 2003). Tumors or tumor 
sub-volumes characterized by poor angiogenesis are likely to be hypoxic and thus are more 
resistant to radiation therapy (Vaupel and Mayer 2007). Several studies showed that the perfu- 
sion inside a tumor prior to surgery or radiation therapy is correlated with local tumor control 
(Preda et al 2014, Yeung et al 2015). 
In recent years, radiomics has become increasingly important for medical image charac- 
terization, both in terms of volume segmentation (Kumar and Mehta 2011, Lin et al 2016) and 
prediction of treatment response (Aerts et al 2014, Itakura et al 2015, Parmar et al 2015, Yang 
et al 2015). Radiomics uses mathematical definitions to investigate regularity (or periodicity), 
directionality and complexity, which are the prominent perceptual texture characteristics (Rao 
and Lohse 1993). Altogether radiomic features provide much more information about a region 
of interest than the mean or maximum intensity values generally used in clinical medicine. 
Various approaches have been developed to identify texture in an image: the statistical-based 
approach, the model-based approach and the transform-based approach. In the statistical-based 
approach, the texture is described by non-deterministic properties that influence the distributions 
of the gray levels of an image (Materka 2004). First-order statistical parameters are calculated 
using a histogram of intensities in the image and do not contain information about the spatial 
distribution of pixels. Higher-order statistical parameters are computed based on the matrices 
describing the spatial changes in pixel intensities, such as the gray level co-occurrence matrix 
(Haralick et al 1973). Another texture analysis method is the model-based approach, which 
uses the stochastic or fractal models to interpret the structure (Materka 2004). Alternatively, 
the transform-based approach allows analyzing the image in the frequency domain. A wavelet 
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transform is of special interest as it provides a wide range of choices for the wavelet function 
and preserves the spatial localization of the frequencies (Materka 2004). 
Further improvement of prognostic models based on CTP using radiomics analysis is an 
interesting but not yet studied topic. To develop a prognostic model for tumor response based 
on radiomic parameters, a set of stable radiomic features has to be defined to assure the compa- 
rability between different studies (Yip and Aerts 2016). Variability of radiomic parameters was 
examined in PET (Galavis et al 2010, Tixier et al 2012, Leijenaar et al 2013, 2015, Yan et al 
2015, Lu et al 2016, van Velden et al 2016), MRI (Mayerhoefer et al 2009, Maani et al 2013) 
and CT images (Cunliffe et al 2012, Duda et al 2013, Mackin et al 2015, Zhao et al 2016) in 
context of for example image reconstruction, discretization and registration. However, a similar 
evaluation for more computationally complex techniques, such as CTP, is still missing. The 
computation of perfusion maps from a repeated CT scan is performed over multiple steps and 
thus a radiomics stability analysis is of great importance for CTP (Fieselmann et al 2011). All 
available CTP software requires input from a user, such as contouring of the artery, voxel size 
or Hounsfield unit threshold adjustment. Vendors offer various approaches for automated artery 
contouring. However, it was shown that they introduce a 10%–65% failure rate due to motion 
artifacts and random noise (Kao et al 2014). The influence on the radiomics signature of the 
CTP computation factors, which cannot be standardized between the scans, is of great impor- 
tance as they can introduce an error to any treatment response prognostic model. 
Therefore, the aim of this study was to investigate the stability of radiomic parameters     
in the CTP maps regarding CTP calculation factors, CTP scanning protocol and image dis- 
cretization to define new and stable parameters for treatment response prognostic models. 
Tumor volume, which is closely related to the UICC T-Stage, is a major prognostic factor for 
local tumor control after chemo-radiotherapy of lung cancer (Karstens et al 1990) and head 
and neck cancer (Studer and Glanzmann 2013). Different studies reported dependencies of 
radiomic parameters on tumor volume (Brooks and Grigsby 2014, Orlhac et al 2014, Hatt    
et al 2015). To show a potential added value of radiomic parameters in treatment response 
prognostic models over the known tumor volume related model, only the radiomic parameters 
uncorrelated with tumor volume were considered. 
 
Materials and methods 
 
Patient population and image acquisition 
This retrospective analysis was performed on two cohorts of patients collected in prospec- 
tive studies approved by a local ethical commission. Informed consent was obtained from   
all patients. Eleven patients with oropharyngeal carcinoma (OPC) and eleven patients with 
non-small cell lung cancer (NSCLC), who underwent tumor CT perfusion (CTP) imaging, 
were included in this analysis. The analyzed tumors were histologically confirmed stages 
T1–T4 and had median sizes of 21.8 cm3 (9.5–42.3 cm3) and 24.3 (5.8–224.2 cm3) in OPC 
and NSCLC, respectively. The image acquisition was performed on two different CT scanners 
(Discovery VCT, GE Healthcare, Waukesha, WI for OPC and SOMATOM Definition Flash, 
Siemens Healthcare, Erlangen, Germany for NSCLC). The CTP scanning protocols suggested 
by the vendors were applied. Scanning parameters are presented in table 1. Iodinated contrast 
medium (40 ml of Ultravist® 370, Bayer Schering Healthcare, Germany) was injected at a flow 
of 7 ml s−1 for NSCLC and 5 ml s−1 in OPC (van Elmpt et al 2013, Veit-Haibach et al 2013). 
After a delay of 3–5 s, the perfusion scans were acquired. Images were reconstructed using 
filtered back projection. In the case of NSCLC the slice thickness was 3 mm and the in-plane 
resolution was in the range of 0.5 × 0.5–1.0 × 1.0 mm2 dependent on patient size, whereas in 
the OPC scans the voxel size was fixed to 0.7 × 0.7 × 5.0 mm3. 
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Table 1. CT perfusion image acquisition parameters for oropharyngeal carcinoma 
(OPC) and non-small cell lung cancer (NSCLC). 
 
Scanning parameters OPC NSCLC 
kV 100 80; 100 
mAs 80 80; 100 
Cranial-caudal coverage (cm) 4 7 
Temporal resolution (s) 1 3 
Number of images 45 60 
Reconstruction increment (mm) 5 3 
Convolution kernel Standard B30f 
CT scanner Discovery VCT, SOMATOM Definition 
 GE Healthcare, flash, Siemens Healthcare, 
 Waukesha, WI Erlangen, Germany 
 
Perfusion maps calculations 
The pre-processing of CT images was performed before perfusion calculation. The in-plane 
resolution of the images was adjusted to the largest used scanning resolution of 1 × 1 mm2 by 
linear interpolation between pixels. To account for respiratory motion, lung scans were rigidly 
registered in tumor region using SmartAdapt® (v. 11, Varian Medical Systems, USA). If a 
tumor was blurred in one single scan, and thus no reliable registration was possible, the linear 
interpolation between two adjacent time points was used to replace the scan. 
For the perfusion computation an in-house developed computer program based on the sin- 
gular value decomposition method was used (Nesteruk et al 2015). Three perfusion maps 
were calculated: blood volume (BV), blood flow (BF) and mean transit time (MTT). These 
maps were normalized to the perfusion parameters inside the artery used for arterial input 
function (AIF) determination, the carotid artery and the aorta for OPC and NSCLC, respec- 
tively. A Hounsfield unit (HU) threshold was used to exclude bone, air and CT artifacts from 
the perfusion calculations (table 2). 
Tumors were contoured by an experienced radiation oncologist (12 years of experience)  
in the anatomical CT scan, which was later used for perfusion calculation. The contours were 
copied on to perfusion maps. To exclude outliers a Gaussian function was fitted to the CTP 
intensities inside the tumor and points outside the 3-sigma limit were removed from further 
analysis. The radiomics signature was studied in these contoured tumor regions. 
 
Radiomics analysis 
The following 3D radiomic features extraction methods were implemented: 
• statistical-based approach: 
O the histogram of intensities (HI) parameters (n = 5) 
O the gray level co-occurrence matrix (GLCM) parameters (n = 14) (Haralick et al 1973) 
O the neighborhood gray tone difference matrix (NGTDM) parameters (n = 4) (Amadasun 
and King 1989) 
O the gray level size zone matrix (GLSZM) parameters (n = 11) (Thibault et al 2009) 
• model-based approach: 
O the fractal dimension (n = 1) (Napolitano et al 2012) 
• transform-based approach 
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Table 2. Studied CT perfusion calculation and image discretization factors. The set 
of reference perfusion calculation factors used for separate evaluation of sources of 
radiomic parameters instability is shown in bold. 
 
 
Type CTP factors 
Levels 
 
 
OPC NSCLC 
Potentially Image discretization 16, 32, 64 
standardizable  (fixed number of bins)  
factors Image discretization 
(fixed intervals) 
Blood volume and blood flow: 0.5%, 1%, 2% 
Mean transit time: 5%, 10%, 20% 
Hounsfield unit (HU) 
intervals for exclusion 
of non-soft tissue from 
lower threshold: 
−20 HU 
lower threshold: 
−450 HU; −400 HU; −350 HU; 
−300 HU; −250 HU; −200 HU; 
the analysis   −150 HU  
upper threshold: upper threshold: 
120 HU; 140 HU; 160 HU; 200 HU 
180 HU; 200 HU; 220 HU; 
240 HU 
 
Voxel size (mm3) 1 × 1 × 5; 2 × 2 × 5; 
3 × 3 × 5; 4 × 4 × 5; 
1 × 1 × 3; 2 × 2 × 3; 
3 × 3 × 3; 4 × 4 × 3; 5 × 5 × 3 
 
 
Non- 
  5 × 5 × 5  
Temporal resolution (s) 1, 2, 3 3, 6 
Artery contouring (AIF)  Perfusion maps calculated based on 5 different contours of 
standardizable  the artery  
factors Noise threshold 
in perfusion maps 
calculation 
10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 
30% 
 
 
 
 
Table 3. The list of stable and uncorrelated radiomic parameters after standardization 
of image discretization, HU threshold, voxel size and temporal resolution. 
Perfusion map Stable parameter 
 
Blood flow entropy, sum entropy, LHH low gray-level zone emphasis 
Mean transit time large zone low gray-level emphasis 
Blood volume difference entropy, coarseness, large zone high gray-level emphasis, HLH 
information measure of correlation 2, LLL coefficient of variation, LLL average 
 
 
The full list of the radiomic features is presented in the supplement (supplementary table 3 
(stacks.iop.org/PMB/61/8736/mmedia)). The wavelet transform was applied to enhance 
details and edges in the maps. The 35 radiomic parameters (from statistical- and model-based 
approach) were computed for a perfusion map and its 3D wavelet transform (8 sub-bands). It 
summed up to 315 radiomic features per each perfusion map (BV, BF and MTT) and together 
945 radiomic features per patient. Radiomics analysis was implemented in Python program- 
ming language (v. 2.7). The wavelet decomposition was performed using PyWavelets library 
and the ‘Coif1’ wavelet as suggested in Aerts et al (2014). The details of the calculations are 
presented in the supplement (section 2). 
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Figure 1. Scheme of the radiomics variability analysis. Perfusion maps were calculated 
using multiple values for 7 perfusion calculation factors. Radiomics variability was 
studied separately for each of the factors. 
 
 
Stability of radiomic parameters in CTP 
The stability of radiomic parameters was studied in regard to perfusion maps calculation 
factors and image discretization. The scheme of the stability analysis is presented in figure 1. 
The list of investigated factors is presented in table 2. They were divided into factors pos- 
sibly standardizable among different scans (image discretization, HU threshold, voxel size 
and CT temporal resolution) and non-standardizable factors (artery contouring and noise 
level). A set of the following reference perfusion computation factors was defined. For 
higher-order statistical analysis and transformed-based analysis, images were discretized  
into 64 bins, which assured the visualization of the inhomogeneity in the image while keep- 
ing the noise at the low level. The reference HU range allowed the best visual separation     
of the tumor and overlapping or adjacent non-perfused tissues/materials. Definitions of 
radiomic parameters were developed assuming square pixels, therefore in this analysis the 
cubic voxels were used as the reference. Their size was adapted to the smallest resolution in 
the image, which corresponded to the slice thickness. Original temporal scanning resolution 
was chosen as the reference. A recommended noise threshold of 20% in perfusion calcul- 
ations using singular value decomposition was included in the reference set (Fieselmann      
et al 2011). As the reference AIF definition the artery contour with the least noisy enhance- 
ment curve was chosen. 
To investigate the stability of the radiomic features in the perfusion maps in respect to a 
particular factor, the maps were calculated multiple times using this reference set and chang- 
ing the factor of interest. The analysis was comprised of four main parts: 
(1) The variability of radiomic parameters with respect to the image discretization method 
(fixed number of bins in comparison to fixed intervals) was studied using the consist- 
ency in the intraclass correlation (ICC) two-way mixed model (IBM SPSS Statistics for 
Windows, v. 22.0, USA). 
(2) The Spearman correlations of tumor volume with radiomic parameters were investi- 
gated in the perfusion maps calculated using the set of reference perfusion computation 
factors. 
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Figure 2. Percentage of unstable radiomic parameters regarding different perfusion 
calculation factors and image discretization. OPC—oropharyngeal cancer, NSCLC— 
non-small cell lung cancer. 
 
 
(3) To further examine the stability of radiomic parameters the ICC was calculated for all 
other factors influencing the perfusion maps computation, except image discretization 
(table 2). The stability was first analyzed according to tumor entity (OPC or NSCLC) and 
only the features stable in both entities were included in the final set. 
(4) The stable parameters were grouped according to inter-parameter Spearman correlations 
and only the parameter with the highest ICC was chosen. 
The acceptance level was 0.9 and 0.7 for the ICC and Spearman correlation, respectively. 
Despite the small cohorts of patients, the high acceptance level in ICC allowed to keep the 
type I and type II errors at the 0.05 and 0.20 levels, respectively (Walter et al 1998). 
 
 
Results 
 
Stability of radiomic parameters in respect to image discretization  method 
The two discretization techniques, with either fixed number of bins or fixed intervals, were 
evaluated using the ICC. They resulted in a similar number of stable radiomic parameters 
(figure 2). The radiomic parameters calculated in the MTT maps and their wavelet transforms 
were the least affected by image discretization. For further analysis, a fixed number of bins 
method was chosen. 
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Figure 3. Relationships between the studied radiomic parameters. Parameters, which 
were excluded because of correlation with tumor size, are marked in gray. Inter-parameter 
correlation groups are marked with the same texture; the most stable parameter in each 
group is additionally marked with a black frame. The white rectangles correspond      
to parameters, which were not stable regarding potentially standardizable factors. 
Columns correspond to different types of images: BF—blood flow, MTT—mean transit 
time, BV—blood volume, none—original image, HHH, HHL, HLH, HLL, LHH, LHL, 
LLH, LLL—3D wavelet transforms. Rows correspond to different radiomic parameters: 
HI—histogram of intensities, GLCM—gray level co-occurrence matrix, NGTDM— 
neighborhood gray tome difference matrix, GLSZM—gray level size zone matrix, 1— 
mean, 2—standard deviation, 3—coefficient of variation, 4—skewness, 5—kurtosis, 
6—energy, 7—entropy, 8—contrast, 9—correlation, 10—homogeneity, 11—variance, 
12—average, 13—sum of entropy, 14—sum of variance, 15—difference entropy, 
16—difference variance, 17—information measure of correlation 1, 18—information 
measure of correlation 2, 19—maximal correlation coefficient, 20—coarseness, 21—
contrast, 22—busyness, 23—complexity, 24—gray-level non-uniformity, 25— size 
zone non-uniformity, 26—small zone emphasis, 27—large zone emphasis, 28— low 
gray-level zone emphasis, 29—high gray-level zone emphasis, 30—small zone low 
gray-level emphasis, 31—small zone high gray-level emphasis, 32—large zone low 
gray-level emphasis, 33—large zone high gray-level emphasis, 34—zone percentage 
35—fractal dimension. 
Correlation of radiomic parameters and tumor volume 
Forty radiomic parameters correlated strongly with tumor volume (Spearman correlation      
r > 0.7, p < 0.05) and were therefore excluded from further analysis. Most of these param- 
eters were calculated based on the NGTDM and the GLSZM (figure 3). None of the 105 
radiomic parameters calculated in the 3 non-transformed maps was correlated with tumor 
volume. 
 
Stability of radiomic parameters 
The stability of radiomic parameters was investigated in respect to perfusion maps calculation 
factors and image discretization (fixed number of bins) using ICC. The scheme showing  the 
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Figure 4. Scheme of exclusion steps performed for the stability analysis. The numbers 
of stable radiomic parameters resulting from analysis of the mixed group of OPC and 
NSCLC patients are shown. 
 
steps of analysis and the corresponding number of stable radiomic parameters is presented   
in figure 4. The potentially standardizable factors introduced more variability into radiomic 
features than the non-standardizable ones (figure 2). The highest variability was observed  
for voxel size. It caused instability of 98% and 97% of the radiomic parameters in OPC and 
NSCLC, respectively. 
A similar percentage of radiomic parameters was unstable in the OPC and NSCLC in 
respect to a particular perfusion computation factor. The highest discrepancy between OPC 
and NSCLC was observed for temporal resolution, which could be caused by a wider range of 
studied temporal resolution in the OPC in comparison to NSCLC. 
Information measure of correlation 1 in MTT maps was the only stable radiomic parameter 
in OPC against all studied factors (standardizable and non-standardizable). Nine other radi- 
omic parameters were stable in NSCLC (supplementary table 1). None of the radiomic param- 
eters was found stable for both tumor entities. To define radiomic parameters that are stable 
regardless of tumor entity, the final set was defined assuming the standardization of image dis- 
cretization, HU threshold, voxel size and temporal resolution according to the reference set. 
 
Inter-parameter correlations 
After standardization of potentially standardizable perfusion calculation factors 382, 338 and 
255 radiomic parameters were stable in OPC, NSCLC and both tumor entities, respectively. 
The average ICC for each stable radiomic parameter is shown in the supplement (supple- 
mentary figure 1). The number of groups found after accounting for the inter-parameter 
Spearman correlation is shown in supplementary table 2. More groups were found for OPC in 
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comparison to NSCLC. Only 10 separate groups were identified in both tumor entities, OPC 
and NSCLC (figure 3). The size of these groups varied from 1 to 91 parameters. From each 
group the parameter with the highest ICC was chosen. This resulted in a set of uncorrelated 
radiomic parameters, which were stable in respect to non-standardizable perfusion calculation 
factors, and were not correlated with tumor volume (table 3). The final groups of correlated 
radiomic parameters depend on the parameters that are stable in the studied cohorts (OPC, 
NSCLC and both tumor entities). Therefore, the final parameters stable in both tumor entities 
not always correspond to the final parameters stable per tumor entity. 
 
Discussion 
 
This study evaluated the stability of radiomic parameters in CT perfusion maps for two tumor 
entities, oropharyngeal carcinoma (OPC) and non-small cell lung cancer (NSCLC), in respect 
to perfusion calculation factors and image discretization. The non-standardizable factors 
(artery contouring and noise level) influenced the stability of fewer radiomic parameters than 
the potentially standardizable ones (ranges of unstable parameters 56%–98% and 43–58%, 
respectively). The lack of any standardization would result in instability of all radiomic param- 
eters, for both tumor entities. Thus they could not be used as an input in a treatment response 
prognostic model. However, a set of 10 uncorrelated and stable radiomic parameters was iden- 
tified after the standardization of image discretization, HU threshold, voxel size and temporal 
resolution. Each of the methods used in the statistical-based radiomics analysis (the histogram 
of intensities, the GLCM, the NGTDM and the GLSZM) was represented in the final feature 
set. Radiomic features calculated in all three perfusion maps can be found in the final set. The 
BV map was characterized by the biggest number of stable radiomic parameters. 
The aim of this study was to identify new imaging parameters for future prognostic models. 
Tumor volume that is closely related to the UICC T-stage is a major prognostic factor for local 
tumor control after chemo-radiotherapy (Karstens et al 1990, Studer and Glanzmann 2013). It 
was reported in the literature that some of the radiomic parameters are correlated with tumor 
volume (Brooks and Grigsby 2014, Orlhac et al 2014, Hatt et al 2015). In this study 40 param- 
eters closely correlated with tumor volume were excluded from further stability analysis with 
the aim to create a model with an added value over the classical volume-related one. 
More radiomic parameters were found to be stable in the OPC in comparison to NSCLC 
regarding non-standardizable factors. Multiple contouring of the supplying artery resulted in 
instability of 567 parameters in NSCLC and only 480 in OPC (supplementary figure 2). The 
lower resolution of OPC maps and small diameter of carotid artery could have caused smaller 
variation in the artery input function and as a result a smaller variation in tumor perfusion. On 
the contrary, OPC maps were more sensitive to changes in the noise threshold, which could 
be caused by a smaller number of voxels used for the radiomic parameters calculation. Due to 
a smaller tumor size and a worse image resolution the median number of voxels used in the 
analysis was 900 in NSCLC and only 174 in OPC. The sensitivity of OPC to noise changes 
caused for example instability of the mean perfusion parameter (supplementary figure 3). Some 
differences in stability of radiomic parameters between tumor sites could be also caused by the 
use of two CT scanners from two manufactures. Mackin et al 2015 showed a substantial influ- 
ence of scanner type on the radiomics stability in CT. However, this study was performed on 
a limited number of radiomic parameters and using 2.5D analysis (Zhang et al 2015). Instead 
of an entity-specific or scanner-specific analysis resulting in a bigger number of stable radi- 
omic parameters, the combined analysis of the data from two tumor entities was performed to 
increase the applicability of the stable radiomic parameters as future prognostic factors. 
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The radiomic features stability was investigated in respect to the defined reference set of 
the calculation factors. Image discretization into 64 bins was defined as a reference instead  
of a fixed-interval approach despite the results from recent studies in [18F]-FDG PET images 
(Leijenaar et al 2015, van Velden et al 2016). It was shown that the fixed-interval technique, 
based on the standardized uptake value, resulted in smaller variations in the radiomics sig- 
nature in comparison to the fixed number of bins also in terms of delineation technique and 
image reconstruction. However, these results refer only to non-transformed images. In addi- 
tion, the definitions of radiomic parameters are not normalized to the number of bins used in 
the analysis. In our CTP study both discretization techniques performed equally good in terms 
of radiomic parameter stability. Considering the arguments listed above, we decided that the 
fixed number of bin discretization is more suitable for our analysis. 
The choice of voxel size is critical for radiomic features determination. A large variation 
of radiomic features in respect to voxel size was reported in (18F)-FDG PET images (Galavis 
et al 2010). Among all studied image reconstruction parameters (reconstruction algorithm, 
iteration numbers, grid size and post-filtering) the grid size was found to cause the highest 
instability of radiomic features (Galavis et al 2010). Similar results were observed in this work 
on CTP. Definitions of radiomic parameters assume the symmetry of voxels and thus, in this 
study, the set of reference factors included the symmetrical voxels despite their low resolution. 
Single CTP examination in head and neck cancer delivers around 0.2 Gy to the patient, thus 
dose reduction is an important topic in CTP (Ramirez-Grialdo 2013, Niesten et al 2014). The 
increase of temporal resolution of the scans is a potential solution. However, it was proven 
to cause large changes in the image intensities, underestimation of MTT and overestimation 
of BV and BF (Wintermark et al 2004). In the radiomics analysis of CTP the instability of 
intensity histogram-based parameters was observed in respect to different temporal resolu- 
tions. Nevertheless, some of the higher order radiomic parameters were found to be stable. A 
treatment response prognostic model based on higher order radiomic parameters could   thus 
allow both for an increase in temporal resolution and a dose reduction. 
Among 945 studied radiomic parameters 255 were found to be stable in both tumor enti- 
ties. However, most of them were correlated with each other and thus created groups. In some 
of the groups the differences in the ICC between different radiomic parameters were minor. 
Despite the fact that only the parameters with highest ICC were included in the final set, all 
the parameters in the groups are good candidates for the input to a prognostic model. Further 
studies are needed to identify the strongest prognostic parameters in these groups. 
Several studies already showed the instability of the radiomics signature in medical images 
in respect to acquisition and post-processing protocols (Mayerhoefer et al 2009, Galavis et al 
2010, Cunliffe et al 2012, Duda et al 2013, Leijenaar et al 2013, 2015, Maani et al 2013, Yan 
et al 2015, van Velden et al 2016). The need for standardization of image discretization and 
voxel size was shown to be of a great importance in PET images (Galavis et al 2010, Leijenaar 
et al 2015, Yan et al 2015, Lu et al 2016). This study showed that in CTP maps additionally 
to the standardization of these two factors the standardization of HU intervals and temporal 
resolution is recommended. 
There are some additional factors, which may influence tumor radiomics signature in CTP, 
but were not evaluated in this study. E.g. it is well known that perfusion estimation depends on 
the used calculation model (Kudo et al 2010) and its influence on radiomic parameters needs 
to be further studied. Additionally, inter-observer variability in tumor contouring was shown 
to influence tumor radiomic features stability in PET and CT images (Leijenaar et al 2013, 
Parmar et al 2014, Lu et al 2016). In this study tumors were contoured by an experienced 
radiation oncologist and inter-observer variability was not considered. 
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Conclusion 
 
CT perfusion calculation factors greatly influence the stability of radiomic parameters. Voxel 
size, image discretization, HU intervals and temporal resolution have to be standardized to 
build a reliable prognostic model based on CTP radiomics analysis. A set of 10 stable radiomic 
parameters in CTP was identified for two tumor entities. This marker set will next be evaluated 
in clinical correlative studies for its propensity to predict treatment outcome. 
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Results
Tumor entity Perfusion map Stable parameter
Blood flow
OPC Mean transit time Information measure of correlation 1
Blood volume
Blood flow LLL mean
NSCLC Mean transit time
HLH Information measure of correlation 1, LHH Information
measure of correlation 1, LLL entropy
Blood volume mean, LHL Information measure of correlation 1, LLL mean,LLL covariance, LLL Information measure of correlation 1
Table S1. List of the stable texture parameters. In the case of NSCLC stable parameters created four groups of correlated
parameters. In each group the most stable parameter was underlined.
Tumor entity Number ofgroups Perfusion map Stable parameter
OPC 34 Blood flow covariance, sum entropy, HHH kurtosis, HHH average,HLH average, LHH skewness, LLL average
Mean transit time
fractal dimension, HLH average, HLL mean, LHH
maximal correlation coefficient, LHL average, LLL
busyness, LLL fractal dimension
Blood volume
covariance, kurtosis, energy, entropy, difference entropy,
coarseness, low gray-level size emphasis, long size high
gray-level emphasis, HHL skewness, HHL average, HLH
average, HLL mean, LHH mean, LHH average, LHL
mean, LHL average, LHH average, LLL standard
deviation, LLL covariance, LLL average
NSCLC 13 Blood flow mean, variance, sum entropy, HLH information measureof correlation 2
Mean transit time LLL entropy
Blood volume
mean, correlation, difference entropy, information
measure of correlation 2, coarseness, long size high
gray-level emphasis, HLL long ize high gray-level
emphasis, LHL long size emphasis
Table S2. List of the stable and uncorrelated texture parameters after standarization of image discretization, HU threshold,
voxel size and temporal resolution. OPC – oropharyngeal carcinoma, NSCLC – non–small cell lung cancer.
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Figure S1. The average intraclass correlation (ICC) in respect to artery contouring and noise threshold (potentially
non–standardizable factors). The correlated texture parameters are marked with the same color. The ICC is given only for the
stable parameters.
Columns correspond to different types of images: BF – blood flow, MTT – mean transit time, BV – blood volume, none –
original image, HHH, HHL, HLH, HLL, LHH, LHL, LLH, LLL – 3D wavelet transforms, H – high–pass filter, L – low–pass
filter.
Rows correspond to different texture parameters: HI – histogram of intensities, GLCM – Gray Level Co-occurrence Matrix,
NGTDM – Neighborhood Gray Tome Difference Matrix, GLSZM – Gray Level Size Zone Matrix, 1 – mean, 2 – standard
deviation, 3 – covariance, 4 – skewness, 5 – kurtosis, 6 – energy, 7 – entropy, 8 – contrast, 9 – correlation, 10 – homogeneity, 11
– variance, 12 – average, 13 – sum of entropy, 14 – sum of variance, 15 – difference entropy, 16 – difference variance, 17 –
information measure of correlation 1, 18 – information measure of correlation 2, 19 – maximal correlation coefficient, 20 –
coarseness, 21 – contrast, 22 – busyness, 23 – complexity, 24 – gray–level non–uniformity, 25 – size zone non–uniformity, 26 –
short size emphasis, 27 – long size emphasis, 28 – low gray–level size emphasis, 29 – high gray–level size emphasis, 30 – short
size low gray–level emphasis, 31 – short size high gray–level emphasis, 32 – long size low gray–level emphasis, 33 – long size
high gray–level emphasis, 34 – size percentage 35 – fractal dimension.
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Figure S2. Robustness of texture parameters regarding artery contouring . The mean values of blood volume and blood flow
(row number 1) were stable for non–small cell lung cancer (NSCLC) but not for oropharyngeal cancer (OPC) in respect to
artery contouring. Changes in the noise caused instability of the mean MTT in both tumor sites.
Columns correspond to different types of images: BF – blood flow, MTT – mean transit time, BV – blood volume, none –
original image, HHH, HHL, HLH, HLL, LHH, LHL, LLH, LLL – 3D wavelet transforms, H – high–pass filter, L – low–pass
filter.
Rows correspond to different texture parameters: HI – histogram of intensities, GLCM – Gray Level Co-occurrence Matrix,
NGTDM – Neighborhood Gray Tome Difference Matrix, GLSZM – Gray Level Size Zone Matrix, 1 – mean, 2 – standard
deviation, 3 – covariance, 4 – skewness, 5 – kurtosis, 6 – energy, 7 – entropy, 8 – contrast, 9 – correlation, 10 – homogeneity, 11
– variance, 12 – average, 13 – sum of entropy, 14 – sum of variance, 15 – difference entropy, 16 – difference variance, 17 –
information measure of correlation 1, 18 – information measure of correlation 2, 19 – maximal correlation coefficient, 20 –
coarseness, 21 – contrast, 22 – busyness, 23 – complexity, 24 – gray–level non–uniformity, 25 – size zone non–uniformity, 26 –
short size emphasis, 27 – long size emphasis, 28 – low gray–level size emphasis, 29 – high gray–level size emphasis, 30 – short
size low gray–level emphasis, 31 – short size high gray–level emphasis, 32 – long size low gray–level emphasis, 33 – long size
high gray–level emphasis, 34 – size percentage 35 – fractal dimension.
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Figure S3. Robustness of texture parameters regarding noise level threshold. Changes in the noise caused instability of the
mean MTT (row number 1) in both tumor sites.
Columns correspond to different types of images: BF – blood flow, MTT – mean transit time, BV – blood volume, none –
original image, HHH, HHL, HLH, HLL, LHH, LHL, LLH, LLL – 3D wavelet transforms, H – high–pass filter, L – low–pass
filter.
Rows correspond to different texture parameters: HI – histogram of intensities, GLCM – Gray Level Co-occurrence Matrix,
NGTDM – Neighborhood Gray Tome Difference Matrix, GLSZM – Gray Level Size Zone Matrix, 1 – mean, 2 – standard
deviation, 3 – covariance, 4 – skewness, 5 – kurtosis, 6 – energy, 7 – entropy, 8 – contrast, 9 – correlation, 10 – homogeneity, 11
– variance, 12 – average, 13 – sum of entropy, 14 – sum of variance, 15 – difference entropy, 16 – difference variance, 17 –
information measure of correlation 1, 18 – information measure of correlation 2, 19 – maximal correlation coefficient, 20 –
coarseness, 21 – contrast, 22 – busyness, 23 – complexity, 24 – gray–level non–uniformity, 25 – size zone non–uniformity, 26 –
short size emphasis, 27 – long size emphasis, 28 – low gray–level size emphasis, 29 – high gray–level size emphasis, 30 – short
size low gray–level emphasis, 31 – short size high gray–level emphasis, 32 – long size low gray–level emphasis, 33 – long size
high gray–level emphasis, 34 – size percentage 35 – fractal dimension.
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Texture analysis
Texture analysis of CT perfusion maps is more demanding in comparison to analysis of PET or CT images. The application
of a HU threshold in the perfusion calculations causes discontinuities in the image, which has to be taken into account in the
texture quantification. ‘Not a number’ value is assigned to these discontinuities in our perfusion calculation software. In this
study the definitions of matrices were adjusted accordingly (see definitions below). The wavelet transform was performed in
the perfusion maps using PyWavelets library and ‘Coif1’ wavelet. Before the transformation, discontinuities in the perfusion
maps were replaced with the mean perfusion value in the tumor to avoid the loss of the outer voxels in the transformation
process (Figure S4). ‘Not a number’ value was assigned back to the voxels in the transformed image that corresponded to the
discontinuities in the original image.
The anisotropy of voxels was not take into account in the calculation of texture and wavelet transform.
The texture parameters studied in this paper are listed in Table S3. Parameters were computed on the different levels: global
(histogram of intensities and fractal dimension), regional (Gray Level Size Zone Matrix) and local (Gray Level Co-occurrence
Matrix and Neighborhood Gray Tome Difference Matrix).
Histogram of intensities
The parameters from the histogram of intensities were calculated in the perfusion maps before a discretization. Let X denotes
the intensities of the 3D image with N voxels. X – mean of X.
mean =
1
N
N
∑
i=1
Xi
standard deviation =
√
1
N−1
N
∑
i=1
(Xi−X)2
covariance =
√
1
N ∑
N
i=1
(
Xi−X
)2
X
skewness =
1
N ∑
N
i=1(Xi−X)3(√
1
N ∑
N
i=1(Xi−X)2
)3
kurtosis =
1
N ∑
N
i=1
(
Xi−X
)4(√
1
N−1 ∑
N
i=1
(
Xi−X
)2)4 −3
Gray Level Co–occurrence Matrix
The parameters from the Gray Level Co–occurrence Matrix1 were calculated in all 26 directions with a distance of one voxel.
The final parameters were the average of all directions. If one of the voxels had a ‘not a number’ value the pair was not taken
into account in the calculations. Let Pi j denotes the (i,j) entry in the Gray Level Co–occurrence Matrix, Ng – number of gray
tones in a studied structure, Pxi – summation of the rows in the P (Pxi =∑
Ng
j=1 Pi j), Pyi =∑
Ng
i=1 Pi j, Px+y(k) =∑
Ng
j=1∑
Ng
j=1 Pi j where
k = i+ j, Px−y(k) = ∑
Ng
j=1∑
Ng
j=1 Pi j where k =| i− j |.
energy =
Ng
∑
i=1
Ng
∑
j=1
P2i j
contrast =
Ng−1
∑
n=0
n2
(
Ng
∑
i=1
Ng
∑
j=1
Pi j
)
, for | i− j |= n
correlation =
∑Ngi=1∑
Ng
j=1 i jPi j−µxµy
σxσy
where: µx = ∑
Ng
i=1∑
Ng
j=1 iPi j , µy = ∑
Ng
i=1∑
Ng
j=1 jPi j , σx = ∑
Ng
i=1∑
Ng
j=1 Pi j(i−µx)2 , σy = ∑
Ng
i=1∑
Ng
j=1 Pi j( j−µy)2.
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sum of squares =
Ng
∑
i=1
Ng
∑
j=1
(i−µ)2Pi j , where µ – mean of P
inverse difference moment (homogeneity) =
Ng
∑
i=1
Ng
∑
j=1
Pi j
1+(i− j)2
sum of average =
2Ng
∑
i=2
i ·Px+y(i)
sum of variance =
2Ng
∑
i=2
(i− sum entropy)2 Px+y(i)
sum entropy =−
2Ng
∑
i=2
Px+y(i) log(Px+y(i))
entropy =−
Ng
∑
i=1
Ng
∑
j=1
Pi j log(Pi j)
difference variance = variance of px−y
difference entropy =−
Ng−1
∑
i=1
Px−y(i) log(Px−y(i))
information measures of correlation 1 =
(
−∑Ngi=1∑
Ng
j=1 Pi j log(Pi j)
)
−
(
−∑Ngi=1∑
Ng
j=1 Pi j log(PxiPy j)
)
max{−∑Ngi=1 Pxi log(Pxi),−∑
Ng
j=1 Py j log(Py j)}
information measures of correlation 2 =
√√√√1− exp[−2(− Ng∑
i=1
Ng
∑
j=1
PxiPy j log(PxiPy j)+
Ng
∑
i=1
Ng
∑
j=1
Pi j log(Pi j)
)]
maximal correlation coefficient =
√√√√second largest eigenvalue of Ng∑
k=1
PikPjk
PxiPyk
Neighborhood Gray Tone Difference Matrix
The Neighborhood Gray Tone Difference Matrix2 was calculated based on 26 adjacent voxels. The voxels with ‘not a number’
value were excluded from the average over the neighborhood region. Let si denotes the ith entry in the Neighborhood Gray
Tone Difference Matrix, Ni – the number of voxels having gray tone i, G – number of gray tones in a studied structure, n –
number of studied voxels.
coarseness =
[
ε+
G
∑
i=1
Ni
n
si
]−1
where ε is a small number to prevent coarseness becoming infinite.
contrast =
[
1
Ng(Ng−1)
G
∑
i=1
G
∑
j=1
Ni
n
N j
n
(i− j)2
][
1
n
G
∑
i=1
si
]
where Ng is the total number of different gray levels present in the image.
busyness =
∑Gi=1
Ni
n si
∑Gi=1∑
G
j=1 i
Ni
n − j
N j
n
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for Nin 6= 0 and
N j
n 6= 0.
complexity =
G
∑
i=1
G
∑
j=1
(| i− j |)
(
Ni
n si +
N j
n s j
)
Ni +N j
for Ni 6= 0 and N j 6= 0.
Gray Level Size Zone Matrix
In the Gray Level Size Zone Matrix3 calculations the voxels with ‘not a number’ value were excluded from the analysis. Let Pi j
denotes the (i,j) entry in the Gray Level Size Zone Matrix, i – gray value, j – size, nr – number of homogeneous areas inside a
studied structure.
gray–level non–uniformity =
1
nr
M
∑
i=1
(
N
∑
j=1
Pi j
)2
size zone non–uniformity =
1
nr
N
∑
j=1
(
M
∑
i=1
Pi j
)2
short size emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j
j2
long size emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j · j2
low gray–level size emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j
i2
high gray–level size emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j · i2
short size low gray–level emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j
i2 · j2
short size high gray–level emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j · i2
j2
long size low gray–level emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j · j2
i2
long size high gray–level emphasis =
1
nr
M
∑
i=1
N
∑
j=1
Pi j · i2 · j2
size percentage =
nr
number of voxels in the studied structure
Fractal dimension
The fractal dimension was calculated using box contouring technique and fixed grid scans excluding the voxels with ‘not a
number’ value.4
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Figure S4. The scheme of wavelet transform in CT perfusion maps, H – high–pass filter, L – low–pass filter.
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Model Level Parameter
Statistical model Global Mean
Histogram of intensities Standard deviation
Covariance
Skewness
Kurtosis
Statistical model Local Energy
Gray Level Contrast
Co–occurrence Matrix Correlation
Sum of squares
Inverse difference moment (homogeneity)
Sum of average
Sum of variance
Sum entropy
Entropy
Difference variance
Difference entropy
Information measures of correlation 1
Information measures of correlation 2
Maximal correlation coefficient
Statistical model Local Coarseness
Neighborhood Gray Contrast
Tone Difference Matrix Busyness
Complexity
Statistical model Regional Gray–level non-uniformity
Gray Level Size Zone Size zone non–uniformity
Matrix Short size emphasis
Long size emphasis
Low gray–level size emphasis
High gray–level size emphasis
Short size low gray–level emphasis
Short size high gray–level emphasis
Long size low gray–level emphasis
Long size high gray–level emphasis
Size percentage
Model–based Global Fractal dimension
Table S3. List of the computed texture parameters.
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Summary
This study shows that higher
pretreatment tumor hetero-
geneity, quantified using
radiomics of contrast-
enhanced computed
tomography, is associated
with worse prognosis in head
and neck squamous cell car-
cinoma and the absence of
human papillomavirus infec-
tion. Overall, our analysis
provides evidence that a
radiomic signature might be
a useful input in risk assess-
ment in addition to clinical
parameters (tumor stage,
tumor volume, and HPV
status).
Purpose: This study aimed to predict local tumor control (LC) after radiochemother-
apy of head and neck squamous cell carcinoma (HNSCC) and human papillomavirus
(HPV) status using computed tomography (CT) radiomics.
Methods and Materials: HNSCC patients treated with definitive radiochemotherapy
were included in the retrospective study approved by the local ethical commission
(93 and 56 patients in the training and validation cohorts, respectively). Three hundred
seventeen CT radiomic features, including those based on shape, intensity, texture, and
wavelet transform, were calculated in the primary tumor region. Cox and logistic
regression models were built to predict LC and HPV status, respectively. The best-
performing features in the univariable analysis were included in the multivariable anal-
ysis after the exclusion of redundant features. The quality of the models was assessed
using the concordance index (CI) for modeling of LC and receiver operating charac-
teristics area under the curve (AUC) for HPV status prediction. The radiomics LC
model was compared to a model incorporating clinical parameters (tumor stage, vol-
ume, and HPV status) and a mixed model.
Results: A radiomic signature comprising 3 features was significantly associated with
LC (CItraining Z 0.75 and CIvalidation Z 0.78), showing that tumors with a more het-
erogeneous CT density distribution are at risk for decreased LC. The addition of clin-
ical parameters to the radiomics model slightly improved the model in the training
cohort but not in the validation cohort. Another radiomic signature showed good
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performance in HPV status prediction (AUCtraining Z 0.85 and AUCvalidation Z 0.78)
and indicated that HPV-positive tumors have a more homogenous CT density
distribution.
Conclusions: Heterogeneity of HNSCC tumor density, quantified by CT radiomics, is
associated with LC after radiochemotherapy and HPV status.  2017 Elsevier Inc. All
rights reserved.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
fifth most common cancer worldwide. The standard of care
for advanced unresectable cases is definitive radio-
chemotherapy. The clinical outcome after radio-
chemotherapy is very heterogeneous, ranging from about
80% locoregional control and 5 years overall survival in
human papillomavirus (HPV)-positive oropharyngeal car-
cinoma (OPC) to below 50% in HPV-negative OPC and
non-OPC (1, 2). In all cases, distant metastasis is infre-
quent and is mainly a consequence of locoregional
treatment failure. Therefore, improvement of radio-
chemotherapy is essential. An important approach is the
development of tumor biomarkers that can predict locore-
gional tumor control to identify patients for treatment
intensification.
Radiomics is a promising tool for noninvasive charac-
terization of tumor phenotype. It extracts a large number of
quantitative features from radiographic images: regions of
interest are characterized regarding their shape, intensities,
and texture of both spatial and frequency domains (for
example, using a wavelet transform) (3). A correlation
between radiomic features and treatment response has been
shown using different image modalities and for different
tumor types (4, 5). To provide a biological interpretation of
radiomics, several groups have tried to relate a radiomic
signature (set of radiomic parameters) to differential gene
expressions, including tumor proliferation and molecular
subtypes (6, 7).
Although several computed tomography (CT)
radiomics-based prognostic models have been proposed for
HNSCC (8), it is not fully understood why a particular
radiomic phenotype is associated with treatment response.
CT radiomics of the primary tumor was successfully used
to stratify patients into low-risk and high-risk groups in
terms of patient overall survival (6, 8-10). It was shown to
further improve survival models based on clinical param-
eters, such as TNM stage and tumor volume (6). Whereas
overall survival is an important clinical endpoint, it is also
influenced by nonetumor-related factors (11), which
cannot be captured by pretreatment radiomics of the pri-
mary tumor. However, especially in the case of HNSCC, it
is important to understand the influence of intratumor het-
erogeneity on the local response to treatment. Therefore, a
study using local tumor control as endpoint is of high
clinical interest. Furthermore, the correlation of radiomic
phenotype to the important outcome prognostic factor HPV
is of interest and links image analysis with tumor biology
(12, 13). Exploratory studies have already indicated a
relationship between HPV infection and the heterogeneity
of imaging-based tumor density (12, 13). However, these
studies were based on small patient numbers and lacked
validation cohorts.
In this study we investigated whether a CT-based
radiomic phenotype of HNSCC is correlated with local
tumor control after radiochemotherapy. Furthermore, using
2 large patient cohorts, we studied the influence of HPV
infection on tumor radiomics.
Methods and Materials
Studied population
This study was a retrospective analysis approved by the
local ethical commission. The training cohort consisted of
93 patients with stage III and IV HNSCC who were
treated between 2003 and 2013 with definitive radiation
therapy (on average 70 Gy) either in combination with
cisplatin (40 mg/m2, up to 7 cycles) or cetuximab (loading
dose 400 mg/m2 followed by 250 mg/m2 weekly). In-
duction chemotherapy or prior surgery (biopsy allowed),
were exclusion criteria. Additionally, data from 56 pa-
tients with the same tumor stages from an institutional
phase 3 prospective study (NCT01435252) with a stan-
dardized planning CT imaging protocol were selected as a
validation cohort. In the latter study, patients were treated
with triple therapy consisting of radiation therapy and
weekly concurrent cisplatin/cetuximab (same doses as in
training cohort) with or without consolidation cetuximab
(500 mg/m2 biweekly  6). Radiation therapy was
delivered with an intensity modulated technique in all
patients.
All patients underwent pretreatment contrast-enhanced
planning CT imaging. Patient characteristics and imaging
protocols are presented in Table 1. In all patients, the HPV
status was determined by immunohistochemical p16
staining. Local recurrence was defined as biopsy-proven
recurrence within the high-dose planning target volume of
the primary tumor. Follow-up consisted of examinations
every 2 to 3 months by ear, nose, and throat specialists and
repeated 18F-fluorodeoxyglucose positron emission to-
mography 18F-FDG PET/CT imaging.
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Radiomics analysis and image postprocessing
An in-house-developed radiomics software implementation
written in Python programming language was used. It
provides 3-dimensional (3D) analysis of medical images
using all 4 feature extraction methods:
1. Shape (nZ11)
2. Intensity (nZ5)
3. Texture: the Gray Level Co-occurrence matrix (nZ14),
the Neighborhood Gray Tone Difference matrix (nZ4)
and the Gray Level Size Zone matrix (nZ11)
4. Wavelet transform using Coiflet function (8 sub-bands,
nZ272)
In total, 317 features were extracted per patient. For
intensity, texture, and wavelet analysis, images were
resized to the symmetrical voxels of size 3.3 mm, corre-
sponding to the lowest image resolution (sagittal) in the
training cohort. Additionally, a Hounsfield Units range of
20 to 180 HU was applied to limit the analysis to soft
tissue only. To quantify the texture, images were resampled
to equally spaced bins of 5 HU. A detailed description of
radiomics implementation is presented in the Appendix
(available online at www.redjournal.org).
The tumor heterogeneity was studied inside the primary
gross tumor volume (GTV) defined on the contrast-
enhanced planning CT by a radiation oncologist with
more than 10 years of experience. Contours were post-
processed to account for metal artifacts occurring in the
CT images. Contours were removed from artifact-affected
slices. Scans with more than a half of the contoured slices
affected by metal artifacts were not included in the
analysis.
Radiomic interfeatures correlations
Radiomic features were grouped according to principal
component analysis using data from the training cohort to
account for the interfeatures correlations. The Horn method
was used to choose the optimal number of retained com-
ponents (14). The contribution of radiomic features to
principal components was determined. Features were
assigned to a principal component to which they contrib-
uted the most. Each principal component corresponded to
Table 1 Studied patient cohorts and imaging protocol details
Characteristic Training cohort Validation cohort
Number of patients 93 56
Number of recurrences 24 (25%) 14 (25%)
Median follow-up [months] 47 (3-156)* 16 (3-28)*
Age [years]* 61.9 (41.9-74.5) 59.8 (47.2-75.7)
HPV status
p16 positive 36 (39%) 26 (46%)
p16 negative 57 (61%) 30 (54%)
Tumor stage
T1/T2 33 (36%) 9 (16%)
T3/T4 60 (64%) 47 (84%)
Nodal stage
N0 15 (16%) 10 (18%)
N1 5 (5%) 4 (7%)
N2 69 (74%) 40 (71%)
N3 4 (5%) 2 (4%)
Tumor site
Oropharynx 70 (75%) 30 (54%)
Hypopharynx 18 (19%) 8 (14%)
Larynx 4 (5%) 9 (16%)
Oral cavity 1 (1%) 9 (16%)
Sex
Female 21 (23%) 13 (23%)
Male 72 (77%) 43 (77%)
Scanning parameters
CT scanners Siemens SOMATOM Volume Zoom (nZ64)
Siemens SOMATOM Definition AS (nZ22)
GE Discovery STE (nZ5)
Siemens SOMATOM Definition AS (nZ56)
Slice thickness [mm] 1.25-3.30 2
In-plane resolution [mm] 0.85-1.95 0.98-1.56
kV 120-140 120
mAs 60-450 183-450
* Median; range in parentheses.
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one group of correlated features. The statistical analysis
was performed in R (version 3.2.4) (15).
Prognostic value of radiomics for local tumor
control
Radiomic features prognostic for local tumor control
were preselected in the univariable Cox regression
analysis. The results were corrected for multiple testing
with a false discovery rate (FDR) <0.20. Additionally,
the correlated features were excluded from further anal-
ysis by selecting only the most prognostic parameter per
principal component feature group. Feature prognostic
value was quantified using a concordance index (CI)
(16). The preselected features were entered in the
multivariable Cox regression analysis. The radiomics-
based model was compared with a multivariable model
created with clinical parameters: tumor volume, T stage
(T1/T2 vs T3/T4), and HPV status. Finally, a mixed
model was created, wherein both radiomic features and
clinical parameters were incorporated in the multivari-
able Cox model. All multivariable models were built
using an Akaike information criterion in the backward
selection of variables. The prognostic value of obtained
models was compared based on the CI, using the Wil-
coxon test (P<.05) and the bootstrap method with 100
randomly selected samples to calculate the CI distribu-
tion. The results were verified in the validation cohort.
Curves were split based on the optimal threshold from
the receiver operating characteristic curve at 18 months
maximizing both sensitivity and specificity and compared
using G-rho test (P<.05).
Prediction of HPV status
The radiomic features for HPV status prediction were also
preselected using principal component analysis in combi-
nation with univariable logistic regression. The univariable
model accuracy was quantified by the area under the
receiver operating characteristic curve (AUC). The results
were corrected for multiple testing with FDR <0.20. A
radiomic feature characterized by the highest AUC was
selected in each principal component group. This set was
later used in multivariable logistic regression with back-
ward selection of the variables. The cutoff threshold of the
final model was set to maximize both sensitivity and
specificity in the training cohort. The results were again
verified in the validation cohort.
Results
Radiomics-based prognostic model for local tumor
control
Nine components were selected in the principal component
analysis, which led to 9 groups of correlated radiomic
features. The group sizes varied from 21 to 66 features. In
the univariable Cox regression analysis, 83 of 317 radiomic
features were found to be prognostic for local tumor control
(FDR <0.20). The list of the most prognostic features,
accounting for interfeature correlations, is shown in
Table 2. In the multivariable analysis with the backward
selection of variables, 3 out of 9 previously mentioned
features were selected (HHH large zone high gray-level
emphasis, LLL sum entropy, and LLH difference variance),
resulting in a model with CI of 0.75. This model was found
to be prognostic also in the validation cohort with
CIZ 0.78 and significant for stratification into groups with
low risk and high risk of recurrence (Fig. 1, Table 3).
Additionally, the model was prognostic in the subgroup
analysis of OPC and of HPV-negative tumors (Table E1 and
Fig. E2 of the Appendix; available online at www
.redjournal.org). Different CT scanners and kV settings
did not show a major influence on the radiomic features
included in the model (Fig. E6; available online at www
.redjournal.org).
Comparison of the radiomics-based and clinical-
based prognostic models for local tumor control
The radiomics-based model was compared with a model
incorporating known prognostic clinical parameters (tumor
volume, T stage, and HPV status) and also with a mixed
model (radiomics and clinical parameters). The parameters
chosen in the multivariable analysis and the results of
Wilcoxon test, studying differences between the models,
are presented in Table 3. The combination of radiomics
(LLH difference variance) and clinical parameters (HPV
and tumor volume) was found to have the highest prog-
nostic power (CI Z 0.80) in the training cohort but per-
formed worse than the radiomics-based model in the
validation cohort. The same trend was observed for the
subgroup of OPC (Table E1 of the Appendix; available
online at www.redjournal.org). In the mixed model, the
Table 2 Uncorrelated (independent) radiomic features
prognostic for local tumor control in the univariable Cox
regression analysis
Feature group Feature name CI FDR
1 LLL sum entropy* 0.75 0.11
2 LHL IMC1 0.67 0.12
3 HHH large zone high gray-level
emphasis*
0.68 0.13
4 HHL contrastNGTDM 0.69 0.19
5 LLH difference variance* 0.65 0.16
6 HLH complexity 0.64 0.16
7 Sum entropy 0.64 0.16
8 LHH MCC 0.68 0.12
9 LHL low gray-level emphasis 0.70 0.12
Abbreviations: CI Z concordance index; FDR Z false discovery
rate.
* The features selected in the multivariable Cox regression analysis.
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single radiomic feature was not significant; however, it had
a significant impact on the improvement of the model
discriminative power (Table E2 of the Appendix; available
online at www.redjournal.org).
Prediction of HPV status
In total, 86 radiomic features were significant for HPV
status prediction (FDR <0.20). Per group of correlated
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Fig. 1. Radiomics-based local tumor control model. The model consists of 3 radiomic features: HHH large size high gray-
level emphasis, LLL sum entropy, and LLH difference variance. Survival curves split significantly (G-rho test P <.001) in
both training and validation cohorts based on the optimal sensitivity-specificity threshold.
Table 3 Comparison of the prognostic models for local tumor control
Model Parameters of the model
Training cohort Validation cohort
CI P CI P
Radiomics HHH large zone high gray-level emphasis
LLL sum entropy
LLH difference variance
0.75 (0.74-0.76) <.001 0.78 (0.77-0.79) <.001
Clinical Stage
Tumor volume
HPV
0.79 (0.78-0.80) 0.73 (0.71-0.75)
Radiomics HHH large zone high gray-level emphasis
LLL sum entropy
LLH difference variance
0.75 (0.74-0.76) <.001 0.78 (0.77-0.79) <.046
Radiomics þ clinical LLH difference variance
Tumor volume
HPV
0.80 (0.79-0.81) 0.76 (0.75-0.77)
Abbreviation: CI Z concordance index (its 95% confidence interval in parentheses).
Wilcoxon test P are given for the comparison of the models performance (radiomics vs clinical and radiomics vs radiomics þ clinical).
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features, the feature characterized with the highest AUC
was chosen (Table 4) and entered in the multivariable
logistic regression. The final model comprised 4 radiomic
features:
1. LLL standard deviation
2. LLL small zone high gray-level emphasis
3. HHL difference entropy
4. Coefficient of variation
The final radiomic model for HPV status prediction
showed a good performance in both the training cohort
(AUCZ 0.85) and the validation cohort (AUCZ 0.78). The
specificity of the model was higher in the validation cohort
than in the training cohort (specificitytraining Z 0.72 and
specificityvalidationZ 0.82), whereas the sensitivitywas lower
(sensitivitytraining Z 0.72 and sensitivitytraining Z 0.62).
Figure 2 presents the receiver operating characteristics for
the model. The HPV radiomic signature was independent
from the local control signature because the radiomic fea-
tures in these 2 models were not correlated and the HPV
predictionmodelwas valid in patient subgroups regardless of
tumor control (Appendix Fig. E3). Similar to the local tumor
control model, we did not observe major variations in our
HPV radiomic signature depending on the CT scanner and
kV settings (Fig. E7 of the Appendix; available online at
www.redjournal.org).
Discussion
This study evaluated the prognostic value of contrast-
enhanced CT-based radiomics in HNSCC regarding local
tumor control and HPV status. The radiomics-based local
control model was compared with a model based on
prognostic clinical parameters (tumor stage, tumor volume,
and HPV status) and with the mixed model (clinical plus
radiomics). The performance of the models was verified
in an independent cohort of patients. Although the
radiomics-based model achieved a lower concordance
index in comparison with the mixed model in the training
cohort, it showed a significantly higher performance in the
validation cohort. The stable performance of the radiomics-
based model in both the training and the validation patient
cohorts emphasizes its high credibility. Radiomics was also
shown to be closely associated with the HPV status with
AUC values of 0.85 and 0.78 in the training cohort and the
validation cohort, respectively.
In the case of HNSCC, locoregional control closely
correlates with overall survival (17). Prediction of local
treatment efficacy is of high interest in modifying treatment
according to the individual tumor’s radiosensitivity. The
radiomics model created by us was highly prognostic for
local tumor control; the addition of the clinically relevant
biomarker, HPV status, could only slightly improve the
model in the training cohort but not in the validation cohort.
Similar results were observed for the analysis of OPC pa-
tients only (Table E1 of the Appendix; available online at
www.redjournal.org), which indicates slight overfitting of
the mixed model (radiomics and clinical predictors) in the
training cohort. The value of the radiomic feature (LLH
difference variance) in the mixed model should be studied
in more detail. This covariate was not significant in the
multivariable modeling but had a positive impact on the
discriminative power of the model, especially in the vali-
dation cohort. The training and validation cohorts were not
perfectly matched. The validation cohort was characterized
by a higher percentage of more advanced tumors, lower
share of OPC, and higher percentage of HPV-positive tu-
mors. Additionally, the follow-up times were longer in the
training cohort; however, a similar percentage of tumor
recurrences was observed in both cohorts. Overall, we
Table 4 Uncorrelated (independent) radiomic features for
HPV status prediction
Feature group Feature name AUC FDR
1 LLL gray-level non-uniformity 0.77 0.053
2 LLL standard deviation* 0.83 0.002
3 Difference entropy 0.76 0.004
4 LLL small zone high gray-level
emphasis*
0.78 0.004
5 HHL difference entropy* 0.67 0.143
6 Compactness 2 0.66 0.077
7 Standard deviation 0.79 0.004
8 Coefficient of variation* 0.69 0.071
9 Spherical disproportion 0.66 0.069
Abbreviations: AUC Z area under the curve; FDR Z false
discovery rate.
* The features selected in the multivariable logistic regression.
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showed that a radiomic signature might be a useful input in
risk assessment in addition to clinical parameters. An
additional validation could confirm or contradict the benefit
of including radiomics in the modeling.
In our study, we observed that local tumor control is
linked more closely to heterogeneity of the CT density than
to tumor shape, including tumor volume. Tumors that are
characterized by more homogenous CT density have a
higher probability of local control (Fig. E4; available online
at www.redjournal.org). The HHH large zone high gray-
level emphasis was lower in the group of controlled tu-
mors, which corresponds to fewer patches of large co-
efficients in the image transformed with 3D high-pass filter.
Additionally, the LLL sum entropy was also lower, which
relates to a more repeatable pattern of intensity changes in
the neighboring voxels. The biology behind this more ho-
mogenous texture is unknown but warrants further inves-
tigation. It can only be speculated that texture heterogeneity
might be related to differential biology within the tumor.
On the biological level, a more heterogeneous microenvi-
ronment (eg, related to tumor perfusion, necrosis, or tumor
hypoxia) is also known to be associated with a more
resistant phenotype, especially in HNSCC. Our findings
agree with the findings of a previously published study
showing that tumor heterogeneity in CT radiomics was
related to worse overall survival (6). Our model shows a
higher performance than the overall survival model, which
suggest that an additional input, for example the radiomics
of lymph node metastasis, might improve the latter.
Another set of CT radiomic features was found to be
associated with p16 staining. The integration in the host
genome and the expression of the viral protein E7, through
inactivation of the retinoblastoma protein, leads to an upre-
gulation of p16INK4a and correlates strongly with active HPV
infection. Therefore, the immunohistochemical detection of
the expression level of p16INK4a is now a widely accepted
surrogate marker for transcriptionally active HPV infections
(18). Our results show that HPV-positive tumors seem to be
more homogenous in CT density (Fig. E5 of the Appendix;
available online at www.redjournal.org). The HPV-positive
tumors were characterized by a significantly lower coeffi-
cient of variation and LLL standard deviation, which refers to
a smaller width of density distribution in the tumor. They also
presented lower LLL small zone high gray-level emphasis,
corresponding to a lower number of small regions with high
intensity. The more homogenous density of HPV-positive tu-
mors also seems to fit the hypothesis that tumor homogeneity
is correlated to a more favorable phenotype of HNSCC. Our
results, observed in 2 independent patient cohorts, support the
hypothesis presented in the explanatory studies (12, 13) that
HPV infection is related to tumor density homogeneity.
Although both local tumor recurrence and HPV radio-
mic signatures refer to heterogeneity in tumor CT density,
they consisted of different radiomic features. No strong
correlation between features in different models was
observed. The local recurrence signature was also prog-
nostic in the subgroup of HPV-negative patients (Fig. E2;
available online at www.redjournal.org). It suggests that the
local recurrence radiomic signature is not driven by HPV
status.
Certain limitationswere present in this study. The analysis
was based on single-center data, although patients enrolled in
this study were divided into training and validation cohorts;
also, the scanning protocol was not standardized for the
training cohort, and 3 different types of CT scanners were
used. The proposed models should be further validated in an
external cohort to test them against different contouring
protocols and different scanners. The interobserver vari-
ability in GTV definition in head and neck cancer is a known
issue (19); however, its influence on CT radiomics remains
unclear. Additionally, the stability of the features should be
evaluated in a test-retest study. Furthermore, patients in the
training and validation cohorts were treated with different
forms of concurrent systemic therapy: with either cisplatin or
cetuximabweekly in the training cohort andwith both agents,
cisplatin and cetuximab, in the consolidation cohort. Of note,
the radiomics model seemed to be robust against the choice
of concurrent systemic therapy. Moreover, the scanning grid
size varied among the patients, which is known to influence
stability of texture (20). However, there is no consensus in the
literature about the best correction method; in our study the
resampling approach to isotropic voxels using linear inter-
polation was used. These results cannot be directly translated
to any other resolution. The investigation of HPV influence
on the tumor structure in CT images is just a first step in
understanding tumor heterogeneity in CT. Further studies
correlating CT radiomics to histology markers and gene
expression are needed.
In conclusion, this study shows that tumor heterogeneity,
quantified using contrast-enhanced CT radiomics, is asso-
ciated with local tumor control and HPV status in HNSCC.
The radiomics-based local tumor control model showed a
better performance than did models incorporating clinical
parameters in our validation cohort. However, this result
should be further investigated on a larger, external valida-
tion set to provide more evidence on the prognostic power
of CT radiomics.
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Radiomics 
 
The following approaches were used to determine radiomics: histogram of intensities analysis, texture 
analysis (the Gray Level Co-occurrence Matrix, the Neighborhood Gray Tome Difference Matrix and the 
Gray Level Size Zone Matrix), shape analysis and wavelet transform analysis. 
 
Histogram of intensities 
 
The parameters from the histogram of intensities were calculated in the perfusion maps before a 
discretization. Let 𝑋 denotes the intensities of the 3D image with 𝑁 voxels. ?̅? - mean of 𝑋. 
 
𝑚𝑒𝑎𝑛 =  
1
𝑁
∑ 𝑋𝑖
𝑁
𝑖=1
 
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑎𝑡𝑖𝑜𝑛 =  √
1
𝑁
∑(𝑋𝑖 − ?̅?)2
𝑁
𝑖=1
 
𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 =
 √
1
𝑁
∑ (𝑋𝑖 − ?̅?)2
𝑁
𝑖=1
?̅?
 
𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 =
 
1
𝑁
∑ (𝑋𝑖 − ?̅?)
3𝑁
𝑖=1
(√
1
𝑁
∑ (𝑋𝑖 − ?̅?)2
𝑁
𝑖=1 )
3 
𝑘𝑢𝑟𝑡𝑜𝑠𝑖𝑠 =
 
1
𝑁
∑ (𝑋𝑖 − ?̅?)
4𝑁
𝑖=1
(√
1
𝑁
∑ (𝑋𝑖 − ?̅?)2
𝑁
𝑖=1 )
4 − 3 
The Gray Level Co-occurrence Matrix 
 
The parameters from the Gray Level Co-occurrence Matrix [1] were calculated in all 26 directions with a 
distance of one voxel. The final parameters were the average of all directions. If one of the voxels had a 
‘not a number’ value the pair was not taken into account in the calculations. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry 
in the Gray Level Co-occurrence Matrix, 𝑁𝑔 - number of gray tones in a studied structure, 𝑃𝑥𝑖 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑗=1 , 
𝑃𝑦𝑗 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1 , 𝑃𝑥+𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1 , where 𝑘 = 𝑖 + 𝑗, 𝑃𝑥−𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1 , where 𝑘 =  |𝑖 − 𝑗|. 
 
𝑒𝑛𝑒𝑟𝑔𝑦 =  ∑ ∑ 𝑃𝑖𝑗
2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 = ∑ ∑(𝑖 − 𝑗)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
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𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  
∑ ∑ 𝑖𝑗𝑃𝑖𝑗 − 𝜇𝑥𝜇𝑦
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
𝜎𝑥𝜎𝑦
 
where: 𝜇𝑥 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 , 𝜇𝑦 =  ∑ ∑ 𝑗𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 , 𝜎𝑥 =  ∑ ∑ 𝑃𝑖𝑗(𝑖 − 𝜇𝑥)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 ,                                          
 𝜎𝑦 =  ∑ ∑ 𝑃𝑖𝑗(𝑗 − 𝜇𝑦)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1  
𝑠𝑢𝑚 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 = ∑ ∑ (𝑖 − 𝜇)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 , where 𝜇 – mean of 𝑃 
𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 (ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦) = ∑ ∑
𝑃𝑖𝑗
1 + (𝑖 − 𝑗)2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝑠𝑢𝑚 𝑜𝑓 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ 𝑖 ∙  𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
 
𝑠𝑢𝑚 𝑜𝑓 𝑣𝑎𝑟𝑎𝑖𝑛𝑐𝑒 = ∑(𝑖 − 𝑠𝑢𝑚 𝑜𝑓 𝑎𝑣𝑒𝑟𝑎𝑔𝑒)2𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
 
𝑠𝑢𝑚 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
log2 𝑃𝑥+𝑦(𝑖) 
𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑃𝑥−𝑦 
𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
log2 𝑃𝑥−𝑦(𝑖) 
𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 1
=  
− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 − (− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 )
𝑚𝑎𝑥 {(− ∑ ∑ 𝑃𝑥𝑖 log2 𝑃𝑥𝑖
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 ) , (− ∑ ∑ 𝑃𝑦𝑗 log2 𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1 )}
 
𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 2
=  √1 − exp [−2 − (− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
) + ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
] 
𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 =  √second largest eigenvalue of ∑
𝑃𝑖𝑘𝑃𝑗𝑘
𝑃𝑥𝑖𝑃𝑗𝑖
𝑁𝑔
𝑘=1
  
 
The Neighborhood Gray Tone Difference Matrix 
 
The Neighborhood Gray Tone Difference Matrix [2] was calculated based on 26 adjacent voxels. The 
voxels with ‘not a number’ value were excluded from the average over the neighborhood region. Let 𝑠𝑖 
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denotes the ith entry in the Neighborhood Gray Tone Difference Matrix, 𝑁𝑖 - the number of voxels having 
gray tone 𝑖, 𝐺 - number of gray tones in a studied structure, 𝑛 - number of studied voxels. 
 
𝑐𝑜𝑎𝑟𝑠𝑒𝑛𝑒𝑠𝑠 =  [𝜖 +  ∑
𝑁𝑖
𝑛
𝐺
𝑖=1
𝑠𝑖]
−1
 
where 𝜖 is a small number to prevent coarseness becoming infinite. 
𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  [
1
𝑁𝑔(𝑁𝑔 − 1)
∑ ∑
𝑁𝑖
𝑛
𝐺
𝑗=1
𝑁𝑗
𝑛
𝐺
𝑖=1
(𝑖 − 𝑗)2] [
1
𝑛
∑ 𝑠𝑖
𝐺
𝑖=1
] 
where 𝑁𝑔 is the total number of different gray levels present in the image. 
𝑏𝑢𝑠𝑦𝑛𝑒𝑠𝑠 =  
∑
𝑁𝑖
𝑛
𝐺
𝑖=1 𝑠𝑖
∑ ∑ 𝑖
𝑁𝑖
𝑛
𝐺
𝑗=1 − 𝑗
𝑁𝑗
𝑛
𝐺
𝑖=1
 
for 
𝑁𝑖
𝑛
≠ 0 and 
𝑁𝑗
𝑛
≠ 0 
𝑐𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 =  ∑ ∑
|𝑖 − 𝑗| (
𝑁𝑖
𝑛 𝑠𝑖 +
𝑁𝑗
𝑛 𝑠𝑗)
𝑁𝑖 + 𝑁𝑗
𝐺
𝑗=1
𝐺
𝑖=1
 
for 𝑁𝑖 ≠ 0 and 𝑁𝑗 ≠ 0 
 
The Gray Level Size Zone Matrix 
 
In the Gray Level Size Zone Matrix [3] calculations the voxels with ‘not a number’ value were excluded 
from the analysis. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry in the Gray Level Size Zone Matrix, 𝑖 - gray value, 𝑗 - 
size, 𝑛𝑟 - number of homogeneous areas inside a studied structure and 𝑝𝑖𝑗 =  𝑃𝑖𝑗 𝑛𝑟⁄ . 
𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑁
𝑗=1
)
2
𝑀
𝑖=1
 
𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑀
𝑖=1
)
2𝑁
𝑗=1
 
𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1
 
𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1
∙ 𝑗2
𝑀
𝑖=1
 
𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1
 
ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1
∙ 𝑖2
𝑀
𝑖=1
 
 102 
 
𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2 ∙ 𝑗2
𝑁
𝑗=1
𝑀
𝑖=1
 
𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙ 𝑖
2
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1
 
𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙ 𝑗
2
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1
 
𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1
∙ 𝑖2
𝑀
𝑖=1
∙ 𝑗2 
𝑠𝑖𝑧𝑒 𝑝𝑟𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
𝑛𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒
 
 
 
Shape 
 
To calculate shape features contours were transformed onto 1 mm isotropic grid. The volume and surface 
estimation was done using marching cubes algorithm implemented in the VTK library [4] (𝑉 - volume, 𝐴 - 
surface). 
 
𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 1 =  
𝑉
(𝜋2𝐴)3/2
 
𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 2 =  36𝜋
𝑉2
𝐴3
 
𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑎𝑙 𝑑𝑖𝑠𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =  
𝐴
4𝜋𝑅2
 
where: 𝑅 is the radius of a sphere with the same volume as the tumor. 
𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑖𝑡𝑦 =  
(36𝜋𝑉2)1/3
𝐴
 
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑜 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 =  
𝐴
𝑉
 
 
𝑚𝑒𝑑𝑖𝑎𝑛 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 - median of distances of each voxel in the region of interest to its surface, calculated 
using distance transform 
𝑆𝐷 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 - standard deviation of distances of each voxel in the region of interest to its surface 
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 3𝐷 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 - the largest pairwise Euclidian distance between voxels of the region of interest 
𝑓𝑟𝑎𝑐𝑡𝑎𝑙 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 - calculated using box contouring technique and fixed grid scans excluding the voxels 
with ‘not a number’ value (Figure 3S) [5].  
𝑓𝑟𝑎𝑐𝑡𝑎𝑙 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 =  −
ln(𝑁(𝑟))
ln(𝑟)
− 𝐼 
where: 𝑟 - size of the contouring box, 𝑁(𝑟) - number of boxes of size r containing at least one voxel, which 
belongs the studied structure, 𝐼 - intercept. 
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Figure 1S. Example of fractal dimension estimation 
 
Wavelet 
The wavelet transform was performed in 3D using Coiflet (‘coif1’) function from package PyWavelets 
(v. 0.2.2). The 5 histogram of intensities features and 29 texture features were calculated on 8 wavelet 
images, which resulted in 272 wavelet features.  
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Results 
 
  Oropharyngeal carcinoma 
  Training Validation 
Model Parameters of the model CI p-value CI p-value 
Radiomics HHH large zone high gray-level emphasis 
LLL sum entropy 
LLH difference variance 
0.79 < 0.001 0.87 < 0.001 
Clinical  Stage 
Volume 
HPV 
0.83 0.75 
Radiomics  HHH large zone high gray-level emphasis 
LLL sum entropy 
LLH difference variance 
0.79 < 0.001 0.87 < 0.046 
Radiomics + 
clinical 
LLH difference variance 
Volume 
HPV 
0.83 0.80 
Table 1S. The three local control prognostic models (radiomics, clinical and mixed) developed for the 
mixed cohort of patients and tested in oropharyngeal carcinoma. The model prognostic value is quantified 
by concordance index (CI). Wilcoxon test p-values are given for the comparison of the models performance. 
 
Model Parameters of the model HR p-value CI 
Radiomics HHH large zone high gray-level 
emphasis LLL sum entropy 
LLH difference variance 
1.30 
2.49 
0.35 
0.077 
0.045 
0.097 
0.75 
Clinical  Stage 
Volume 
HPV 
2.48 
1.02 
0.10 
0.172 
0.021 
0.002 
0.79 
Radiomics 
+ clinical 
LLH difference variance 
Volume 
HPV 
0.50 
1.02 
0.11 
0.141 
0.007 
0.004 
0.80 
Clinical 2 Volume 
HPV 
1.02 
0.09 
< 0.001 
< 0.001 
0.77 
Table 2S. Details of the tumor local recurrence prognostic models, HR – hazard ratio, p-value – from the 
multivariate Cox model, CI – concordance index. 
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Figure 2S. Radiomics-based local tumor control model. Survival curves split significantly (G-rho test            
p-value < 0.001) in both training and validation cohorts as well as the subgroup of HPV negative tumors 
based on the optimal sensitivity-specificity threshold of the training cohort. 
 
 
Figure 3S. The receiver operating characteristics for HPV status prediction using radiomics in patient cohort 
with and without local tumor control. 
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Figure 4S. Pre-treatment CT radiomic features prognostic for local tumor control 
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Figure 5S. CT radiomic features for prediction of status 
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Figure 6S. The influence of CT scanner type on radiomics-based local tumor control model. Only the 
parameter HHH large zone high gray-level emphasis differs between the scanners in tumors where local 
control was achieved (Wilcoxon test p-value < 0.05).  
 
 109 
 
 
Figure 7S. The influence of CT scanner type on radiomics-based HPV prediction model. Only the parameter 
coefficient of variation showed a significant difference between the scanners in HPV negative tumors 
(Wilcoxon test p-value < 0.05). 
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ABSTRACT
Purpose: An association between radiomic features extracted from CT and local tumor control in the
head and neck squamous cell carcinoma (HNSCC) has been shown. This study investigated the value
of pretreatment functional imaging (18F-FDG PET) radiomics for modeling of local tumor control.
Material and Methods: Data from HNSCC patients (n¼ 121) treated with definitive radiochemotherapy
were used for model training. In total, 569 radiomic features were extracted from both contrast-
enhanced CT and 18F-FDG PET images in the primary tumor region. CT, PET and combined PET/CT
radiomic models to assess local tumor control were trained separately. Five feature selection and three
classification methods were implemented. The performance of the models was quantified using con-
cordance index (CI) in 5-fold cross validation in the training cohort. The best models, per image modal-
ity, were compared and verified in the independent validation cohort (n¼ 51). The difference in CI was
investigated using bootstrapping. Additionally, the observed and radiomics-based estimated probabil-
ities of local tumor control were compared between two risk groups.
Results: The feature selection using principal component analysis and the classification based on the
multivariabale Cox regression with backward selection of the variables resulted in the best models for
all image modalities (CICT¼ 0.72, CIPET¼ 0.74, CIPET/CT¼ 0.77). Tumors more homogenous in CT density
(decreased GLSZMsize_zone_entropy) and with a focused region of high FDG uptake (higher GLSZMSZLGE)
indicated better prognosis. No significant difference in the performance of the models in the validation
cohort was observed (CICT¼ 0.73, CIPET¼ 0.71, CIPET/CT¼ 0.73). However, the CT radiomics-based model
overestimated the probability of tumor control in the poor prognostic group (predicted ¼ 68%,
observed ¼ 56%).
Conclusions: Both CT and PET radiomics showed equally good discriminative power for local tumor
control modeling in HNSCC. However, CT-based predictions overestimated the local control rate in the
poor prognostic validation cohort, and thus, we recommend to base the local control modeling on the
18F-FDG PET.
ARTICLE HISTORY
Received 1 May 2017
Accepted 14 June 2017
Introduction
Head and neck cancer squamous cell carcinomas (HNSCC)
show a heterogeneous response to radiochemotherapy with
locoregional control and five-year overall survival ranging
from below 50% to 80% [1–4]. Few biomarkers related to
tumor response to a therapy are already available for this
tumor entity, for example: human papillomavirus infection
[1–2], overexpression of epidermal growth factor receptor [5],
tumor hypoxia or overexpression of cyclin D1 [6]. Apart from
the interpatient variations, an intratumor heterogeneity in
treatment response is observed. The tissue-based biomarkers
from tumor biopsies may not account for intratumor hetero-
geneity, except for selected markers and marker profiles [7],
and thus, other approaches should be investigated.
Radiation oncology is an imaging driven discipline incor-
porating precision medicine since many years. Each treat-
ment plan is personalized based on pretreatment imaging.
So far images collected in radiation oncology are a widely
unused source of data, which could have a much higher
impact on radiation treatment. However, an expert-based,
observer specific analysis would limit the applicability of a
decision support system. Radiomics is a method for quantita-
tive analysis of medical images [7,8]. It provides tools for
comprehensive image analysis on different scales: shape,
intensity, texture and transform-based analysis. Its potential
as a prognostic or predictive biomarker has been studied for
different image modalities and tumor entities [9–11].
On the level of anatomical imaging, pretreatment CT
radiomics was found to be prognostic for local tumor control
[12] and overall survival [11,13–15] in head and neck cancer,
significantly stratifying patients into low- and high-risk
groups. Those studies showed that tumors, which are hetero-
geneous in terms of CT density are associated with a worse
prognosis. The analysis of heterogeneity in functional
CONTACT Marta Bogowicz marta.nesteruk@usz.ch Department of Radiation Oncology, University Hospital Zurich, R€amistrasse 100, Zurich, 8091,
Switzerland
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imaging could potentially further improve the imaging-based
prognostic models. In head and neck cancer, texture of
dynamic contrast-enhanced MRI (DCE-MRI) showed differences
throughout the course of radiochemotherapy [16]. However,
these differences were not correlated with local treatment fail-
ure. Another DCE-MRI study suggested that the histogram
analysis provides parameters prognostic for progression-free
survival and overall survival in stage IV HNSCC [17]. Conflicting
results have been published regarding the role of pretreat-
ment 18F-FDG PET as a prognostic factor in head and neck
cancer. Some retrospective data showed an association
between disease-free survival and increased maximum as well
as mean standardized uptake value (SUV), whereas other
groups did not observe such a correlation [18]. Recently,
Vallieres et al. [19] tried to predict locoregional control using
combined PET and CT radiomics. This study was not success-
ful. Considering the increasing evidence of the association
between CT radiomics and local tumor control [12], the mixed
experiences using functional and anatomical imaging could
be explained by other non-tumor related factors influencing
nodal recurrence or too large number of studied radiomic fea-
tures in relation to number of included patients.
In this work, we evaluate whether the metabolic informa-
tion captured by 18F-FDG PET improves the prediction of
local tumor control compared to the anatomical information
from CT. Additionally, we investigate if the combination of
both CT and PET can further improve the modeling.
Material and methods
Studied population and imaging protocol
Two cohorts of head and neck squamous cell carcinoma
(HNSCC) patients were analyzed, a retrospective cohort of
121 patients (training cohort) with stage-III or stage-IV
HNSCC and 51 patients (validation cohort) with the same
tumor stages from a prospective phase-II study
(NCT01435252). Inclusion criteria were as follows: treatment
with definitive radiochemotherapy, contrast-enhanced plan-
ning CT and diagnostic 18F-FDG PET images available, no
induction chemotherapy, no surgery (biopsy allowed), no
previous or other simultaneous malignancies. Patients in the
training cohort were treated with 70Gy and concomitant
weekly cisplatin (40mg/m2, up to 7 cycles) or cetuximab
(loading dose 400mg/m2 followed by 250mg/m2 weekly),
whereas the validation cohort received triple therapy consist-
ing of radiotherapy (70 Gy) and weekly concurrent cisplatin/
cetuximab (same doses as in training cohort) with or without
consolidation cetuximab (500mg/m2 biweekly 6). In both
cohorts, the elective lymph nodes were irradiated with 54Gy.
The radiation dose was delivered using intensity modulated
and simultaneous integrated boost technique in all patients.
Follow-up included examinations by otorhinolaryngology
specialists every 2–3 months and repetitive 18F-FDG PET/CTs.
Local recurrence was proven by a biopsy in the region of pri-
mary tumor. Further details on the patient population are
presented in Table 1.
All patients underwent a diagnostic 18F-FDG PET scan and
a contrast-enhanced planning CT. On average, the scans
were performed within 25 days. In the case of PET imaging,
an activity of 178–513 MBq was administered intravenously
1 h prior to the scan and after the measurement of blood
sugar level. In the retrospective cohort, 2D or 3D iterative
image reconstruction was used, whereas the images of the
validation cohort were reconstructed with 3D algorithm.
Before the CT imaging, iodine contrast was injected intraven-
ously. Its dose varied among the patients in the training
cohort but was standardized in the validation cohort. Also
the scanner type and the scanning parameters: tube current
and kV, varied between the patients in the training cohort.
Specific details as well as the information about image reso-
lution are shown in Table 2.
Image preprocessing and radiomics
The primary tumor was separately segmented in the CT and
PET images. The CT segmentation was performed manually.
In all cases, two radiation oncologists, both having more
than 10 years of experience, were involved in the process.
Contours were later postprocessed for the presence of metal
artifacts to exclude non-tumor related effects. If a certain
tumor slice was affected by any artifacts, the entire tumor
contour was erased from that slice. Tumors with more than
50% of volume not suitable for the analysis were not
included in the study. Additionally, the voxels outside of soft
tissue Hounsfield unit (HU) range (20 HU to 180 HU) were
discarded. The tumor in the PET image was autosegmented
using a gradient-based method implemented in MIMVISTA
(MIM Software Inc., Cleveland, OH). The contours and images
were linearly interpolated to cubic voxels. The voxel size cor-
responded to the largest dimension in the original dataset:
3.3mm in CT (slice thickness) and 5.5mm in PET (in-plane
resolution).
A fully DICOM compatible, in-house developed
radiomics software implementation written in the Python
Table 1. Detailed patients characteristic.
Training cohort Validation cohort
Number of patients 121 51
Number of recurrences 35 (29%) 15 (29%)
Median follow-up [months] 64 22
Age [years]a 59 (34–73) 58 (47–75)
HPV status
p16 positive 25 (21%) 28 (55%)
p16 negative 37 (31%) 23 (45%)
not known 59 (48%) 0 (0%)
Tumor stage
T1/T2 45 (37%) 6 (12%)
T3/T4 76 (63%) 45 (88%)
Nodal stage
N0 26 (22%) 9 (18%)
N1 10 (8%) 3 (6%)
N2 81 (67%) 37 (72%)
N3 4 (3%) 1 (2%)
Tumor site
Oropharynx 80 (66%) 28 (55%)
Hypopharynx 24 (20%) 8 (16%)
Larynx 10 (8%) 7 (13%)
Oral cavity 7 (6%) 8 (16%)
aMinimum and maximum age.
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programing language was used. It provides 3D implemen-
tation of feature extraction methods for four types of
features:
 shape (n¼ 18)
 intensity (n¼ 19)
 texture: the Gray Level Co-occurrence Matrix (n¼ 26), the
Neighborhood Gray Tone Difference Matrix (n¼ 4) and
the Gray Level Size Zone Matrix (n¼ 14)
 wavelet transform using Coiflet function (8 sub-bands,
n¼ 488).
For each patient, 569 CT radiomic features and 569 PET
radiomic features were extracted from the tumor volumes.
For the texture and wavelet analysis, images were discre-
tized to a fixed bin size of 5 HU and 0.25 SUV in the CT
and PET, respectively. This choice of bin sizes resulted in
similar numbers of bins in both modalities – on average
35 and 36 bins were analyzed in CT and PET, respectively.
The details of the implementation are presented in the
supplement.
Prognosis of local tumor control using radiomics
Three separate models to predict local tumor control were
trained: CT based, PET based and the model comprising both
CT and PET radiomic features. The model training consisted
of two steps: feature selection and classification. Several fea-
ture selection and classification methods were used to
reduce the model training method bias on the comparison
between modalities and to train the best possible model.
In the feature selection step, we considered:
 the principal component analysis (PCA) combined with
univariable Cox regression,
 the Pearson correlation between the features and the
principal components,
 the average clustering,
 the mutual information method,
 the minimum redundancy maximum relevance method.
The classification was performed using:
 the multivariable Cox regression with backward selection
of the variables,
 the least absolute shrinkage and selection operator
(LASSO),
 the random forest.
All the methods are described in the supplement.
Per image modality, the model characterized by the largest
concordance index (CI) in the 5-fold cross validation in the
training cohort and the smallest number of included features
was selected for further validation and comparison.
The risk group stratification was performed based on the
trained models. The thresholds were chosen to obtain
the same level of sensitivity and specificity in the receiver
operating characteristic curve for local tumor control at
18 months.
Models validation and comparison
The radiomics-based local tumor control prognostic models,
based on different imaging modalities, were verified and
compared in the independent validation cohort. First, the
differences in CI were investigated using Wilcoxon test (p-
value< 0.05) and the bootstrap method with 100 randomly
selected samples to calculate the CI distribution. Next, the
risk group stratification was studied with the G-rho test.
Finally, the linear dependence of the predicted and observed
tumor control probabilities at 18 months for two risk groups
was determined, to compare the stratifications from the dif-
ferent models. In this regard, a good model is defined by a
linear dependence with slope equals 1.
Results
Radiomics-based models of local tumor control
Using different combinations of five feature selection and
three classification methods, 15 local tumor control prognos-
tic models were trained per image modality. They were
Table 2. The scanning parameters for training and validation cohorts and two image modalities.
Modality Scanning parameters Training cohort Validation cohort
CT Scanners Siemens SOMATOM Volume zoom (n¼ 83)
Siemens SOMATOM Definition AS (n¼ 23)
GE Discovery STE (n¼ 15)
Siemens SOMATOM Definition AS (n¼ 51)
Slice thickness [mm] 1.25–3.30 2
In-plane resolution [mm] 0.85–1.95 0.98–1.56
kV 120;140 120
mAs 60–450 183–450
PET Scanners GE Discovery STE (n¼ 51)
GE Discovery 690 (n¼ 3)
GE Discovery HR (n¼ 24)
GE Discovery LS (n¼ 20)
GE Discovery RX (n¼ 23)
GE Discovery STE (n¼ 35)
GE Discovery 690 (n¼ 7)
GE Discovery RX (n¼ 9)
Reconstruction 2D (n¼ 61)
3D (n¼ 60)
2D (n¼ 0)
3D (n¼ 51)
Slice thickness [mm] 3.3; 4.3 3.3
In-plane resolution [mm] 2.7–5.5 2.7–5.5
Administered 18F-FDG activity [MBq] 351 (237–513)a 326 (178–406)a
aMinimum and maximum administered activity.
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compared based on the 5-fold cross-validated concordance
index in the training cohort and the number of included fea-
tures (Supplement Table 1S). The combination of feature
selection using the PCA and univariable modeling and classi-
fication using the Cox regression with backward selection
resulted in the least complicated model with the best dis-
criminative power. This hold true for both PET and CT
modeling.
The PCA resulted in the preselection of 12 CT features,
five PET features and 11 features from the combined CT
and PET feature set. Final CT- and PET-based tumor local con-
trol models consisted of two radiomic features (CT:
GLSZMsize_zone_entropy, HLH intensityenergy; PET: spherical dis-
proportion, GLSZMSZLGE; see discussion paragraphs two and
three for the interpretation of the features). The combined
model comprised two features, a combination of CT and PET
features, which were also selected in the single modality
modeling (CT HLH intensityenergy and PET GLSZMSZLGE). All
models showed a similar discriminative power in the training
cohort using 5-fold cross-validation: CICT¼ 0.72, CIPET¼ 0.74,
CIPET/CT¼ 0.77.
Validation of the local tumor control models and their
comparison
The comparison of the local tumor control models was based
on the data from the validation cohort. Studied radiomics-
based models did not differ significantly in terms of discrim-
inative power: CICT¼ 0.73, CIPET¼ 0.71, CIPET/CT¼ 0.73. All
models significantly stratified patients into low- and high-risk
groups of tumor recurrence (Figure 1). For the validation
cohort, the use of combined PET and CT radiomics did not
bring an added value to local tumor control modeling in
HNSCC compared to single-modality radiomics.
There was a significant correlation (r¼ 0.62, p-value
< 0.001) between the rankings of the patients in PET and CT
radiomics models. However, the stratification of patients into
low- and high-risk groups of tumor recurrence was different
in 30% of the cases. Although this concerned mostly the
patients close to the stratification thresholds, a group of
seven patients, who were ranked low based on the CT model
and high based on the PET model, was identified
(Figure 2(a)). The observed and model-based estimated prob-
abilities of local tumor control at 18 months were compared
for both risk groups (Figure 2(b)). The PET-based model gave
a better estimation with a linear regression slope of 1.12 in
comparison to 0.58 in the CT-based model. The latter model
overestimated the probability of tumor control in the poor
prognosis group. Those results are consistent with the differ-
ential classification of the aforementioned seven patients.
Discussion
Identification of new biomarkers in head and neck cancer is
crucial to improve heterogeneous treatment outcome after
definitive radiochemotherapy. A potential source of novel
biomarkers could be radiomics, which can capture spatial
tumor heterogeneity in terms of morphology or tumor
biology, depending on the analyzed image type. This study
showed that both heterogeneity in tumor CT density and in
tumor metabolic activity, measured by 18F-FDG PET, are
prognostic for local tumor control in HNSCC. CT radiomics
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Months
Lo
ca
l c
on
tro
l r
a
te
CT based model
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Months
Lo
ca
l c
on
tro
l r
a
te
PET based model
0 5 10 15 20 25 30
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Months
Lo
ca
l c
on
tro
l r
a
te
PET/CT based model(c)
(a)
(b)
<= threshold training
> threshold training
<= threshold validation
> threshold validation
70 68 64 62 58 56             53 
51 42 35 27 24 23             20 
30 28 21     18 16 3 
19 13 9      8 7 1 
<= threshold training
> threshold training
<= threshold validation
> threshold validation
69 67 65 60 58 55              54 
51 42 33 28 24 24              19 
17 17 15      12 11   2 
34 26 17      15 12 2 
<= threshold training
> threshold training
<= threshold validation
> threshold validation
66 65 62 57 54 52             49 
54 44 36 31 28 27             24 
19 19 17     14 13 2 
32 24 15     13 10 2 
Figure 1. Radiomics-based local tumor control prognostic models: (a) CT-based
radiomics, (b) PET-based radiomics, (c) CT- and PET-based radiomics. Tumor
control curves split significantly (G-rho test p-value< 0.05) in both training and
validation cohorts based on the optimal sensitivity-specificity thresholds at
18 months.
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and PET radiomics-based models showed a similar discrimina-
tive power (CI around 0.7) in the training as well as in the
independent validation datasets. They also significantly strati-
fied patients into low- and high-risk groups of tumor recur-
rence. However, the probability of tumor control in poor
prognostic cohort was overestimated using the CT-based
model, which was not observed in the PET-based radiomics
model. Overall, the multimodality radiomics combining PET
and CT did not improve the local tumor control modeling.
On the level of morphological imaging, head and neck
tumors characterized by increased heterogeneity in CT dens-
ity (increased GLSZMsize_zone_entropy) were associated with
worse prognosis (Supplement Figure 2S). This result is con-
sistent with previously published studies investigating local
control [12] and overall survival [13,15] as endpoints. To
understand the underlying biological processes of these find-
ings, it would be of great interest to investigate if radiomic
features corresponding to heterogeneity correlate with
histopathological stainings of cell proliferation, microvessel
density or hypoxia.
Regarding tumor metabolic activity, round tumors based
on the PET signal autosegmentation (smaller spherical dispro-
portion) with a focused region of high FDG uptake sur-
rounded by a rim of low FDG uptake (higher GLSZMSZLGE)
were associated with a better prognosis (Supplement Figure
2S). This confined FDG uptake could correlate with a less
infiltrative phenotype. On the other hand, a rim of low FDG
uptake could correspond to inflammation, which has been
previously correlated to favorable prognosis in HNSCC [20].
These radiomic features did not correlate with tumor volume,
range of the SUV or maximum SUV. Additionally, in the
studied cohorts of patients the standard PET measures, mean
and maximum SUV, were not prognostic for tumor control.
Moreover, other studies have shown that those standard PET
measures correlate with tumor stage [18,21], whereas the
predictions based on our PET radiomics model were inde-
pendent of tumor stage (Supplement Figure 2S). This demon-
strates, on a clinically relevant dataset, that radiomics is an
added value in comparison to standard PET measures in
terms of local tumor control prediction.
This study shows a link between CT radiomics, PET radio-
mics as well as combined PET and CT radiomics and local
tumor control in head and neck cancer. It is contradictory to
the study of Vallieres et al. [19] in which no correlation
between locoregional control and PET/CT radiomics was
found. To translate our results to locoregional control model-
ing, the inclusion of additional parameters, for example
lymph node-specific radiomics, should be considered. In our
study, the combination of PET and CT radiomics as well as
single modality radiomics resulted in equally good discrim-
inative power of the local tumor control.
The detailed comparison of the single modality models
revealed that despite the significant stratification into risk
groups by both modalities, the CT radiomics model substan-
tially overestimates the probability of tumor control in the
high-risk group. The subgroup of patients, for whom the
risk-group classification depended on image modality, was
identified. Most of those cases (70%) was affected by the CT
artifacts in the tumor region. Although, the slices with arti-
facts were removed from the radiomics analysis this proced-
ure seems to have influenced the results. Those slices could
have contained a crucial information about tumor heterogen-
eity. Another source of error could be a variable contrast
dose between training and validation cohorts. In such a set-
ting, PET radiomics, despite its low resolution, appears to be
better suited for the prognostic modeling in head and neck
region.
Data in the training cohort were acquired using different
scanners as well as different scanning and reconstruction set-
tings, which might have influenced the modeling. Validation
of the models in the independent dataset with standardized
imaging protocol suggests the models’ robustness, but it
should be studied in more detail.
(b)
(a)
Figure 2. The comparison of risk group stratification in the validation cohort by
CT- and PET-based radiomics models (a) the repeatability of patients’ ranking
based on CT and PET radiomics models and differences in risk group stratifica-
tion, (b) the relation between observed and radiomics model-based estimated
probabilities of local tumor control at 18 months for risk groups defined using
the radiomics models.
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Further research in this area should be performed to
address certain limitations of this study. A bigger dataset
could be used for training a combined model to check for
possible overfitting in the presence of the large number of
input features. Additionally, this single institution study
should be validated against multicenter data as well as inter-
observer variability of gross tumor volume definition [22].
Moreover, it is known that not the entire tumor exhibits
increased metabolic activity. Thus, parts of the tumor may
have been missed by the autosegmentation. The PET-radio-
mics based on the treatment planning GTV could further
improve the predictions. It would also eliminate a potential
bias introduced by tumor progression between CT and PET
scans [23]. Previous works [12–13] have shown that the inclu-
sion of clinical parameters (tumor stage or volume) may
result in more accurate predictions. However, so far other
important clinical factors, such as smoking status or perform-
ance status, were not studied in combination with radiomics.
In conclusion, both CT and PET radiomics show potential
to be a prognostic biomarker in head and neck cancer, with
equally good discriminative power. However, the presence of
CT artifacts may alter the CT-based predictions and therefore,
radiomics-based outcome modeling in HNSCC appears to be
more robust using 18F-FDG PET. Additionally, no benefit
from combining CT and FDG-PET radiomics into one prog-
nostic model was observed. Further validation of these
results in a multicenter setting and against different CT arti-
facts correction protocols is needed.
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Radiomic features 
The following approaches were used to determine radiomics: histogram of intensities analysis, 
texture analysis (the Gray Level Co-occurrence Matrix, the Neighborhood Gray Tone Difference 
Matrix, the Gray Level Size Zone Matrix and the Gray Level Run Length Matrix), shape analysis 
and wavelet transform analysis. 
 
Histogram of intensities 
 
The parameters from the histogram of intensities were calculated in the perfusion maps before a 
discretization. Let 𝑋 denotes the intensities of the 3D image with 𝑁 voxels. ?̅? - mean of 𝑋, 𝑁𝑔 - 
number of gray levels in the image, 𝑝𝑖 - the occurrence probability of gray level 𝑖. 
1) 𝑚𝑒𝑎𝑛 =  
1
𝑁
∑ 𝑋𝑖
𝑁
𝑖=1  
2) 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑎𝑡𝑖𝑜𝑛 =  √
1
𝑁
∑ (𝑋𝑖 − ?̅?)2
𝑁
𝑖=1  
3) 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑁
∑ (𝑋𝑖 − ?̅?)
2𝑁
𝑖=1  
4) 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 =
 √
1
𝑁
∑ (𝑋𝑖−?̅?)
2𝑁
𝑖=1
?̅?
 
5) 𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 =
 
1
𝑁
∑ (𝑋𝑖−?̅?)
3𝑁
𝑖=1
(√
1
𝑁
∑ (𝑋𝑖−?̅?)
2𝑁
𝑖=1 )
3 
6) 𝑘𝑢𝑟𝑡𝑜𝑠𝑖𝑠 =
 
1
𝑁
∑ (𝑋𝑖−?̅?)
4𝑁
𝑖=1
(√
1
𝑁
∑ (𝑋𝑖−?̅?)
2𝑁
𝑖=1 )
4 − 3 
7) 𝑚𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
1
𝑁
∑ |𝑋𝑖 − ?̅?|
𝑁
𝑖=1  
8) 𝑟𝑜𝑏𝑢𝑠𝑡 𝑚𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
1
𝑁
∑ |𝑋10−90,𝑖 − ?̅?10−90|
𝑁10−90
𝑖=1  
where: 𝑁10−90- number of voxel in the range from and 10th percentile and 90th percentile, ?̅?10−90 
- mean value of voxel in the range from 10th percentile and 90th percentile  
9) 𝑒𝑛𝑒𝑟𝑔𝑦 =  ∑ 𝑋𝑖
2𝑁
𝑖=1  
10) 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 =  − ∑ 𝑝𝑖
𝑁𝑔
𝑖=1
log2 𝑝𝑖 
11) 𝑟𝑜𝑜𝑡 𝑚𝑒𝑎𝑛 𝑠𝑞𝑢𝑎𝑟𝑒 =  √
𝑒𝑛𝑒𝑟𝑔𝑦
𝑁
 
12) 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  ∑ 𝑝𝑖
𝑁𝑔
𝑖=1
 
13) 𝑚𝑖𝑛𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒 = min(𝑋)  
14) 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑣𝑎𝑙𝑢𝑒 = max(𝑋) 
15) 𝑚𝑒𝑑𝑖𝑎𝑛 –  the median value of 𝑋 
16) 10𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 – 10th percentile of 𝑋 
17) 90𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 – 90th percentile of 𝑋 
18) interqurtile range = 90𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒 −  10𝑡ℎ𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑖𝑙𝑒    
19) 𝑟𝑎𝑛𝑔𝑒 = max(𝑋) − min(𝑋)  
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The Gray Level Co-occurrence Matrix (GLCM) 
 
The parameters from the Gray Level Co-occurrence Matrix [1] were calculated in all 26 directions 
with a distance of one voxel. The final parameters were the average of all directions. If one of the 
voxels had a ‘not a number’ value the pair was not taken into account in the calculations. Let 𝑃𝑖𝑗 
denotes the (𝑖, 𝑗) entry in the Gray Level Co-occurrence Matrix, 𝑁𝑔 - number of gray tones in a 
studied structure, 𝑃𝑥𝑖 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
, 𝑃𝑦𝑗 = ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
, 𝑃𝑥+𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1
, where 𝑘 = 𝑖 + 𝑗, 
𝑃𝑥−𝑦(𝑘) = ∑ ∑ 𝑃𝑖𝑗
𝑁𝑔
𝑖=1
𝑁𝑔
𝑗=1
, where 𝑘 =  |𝑖 − 𝑗|. 
 
20) 𝑒𝑛𝑒𝑟𝑔𝑦 =  ∑ ∑ 𝑃𝑖𝑗
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
21) 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 = ∑ ∑ (𝑖 − 𝑗)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
22) 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  
∑ ∑ 𝑖𝑗𝑃𝑖𝑗−𝜇𝑥𝜇𝑦
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
𝜎𝑥𝜎𝑦
 
where: 𝜇𝑥 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
, 𝜇𝑦 =  ∑ ∑ 𝑗𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
, 𝜎𝑥 =  ∑ ∑ 𝑃𝑖𝑗(𝑖 − 𝜇𝑥)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
,                                        
  𝜎𝑦 =  ∑ ∑ 𝑃𝑖𝑗(𝑗 − 𝜇𝑦)
2𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
23) 𝑠𝑢𝑚 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 = ∑ ∑ (𝑖 − 𝜇)2𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
  
where 𝜇 – mean of 𝑃 
24) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 (ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦) = ∑ ∑
𝑃𝑖𝑗
1+(𝑖−𝑗)2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
25) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑚𝑜𝑚𝑒𝑛𝑡 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃𝑖𝑗
1+
(𝑖−𝑗)2
𝑁𝑔
2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
26) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = ∑ ∑
𝑃𝑖𝑗
1+|𝑖−𝑗|
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
27) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 = ∑ ∑
𝑃𝑖𝑗
1+
|𝑖−𝑗|
𝑁𝑔
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
28) 𝑠𝑢𝑚 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ 𝑖 ∙  𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
 
29) 𝑠𝑢𝑚 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
log2 𝑃𝑥+𝑦(𝑖) 
30) 𝑠𝑢𝑚 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = ∑ 𝑃𝑥+𝑦(𝑖)
2𝑁𝑔
𝑖=2
∙ (𝑖 − 𝑠𝑢𝑚 𝑎𝑣𝑒𝑟𝑎𝑔𝑒)2 
31) 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
32) 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = − ∑ 𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
log2 𝑃𝑥−𝑦(𝑖) 
33) 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 1 (𝐼𝑀𝐶1) =
 
− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
−(− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
)
𝑚𝑎𝑥{(− ∑ ∑ 𝑃𝑥𝑖 log2 𝑃𝑥𝑖
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
),(− ∑ ∑ 𝑃𝑦𝑗 log2 𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
)}
 
34) 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 2 (𝐼𝐶𝑀2) =
 √1 − exp [−2 − (− ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑥𝑖𝑃𝑦𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
) + ∑ ∑ 𝑃𝑖𝑗 log2 𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
] 
35) 𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (𝑀𝐶𝐶) =  √second largest eigenvalue of ∑
𝑃𝑖𝑘𝑃𝑗𝑘
𝑃𝑥𝑖𝑃𝑗𝑖
𝑁𝑔
𝑘=1   
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36) 𝑗𝑜𝑖𝑛𝑡 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 = max (𝑃𝑖𝑗) 
37) 𝑗𝑜𝑖𝑛𝑡 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
38) 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ 𝑖𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
 
39) 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = ∑ 𝑃𝑥−𝑦(𝑖)
𝑁𝑔−1
𝑖=0
∙ (𝑖 − 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒)2 
40) 𝑑𝑖𝑠𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦 =  ∑ ∑ |𝑖 − 𝑗|
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
𝑃𝑖𝑗 
41) 𝑖𝑛𝑣𝑒𝑟𝑒𝑠𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 2 ∑ ∑
𝑃𝑖𝑗
(𝑖−𝑗)2
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
42) 𝑎𝑢𝑡𝑜𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛 =  ∑ ∑ 𝑖𝑗𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
43) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑡𝑒𝑛𝑑𝑒𝑛𝑐𝑦 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
2
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
44) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠ℎ𝑎𝑑𝑒 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
3
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
45) 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑝𝑟𝑜𝑚𝑖𝑛𝑒𝑛𝑐𝑒 = ∑ ∑ (𝑖 + 𝑗 − 𝜇𝑥 − 𝜇𝑦)
4
𝑃𝑖𝑗
𝑁𝑔
𝑗=1
𝑁𝑔
𝑖=1
 
 
The Neighborhood Gray Tone Difference Matrix (NGTDM) 
 
The Neighborhood Gray Tone Difference Matrix [2] was calculated based on 26 adjacent voxels. 
The voxels with ‘not a number’ value were excluded from the average over the neighborhood 
region. Let 𝑠𝑖 denotes the ith entry in the Neighborhood Gray Tone Difference Matrix, 𝑁𝑖 - the 
number of voxels having gray tone 𝑖, 𝐺 - number of gray tones in a studied structure, 𝑛 - number 
of studied voxels. 
 
46) 𝑐𝑜𝑎𝑟𝑠𝑒𝑛𝑒𝑠𝑠 =  [𝜖 + ∑
𝑁𝑖
𝑛
𝐺
𝑖=1 𝑠𝑖]
−1
 
where 𝜖 is a small number to prevent coarseness becoming infinite. 
47) 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  [
1
𝑁𝑔(𝑁𝑔−1)
∑ ∑
𝑁𝑖
𝑛
𝐺
𝑗=1
𝑁𝑗
𝑛
𝐺
𝑖=1 (𝑖 − 𝑗)
2] [
1
𝑛
∑ 𝑠𝑖
𝐺
𝑖=1 ] 
where 𝑁𝑔 is the total number of different gray levels present in the image. 
48) 𝑏𝑢𝑠𝑦𝑛𝑒𝑠𝑠 =  
∑
𝑁𝑖
𝑛
𝐺
𝑖=1 𝑠𝑖
∑ ∑ 𝑖
𝑁𝑖
𝑛
𝐺
𝑗=1 −𝑗
𝑁𝑗
𝑛
𝐺
𝑖=1
 
for 
𝑁𝑖
𝑛
≠ 0 and 
𝑁𝑗
𝑛
≠ 0 
49) 𝑐𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 =  ∑ ∑
|𝑖−𝑗|(
𝑁𝑖
𝑛
𝑠𝑖+
𝑁𝑗
𝑛
𝑠𝑗)
𝑁𝑖+𝑁𝑗
𝐺
𝑗=1
𝐺
𝑖=1  
for 𝑁𝑖 ≠ 0 and 𝑁𝑗 ≠ 0 
 
The Gray Level Size Zone Matrix (GLSZM) 
 
In the Gray Level Size Zone Matrix [3] calculation the voxels with ‘not a number’ value were 
excluded from the analysis. Let 𝑃𝑖𝑗 denotes the (𝑖, 𝑗) entry in the Gray Level Size Zone Matrix, 𝑖 - 
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gray value, 𝑗 - size, 𝑛𝑟 - number of homogeneous areas inside a studied structure and                 
𝑝𝑖𝑗 =  𝑃𝑖𝑗 𝑛𝑟⁄ , 𝜇𝑖 =  ∑ ∑ 𝑖𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1 , 𝜇𝑗 =  ∑ ∑ 𝑖𝑃𝑖𝑗 .
𝑁
𝑗=1
𝑀
𝑖=1  
50) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 (𝐺𝐿𝑁𝑈) =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑁
𝑗=1 )
2𝑀
𝑖=1  
51) 𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑛𝑜𝑛 − 𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 (𝑆𝑍𝑁𝑈) =  
1
𝑛𝑟
∑ (∑ 𝑃𝑖𝑗
𝑀
𝑖=1 )
2𝑁
𝑗=1  
52) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝑆𝑍𝐸) =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
53) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝐿𝑍𝐸) =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑗
2𝑀
𝑖=1  
54) 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝐿𝐺𝑍𝐸) =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
55) ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑧𝑜𝑛𝑒 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝐻𝐺𝑍𝐸) =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1  
56) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝑆𝑍𝐿𝐺𝐸) =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗
𝑖2∙𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
57) 𝑠𝑚𝑎𝑙𝑙 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝑆𝑍𝐻𝐺𝐸) =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑖
2
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1  
58) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 𝑙𝑜𝑤 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝐿𝑍𝐿𝐺𝐸) =  
1
𝑛𝑟
∑ ∑
𝑃𝑖𝑗 ∙𝑗
2
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1  
59) 𝑙𝑎𝑟𝑔𝑒 𝑧𝑜𝑛𝑒 ℎ𝑖𝑔ℎ 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑒𝑚𝑝ℎ𝑎𝑠𝑖𝑠 (𝐿𝑍𝐻𝐺𝐸) =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗
𝑁
𝑗=1 ∙ 𝑖
2𝑀
𝑖=1 ∙ 𝑗
2 
60) 𝑠𝑖𝑧𝑒 𝑝𝑟𝑒𝑐𝑒𝑛𝑡𝑎𝑔𝑒 =  
𝑛𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑜𝑥𝑒𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑑 𝑠𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒
 
61) 𝑔𝑟𝑎𝑦 𝑙𝑒𝑣𝑒𝑙 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑖 − 𝜇𝑖)
2𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
62) 𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =  
1
𝑛𝑟
∑ ∑ (𝑗 − 𝜇𝑗)
2
𝑃𝑖𝑗
𝑁
𝑗=1
𝑀
𝑖=1  
63) 𝑠𝑖𝑧𝑒 𝑧𝑜𝑛𝑒 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 =  
1
𝑛𝑟
∑ ∑ 𝑃𝑖𝑗 log (𝑃𝑖𝑗)
𝑁
𝑗=1
𝑀
𝑖=1  
 
Shape 
 
In the USZ implementation: to calculate shape features contours were transformed onto 1 mm 
isotropic grid. The volume and surface estimation was done using marching cubes algorithm 
implemented in the VTK library [4]. 
64) 𝑉 – volume 
65) 𝐴 – surface 
66) 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 1 =  
𝑉
(𝜋2𝐴)
3
2
 
67) 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠 2 =  36𝜋
𝑉2
𝐴3
 
68) 𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑎𝑙 𝑑𝑖𝑠𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =  
𝐴
4𝜋𝑅2
 
where: 𝑅 is the radius of a sphere with the same volume as the tumor. 
69) 𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑖𝑡𝑦 =  
(36𝜋𝑉2)
1
3
𝐴
 
70) 𝑎𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑡𝑦 = (
1
36𝜋
𝐴3
𝑉2
)
1
3
− 1 
71) 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑜 𝑣𝑜𝑙𝑢𝑚𝑒 𝑟𝑎𝑡𝑖𝑜 =  
𝐴
𝑉
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72) 𝑚𝑒𝑑𝑖𝑎𝑛 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 - median of distances of each voxel in the region of interest to its 
surface, calculated using distance transform 
73) 𝑆𝐷 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 - standard deviation of distances of each voxel in the region of interest to 
its surface 
74) 𝑚𝑎𝑥𝑖𝑚𝑢𝑚 3𝐷 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 - the largest pairwise Euclidian distance between voxels of the 
region of interest 
75) 𝑐𝑒𝑛𝑡𝑒𝑟 𝑜𝑓 𝑚𝑎𝑠𝑠 𝑠ℎ𝑖𝑓𝑡 = geometric center of the mass – gray levels weighted center of the 
mass 
76) 𝑓𝑟𝑎𝑐𝑡𝑎𝑙 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 - calculated using box contouring technique and fixed grid scans 
excluding the voxels with ‘not a number’ value (Figure 1S) [5].  
𝑓𝑟𝑎𝑐𝑡𝑎𝑙 𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛 =  −
ln(𝑁(𝑟))
ln(𝑟)
− 𝐼 
where: 𝑟 - size of the contouring box, 𝑁(𝑟) - number of boxes of size r containing at least 
one voxel, which belongs the studied structure, 𝐼 - intercept. 
 
 
Figure 1S. Example of fractal dimension estimation 
 
77) 𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠 – the largest eigenvalue in the principal component analysis 
78) 𝑚𝑖𝑛𝑜𝑟 𝑎𝑥𝑖𝑠 – the second largest eigenvalue in the principal component analysis 
79) 𝑙𝑒𝑎𝑠𝑡 𝑎𝑥𝑖𝑠 – the smallest eigenvalue in the principal component analysis 
80) 𝑎𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 =
𝑚𝑖𝑛𝑜𝑟 𝑎𝑥𝑖𝑠
𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠
  
81) 𝑓𝑙𝑎𝑡𝑛𝑒𝑠𝑠 =  
𝑙𝑒𝑎𝑠𝑡 𝑎𝑥𝑖𝑠
𝑚𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠
  
 
Wavelet 
The wavelet analysis was preformed using the Python library PyWavelets version 0.3.0 and the 
‘Coif1’ wavelet as the filter. To account for the boundary effects the entire image set was filtered 
after the resizing to cubic voxels but before any image segmentation/resegmentation.  
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Feature selection 
a) The principal component analysis combined with univariable Cox regression 
The Horn method [6] was used to define the number of retained principal components. Next each 
of the radiomic features was assigned to the principal component based on its largest contribution 
to certain component [7]. Per principal component related group, the features with the highest 
concordance index (CI) and corresponding false discovery rate < 0.2 in the univariable Cox 
regression was selected. 
b) The Pearson correlation between the features and the principal components  
The Horn method [6] was used to define the number of retained principal components. Next, for 
each principal component one feature was selected to represent it. To that end we determined 
the feature that correlated the most (the largest Pearson correlation coefficient) with the principal 
component. In the contrary to the method a) no information about prognostic power of radiomic 
features was used. 
c) The average clustering 
The average clustering [8] was performed based on the Pearson correlations between radiomic 
features. The distance cut-off was set to 0.5. For each of the defined groups, the feature with the 
highest variance was selected to represent it. 
d) The mutual information  
The mutual information [9] between the radiomic features and tumor control probability was 
computed. The feature’s selection threshold was defined as 80% of maximum mutual information 
between tumor control probability and any of the radiomic features. 
e) The minimum redundancy maximum relevance  
The ensemble maximum relevance minimum redundancy (MRMR) method was used [10].  It was 
partiality combined with the principal component analysis. The feature count was defined as the 
number of principal components, which explains 95% of data variance. The MRMR was repeated 
1000 randomly selecting samples using bootstrap procedure. The redundancy between the 
features was defined as the Spearman correlation. Features, which achieved at least 80% 
selection rate were included in the final set. 
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Feature classification 
a) The multivariable Cox regression with backward selection of the variables 
The preselected features were used in the multivariable Cox regression with backward selection 
of the variables based on the Akaike information criterion [11]. Features, which had at least 80% 
selection rate in 5-fold cross-validation were chosen to the final model.  
b) The least absolute shrinkage and selection operator 
The least absolute shrinkage and selection operator [12] (100 times 5-fold cross-validated) was 
used for variable selection in multivariable Cox regression. Features, which had at least 70% 
selection rate were chosen to the final model.  
c) The random forest  
The random forest model was trained using 1000 trees and Breiman-Cutler permutation was 
calculate variable importance [13]. Features were selected based on the minimization of the out-
of-bag error. The additional constrain was set for the maximal number of features n=5. 
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Results 
a) 
  Cox backward LASSO RF 
PCA univariable Cox CI 0.72 (0.64-0.90)  0.69 (0.59-0.85)  0.65 (0.54-0.88) 
n 2  1  3 
PCA correlation CI 0.68 (0.53-0.83)  0.69 (0.56-0.85)  0.55 (0.44-0.77) 
n 5  1  3 
average clustering CI -  0.67 (0.47-0.90)  0.69 (0.64-0.80) 
n -  1  5 
mutual information CI 0.71* (0.60-0.90)  0.71* (0.60-0.90)  0.68** (0.63-0.71) 
n 1  1  2 
minimum redundancy 
maximum relevance 
CI 0.71* (0.60-0.90)  0.71* (0.60-0.90)  0.68** (0.63-0.71) 
n 1  1  2 
 
b)  
  Cox backward LASSO RF 
PCA univariable Cox CI 0.74** (0.62-0.80) 0.70 (0.56-0.80) 0.70 (0.57-0.81) 
n 2 2 2 
PCA correlation CI 0.66 (0.54-0.74) 0.62 (0.55-0.71) 0.64 (0.60-0.74) 
n 3 1 3 
average clustering CI 0-67 (0.64-0.76) 0.67 (0.62-0.76) 0.54 (0.39-0.68) 
n 2 2 5 
mutual information CI 0.74** (0.62-0.80) 0.70 (0.66-0.74) 0.68 (0.57-0.80) 
n 2 1 3 
minimum redundancy 
maximum relevance 
CI 0.71 (0.57-0.81) 0.66 (0.62-0.79) 0.60 (0.50-0.66) 
n 1 1 3 
 
Table 1S. The concordance indexes (CI) for radiomics-based local tumor control models trained 
with a different comibantions of features selection and classifications a) CT radiomics, b) PET 
radiomics. The results were based on the 5-fold cross-valdiation in the training cohort. The 
maxiumim and minimum CI obtianed in the cross-valdation are presented in the brackets.  
Additionaly, the number of features (n) included in the multivariable model is shown. The 
combination of the principal component analysis combined with univariable Cox regression and 
the multivarible Cox regression with backward selection of the variables resulted in the best 
models considering both CT and PET features (in bold). The combination of avarage clustering 
and Cox multivariable regression failed to optimize a model due to too large number of input 
variables (n=66). * the same final model containing 1 feature, ** the same final model containing 
2 features. PCA univariable Cox - the principal component analysis combined with univariable 
Cox regression, PCA correlation - the Pearson correlation between the features and the principal 
components, Cox backward - the multivarible Cox regression with backward selection of the 
variables, LASSO - the least absolute shrinkage and selection operator, RF - the random forest. 
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Figure 2S. The CT (a and b) and PET (d and e) radiomics signature prognostic for local tumor 
recurrence in head and neck cancer. All radiomic features differed significantly (Wilcoxon test      
p-value < 0.05) between the controlled tumors and recurrences. The predictions based on the 
radiomics model was independent from the tumor stage (c and f). 
 
Figure 3. The concordance index distributions in the validation dataset for different local tumor 
control radiomics models. The distributions were obtained using the bootstrap method. None of 
the models showed a superior discriminative power. 
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Chapter 4 
Discussion and outlook 
 
 
4.1 Main findings 
This PhD project aimed to identify imaging phenotypes related to worse prognosis in radiotherapy of 
head and neck squamous cell carcinoma (HNSCC). Three types of images were analyzed:  
 computed tomography (CT) related to density 
 computed tomography perfusion (CTP) related to perfusion 
 18F-fludeoxyglucose (18F-FDG) positron emission tomography (18F-FDG PET) related to 
metabolism.  
In the Chapter 3.1, I have shown that tumor perfusion depended on the HNSCC subtype and tumor 
metabolism depended on tumor stage. Moreover, increased blood volume and mean transit time in 
tumor in comparison to surrounding tissue can be linked to HNSCC subgroups associated with worse 
treatment outcome (HPV negative and T3/T4 stage tumors). Tumor perfusion, assessed by the CTP, 
provides additional information in comparison to routinely acquired CT and PET images. However, 
during this examination a high radiation dose is delivered to a patient. Therefore, in Chapter 3.2 I have 
proposed a modified CTP imaging protocol, which enables dose reduction and maintenance of image 
quality. I have further studied the CTP imaging in context of radiomics analysis (Chapter 3.4) and 
identified 10 groups of CTP radiomic features, which were uncorrelated and robust against CTP 
calculation factors.  
Radiomics is a relatively new, but rapidly growing field of research [17]. Therefore, a large effort is 
made to provide better understanding of the implemented processes, their impact on models stability 
as well as the interpretation of radiomics-based prognostic models. In Chapter 3.3, I have compered 
two independent radiomics software implementations in the context of reproducibility of prognostic 
models. My results have shown, for the first time on a clinically relevant dataset, that radiomics model 
developed with one implementation cannot be transferred to another radiomics implementation 
without a detailed comparison. In another study, I have observed an association of CT radiomics with 
local tumor control and HPV status (Chapter 3.5). Tumors more heterogeneous in CT density were 
linked to worse tumor control and HPV negative status. The CT radiomics model for local tumor control 
showed a higher prognostic power than a model based on clinical parameters (tumor stage, volume 
and HPV status). Further, I have investigated an improvement of local tumor control radiomics-based 
model by inclusion of the 18F-FDG PET imaging (Chapter 3.6). Interestingly, the metabolic information 
assessed by PET imaging did not increase the prognostic power of the model in comparison to CT 
radiomics. Nonetheless, my radiomics-based local tumor control models showed a higher prognostic 
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power than previously published models for loco-regional control and overall survival [69, 104, 105]. 
It showed a close link of primary tumor radiomics to a direct endpoint – local control. Consequently, 
to improve models for the composite endpoints, they should be trained on data from primary tumor 
radiomics and additional input such as clinical parameters or lymph nodes radiomics. 
These main findings are discussed in light of the available literature and future studies directions in the 
following subsections of the discussion:   
 software used for radiomics studies (concerns results in Chapters 3.3-3.6) 
 challenges of radiomics (concerns results in Chapters 3.3-3.6) 
 radiomics as a non-invasive imaging biomarker (concerns results in Chapters 3.5-3.6)  
 heterogeneity of head and neck cancer in terms of imaging phenotypes (concerns results in 
Chapters 3.1 and 3.5-3.6).  
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4.2   Radiomics software implementation development 
The first part of radiomics-related studies was devoted to development of radiomics software 
implementation. I have developed a stand-alone application written in Python programing language 
(version 2.7). Development of an own implementation brings an advantage in full understanding of the 
processes behind the complex calculation and the possibility for further extension of the 
implementation with new and unique radiomic features.  On the other hand, radiomics is a relatively 
new field of research [17], which lacks standardization. The use of an independent implementation 
may introduce bias to the trained models. Our group is a part of Image Biomarkers Standardization 
Initiative (IBIS). It was initiated by Alex Zwanenburg (OncoRay–National Center for Radiation Research 
in Oncology, Dresden, Germany) and currently involves 19 institutions from 8 countries. It aims to 
provide clear guidelines for radiomics implementation, from image pre-processing to the calculation 
of the features [68]. This is an ongoing work and therefore the results are not part of the thesis. 
My radiomics application is fully DICOM (Digital Imaging and Communications in Medicine) 
compatible, which allows for a direct analysis of all medical image modalities without any compression. 
Currently, the analysis can be performed on CT, PET, CTP and MR, including both clinical and preclinical 
images. The analysis is performed in a region of interest (ROI) defined in a DICOM structure file, which 
enables a precise definition of analyzed region. Currently the software encompasses all standard 
radiomic descriptors:  
 shape-based,  
 intensity-based,  
 texture-based (the Gray-Level Co-Occurrence Matrix, the Neighborhood Gray Tone Difference 
Matrix, the Gray Level Size Zone Matrix, the Gray Level Run Length Matrix, the Gray Level Distance 
Zone Matrix and the Neighboring Grey Level Dependence Matrix [68]) 
 transform-based (wavelet transform). 
In total, it provides 1404 radiomic features calculated per image. It enables image discretization into 
fixed number of bins or fixed bin size. It provides image pre-processing (image and ROI resizing to a 
cubic voxels), 2D and 3D image analysis. Further details on the implementation, including definition of 
single features, can be found in Chapter 3.3 supplement.
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4.3 Challenges in radiomics  
 
A large part of radiomics studies is focused on providing proof for radiomics credibility and assuring 
the reproducibility of trained models. The main challenges in radiomics can be divided into: 
standardization, robustness against image acquisition, reconstruction and quality, and finally data 
dimensionality reduction and modeling.  
 
4.3.1 Radiomics standardization 
Recently, the Image Biomarker Standardization Initiative (IBIS) provided a compendium of radiomic 
feature definitions and thus contributed greatly to that field [68]. The compendium standardizes 
nomenclature and contains a clear description of feature extraction methods for shape, intensity and 
texture analysis. Most of the radiomics studies are conducted using in-house developed 
implementations or open source codes [93]. The efforts of IBIS helped to improve the reproducibility 
of radiomic features between different software implementations [106]. Its current efforts are focused 
on the standardization of an image pre-processing workflow.  
In parallel, I have investigated an influence of different radiomics implementations on the 
reproducibility of prognostic models (Chapter 3.3). I have compared results from two implementations 
being a part of IBIS (University Hospital Zurich, Zurich, Switzerland and MAASTRO clinic, Maastricht, 
the Netherlands). Both implementations were used to train separate local control prognostic models 
using 3 months post-radiochemotherapy 18-FDG PET scans of patients with head and neck cancer. My 
final models were reproducible between the implementations, both in the training and validation 
cohorts. However, in the univariate analysis I have observed that the majority of studied features was 
not reproducible, despite the fact that only features based on the same definition were selected for 
this study. I was able to identify steps in the radiomics workflow, which influenced our results (contour 
mask creation from contour points to voxels, discretization of wavelet transformed images and type 
of wavelet transform decimated vs undecimated). These steps are rarely described in detail in 
radiomics papers. Our study highlights the importance of radiomics workflow reporting. Additionally, 
the high reproducibility of intensity and texture features, despite slightly different contour mask 
creation methods, indicates lower importance of contour mask creation method in the workflow 
standardization. Especially in comparison to the interobserver contouring variability, which is one 
order of magnitude larger [107].  
My results also show, for the first time on a clinically relevant model and dataset, that a model 
developed by one institution should not be directly transferred to another center, which uses a 
different radiomics implementation, without rigorous comparison. 
 
4.3.2  Radiomics robustness and stability 
Higher reproducibility, lower interobserver variability and automatization, which enables the high-
throughput analysis, are some of the arguments to favor the quantitative over qualitative image 
analysis. However, the results of quantitative image analysis can be more sensitive to changes in image 
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quality. Not only the advanced parameters such as texture, but also for example mean SUV depends 
on voxel size due to partial-volume effect [108]. Table 1 lists some of the factors influencing image 
quality for the three modalities studied in this project. Some factors are modality-dependent, whereas 
the others influence multiple modalities. A direct translation of robustness studies between modalities 
is not trivial. For example, the iodine contrast concentration might influence both contrast enhanced 
CT and CTP imagining however, the magnitude of difference will be most likely modality-dependent.    
 
Factor influencing image quality CT CTP FDG PET 
Reconstruction method ✔ ✔ ✔ 
Spatial resolution ✔ ✔ ✔ 
Uptake time / scan delay time after contrast administration ✔ ✔ ✔ 
Scanner type ✔ ✔ ✔ 
Scanner calibration ✔ ✔ ✔ 
Blood glucose level   ✔ 
Dose of FDG   ✔ 
Dose of contrast     ✔* ✔  
Tube voltage ✔ ✔  
Tube current ✔ ✔  
Temporal resolution  ✔  
Artery input function  ✔  
Nosie threshold in the calculation  ✔  
Table 1. Summary of the main factors influencing image quality in computed tomography (CT), 
computed tomography perfusion (CTP) and fluorodeoxyglucose positron emission tomography 
(FDG PET); * - only for the contrast enhanced CT.  
 
Multiple studies indicated voxel size as a parameter having large influence on the stability of radiomic 
features in different imaging modalities [109, 110]. I have also confirmed this in CT perfusion (CTP) 
imaging (Chapter 3.4). Recent studies have shown that voxel resampling to a fixed dimensions across 
a dataset can increase the stability [110, 111]. However, the question as to what is the best voxel 
dimension requires further investigation. Voxels can be resampled to small dimensions assuring high 
resolution but introducing a bias from interpolation. On contrary, a lowest resolution available in the 
dataset can be used, which introduces smoothing and might cause loss of information. Currently it is 
not clear, which method is preferable for radiomics. 
In the analysis of retrospective data, the influence of imaging protocol on image quality and radiomics 
analysis can be difficult to assess. One of the examples is image reconstruction method. Raw data, 
which is mostly deleted few days after the examination, are required to compare different 
reconstruction settings. In the process of image reconstruction, differences in image quality can be 
caused by for example: the filtered back-projection (FBP) reconstruction vs the iterative 
reconstruction, a kernel used in the FBP, parameters of iterative reconstruction and 2D vs 3D 
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reconstruction [112-114]. To compare a 2D vs 3D image reconstruction, data have to be additionally 
acquired in 2D, which is no longer a standard practice and would require an additional approval from 
an ethics committee. Another example is the scanner type influence on image quality. Both, influence 
of scanner type and reconstruction method, can be studied using a phantom [110, 115]. However, it 
may be difficult to reproduce the complex patient anatomy or tumor metabolism in a phantom [115]. 
Moreover, some of the old scanners may have already been replaced. To overcome this, I have trained 
my radiomics prognostic models on retrospective data however, the validation was performed in a 
prospective cohort with a standardized imagining protocol (Chapters 3.3, 3.5 and 3.6). For example, 
PET data in our training cohort were reconstructed with 2D or 3D iterative algorithm, but in the 
validation cohort all data were reconstructed with 3D algorithm. Using this approach the balance of 
the data has to be checked to avoid bias. For my CT signatures, for local tumor control and HPV status, 
I have shown that the selected features differed between patient groups (local control vs no local 
control and HPV+ vs HPV-) but not between different scanners (Chapter 3.5). Only two features 
showed a small dependency on the scanner type, but both signatures were valid in the third scanner 
type used in the validation cohort. Of course this alternative method does not assure the stability of 
the models among all possible scanners types and vendors however, it increases their credibility. 
Training a model on heterogeneous data can also cause an underestimation of the power of the model. 
Nevertheless, it is of a lower clinical significance than model overfitting to a restricted but not well-
documented population.  
The quality of CTP is affected by acquisition and computation factors, which are specific for this 
modality: temporal resolution, arterial input function definition and noise threshold cutoff in the 
calculation. To my knowledge, my study is the only work in radiomics field trying to quantify the 
influence of CTP-specific factors on the stability of CTP radiomics (Chapter 3.4). I have analyzed 945 
radiomics features in both lung and head and neck cancer patients. I have identified only 255 features 
stable in respect to non-standardizable CTP calculation factors (arterial input function definition and 
noise threshold). Within this subset, after the correction for inter-features correlation and correlation 
with tumor volume, I have identified only 10 independent groups. This greatly reduces the number of 
CTP radiomics features suitable for prognostic modeling. Additionally, my study showed that stability 
of the features is tumor site dependent. This was recently confirmed in CT thoracic imaging by Larue 
et al [116]. 
The CTP imaging is a dose intense examination. Therefore, I have adapted our clinical protocol to 
reduce delivered dose and maintain signal to noise ratio. It was done by the application of an iterative 
reconstruction algorithm as well as tube current and voltage adaptation (Chapter 3.2). Based on a 
phantom study and measurements using thermoluminescent dosimeters, I have shown that the dose 
reduction by factor of 2 is feasible without a decrease in image quality. Further investigation of the 
influence of the new CTP protocol on stability of radiomic features based on patient data is needed. 
 
4.3.3  Outcome modeling and correlation to clinical parameters 
Modeling and data dimensionality reduction is a challenge not only in radiomics but also in genomics, 
proteomics, metabolomics and in general any kind of -omics analysis [117]. To handle a large 
dimensionality of data and relatively few events machine learning approaches are tested. Pamar et al  
[118] has shown that different combinations of feature selection and classification methods (training 
method) resulted in different CT radiomic signatures for overall survival in lung cancer, characterized 
by different prognostic power with concordance index (CI) ranging from 0.50 (random prediction) to 
Chapter 4 Discussion and outlook: Challenges in radiomics 
135 
 
0.69. The same group investigated the impact of training method on prognostic signature for overall 
suvival in head and neck cancer [119]. Similarly, they observed a wide range of CI (0.50 – 0.79) 
dependent on the used method. Additionally, they found that the method providing ‘the best’ 
signature, the singature with the highest CI, was dependent on tumor entity. The studies of Pamar et 
al and Leger et al [104] showed that the performance of trained models was influenced in a larger 
extent by the feature selection method than the classification method. Recently, Zhang et al [120] 
studied performance of machine learning classifiers in MRI radiomics in nasopharyngeal cancer. The 
method providing the best results in MRI radiomics was different than the method found by Pamar et 
al in CT radiomics in head and neck cancer [119]. Another study showed that the performance of 
machine learning methods was influenced by the studied endpoint and sample size [121].  
To that end, I have investigated few feature selection and classification methods (including traditional 
statistical methods and machine learning methods) for training local tumor contol models in head and 
neck cancer usning CT or PET radiomics (Chapter 3.6). I have observed that the same method (principal 
component analysis combined with multivariable Cox regression) resulted in the best models for both 
imaging modalities. My results suggest that the imaging modality may not be a critical factor in training 
method selection. In the future, studies correlating radiomic sigature to clinical endpoint should 
investigate several methods for model training. Currently, it is not clear which factor has the biggest 
influence on perofrmnace of those methods: tumor site, sample size, clinical endpoint or image 
modality. 
In conclusion, my work in the field of robustness in radiomics contributed to higher creadibility of 
radiomics models. I have shown that the models trained on retrospective and heterogenous data can 
be reproduced on a prospective cohort with a standardized imaging protocol. In light of muliptle 
workflow steps influencing the output of radiomics software implementation, I recommend, 
addtionally to thorough reporting of the methodology, an online publication of sample dataset (images 
together with computed radiomic siganture) to allow for a comparison between implementiations. 
Finally, I have identified a set of stable CTP radiomic features in respect to perfusion calculation factors. 
Those features should be tested for their prognostic power in a clinically relevant dataset.
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4.4 Radiomics as a non-invasive imaging biomarker 
The potential of radiomics as a non-invasive biomarker in head and neck cancer has been recognized 
[84]. As part of this PhD project, I have trained and validated a CT radiomics based prognostic model 
for local tumor control in head and neck squamous cell carcinoma (HNSCC) (Chapter 3.5). I have 
observed that tumors more heterogeneous in CT density are at higher risk of recurrence. These 
findings are consistent with a previously published CT model for overall survival by Aerts et al. [69]. 
Additionally, the prognostic power of my model (concordance index CI = 0.78) was higher than the 
prognostic power of CT radiomics overall survival model (CI = 0.69). This supports the hypothesis 
presented in Chapter 2 that primary tumor heterogeneity is not sufficient to describe such a complex 
endpoint as overall survival [122]. In my training cohort, the prediction of local tumor control only 
slightly improved when CT radiomics was combined with clinical prognostic factors (tumor stage, 
volume and HPV status). In the validation cohort CT radiomics showed higher prognostic power than 
a combined model. Additionally, the CT radiomics model was also prognostic in the subgroup of HPV 
negative tumors, with a significant split into two risk groups.   
In the next study, I have compared the prognostic power of CT and 18F-FDG PET radiomics in the same 
cohort of HNSCC (Chapter 3.6). I have found, that the round tumors (based on PET signal 
autosegmentation) with a focused region of high FDG uptake surrounded by a rim of low FDG uptake 
were associated with better prognosis. In my early study (Chapter 3.1), I have observed that some of 
the PET measures depended on tumor stage, for example SUV mean. In contrary, my PET radiomics 
model was not tumor stage dependent. In the comparison to CT radiomics, the radiomics analysis of 
tumor metabolism using 18F-FDG PET did not improve the prediction of local tumor control. Both 
models showed similar prognostic power in the validation cohort. Additionally, the combination of CT 
and PET radiomics did not improve the modeling. Nevertheless, the PET radiomics model showed a 
better calibration in the validation set in comparison to the CT model. Some of the misclassified 
patients were affected by CT artifacts in the tumor region, which might have affected the calibration. 
Further, the analysis of 3 months post-treatment 18F-FDG uptake also did not improve the prediction 
of local tumor control (Chapter 3.3) in comparison to pre-treatment imaging. In that study the 
radiomics was calculated in the location of primary tumor (the primary tumor contours were 
transferred to post-treatment imaging using rigid registration). A deformable registration or an 
independent primary tumor bed definition on post-treatment imaging could be considered in the 
future to improve the predictions.  
In the context of correlation between tumor biology and radiological phenotype, to the best of my 
knowledge, my study investigating HPV CT radiomics signature was the first one in HNSCC with an 
independent validation (Chapter 3.5). My results obtained on two independent cohorts of patients, 
supported the hypothesis from exploratory studies [99, 100] that HPV-positive tumors are more 
homogenous in CT density.  
The CT radiomics signature for HPV status was independent from my CT radiomic signature for local 
tumor control, despite the fact that they both point to tumor heterogeneity. The local control signature 
identifies more heterogeneous tumors as a group with worse prognosis. In the same line, the HPV 
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signature indicates that more heterogeneous tumors are HPV negative and this subgroup is known to 
be linked to worse prognosis. However, these signatures comprised different radiomic features and 
the predictions obtained from both models were not correlated. For example, the CT radiomics 
signature for HPV status prediction was valid in the subcohorts of patients with and without local 
tumor control (Chapter 3.5 supplement). 
In the future, our group plans to further validate the obtained results in external datasets. Especially, 
the PET radiomics results may be biased by single institution data considering the influence of scanner 
calibration on the conversion to activity measurements [123]. We also plan to investigate in more 
detail, the unexpected results suggesting that PET radiomics does not improve the predictions of local 
tumor control in comparison to CT radiomics. Our results were obtained based on the analysis of 
autosegmented PET volume. It is well-known that parts of tumors do not exhibit increased metabolism. 
Possibly, PET radiomics performed on the entire GTV will improve local tumor control predictions. 
Metal artifacts are a common concern in head and neck cancer imaging. In my CT radiomics projects, I 
have excluded the CT slices affected by artifacts from the analysis. However, a worse calibration in CT 
radiomics model vs PET radiomics model correlated with the presence of artifacts in some on the 
misclassified cases. Possibly, my artifacts exclusion technique biased the CT radiomics results. Future 
studies investigating the impact of the artifacts on the modeling (percentage of volume affected by 
artifacts or iterative reconstruction algorithms for artifacts reduction) are needed.  
In the context of endpoint selection, I have shown that my CT radiomics local tumor control model is 
more prognostic than overall survival (OS) model [69] and loco-regional control (LRC) model [104]. 
Recently, Leger et al have also reported that CT radiomics has a higher prognostic power for prediction 
of LRC than OS [104]. This observation holds true also for the PET radiomics. I have found a significant 
association between PET radiomics and local tumor control, whereas Vallières et al have not observed 
any association with LRC [105]. In the future, we plan to investigate whether the prediction of more 
complex endpoints can be improved by inclusion of lymph node radiomics to LRC modeling and other 
non-tumor related factors (overall patient status, alcohol consumption, tobacco abuse and age) to OS 
modeling. 
In conclusion, the results from this PhD project support the importance of radiomics in outcome 
modeling in HNSCC and indicate the areas for further research in this field. Finally, we plan to continue 
our efforts to find a link between the radiological tumor phenotype with tumor biology via the 
correlation of radiomic features with histopathology (cell proliferation, microvessl density or hypoxia).
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4.5 Heterogeneity of head and neck cancer and its 
implication on radiotherapy 
 
HNSCC has long been considered as a uniform disease [124]. The detailed histopathology and genetic 
studies changed that assumption. The histopathology studies revealed three main variants of head and 
neck tumors: basaloid, spindle-cell and papillary [124]. HPV positive tumors were found to belong to 
the basaloid subtype. Additionally, the genetic profile and mutation rate was found to be HNSCC 
subtype dependent [125]. HPV negative tumors exhibit twice the mutation rate of HPV positive ones. 
Similarly, laryngeal cancer is characterized by a higher mutation rate than oral cavity, oropharynx or 
hypopharynx cancers. My imaging-based study correlating perfusion and FDG uptake in the HNSCC, 
showed its dependency on tumor subtype (Chapter 3.1). Only the subgroup of HPV positive tumors 
showed positive correlation between mean blood flow and mean SUV. This can explain the 
inconclusive results published by other groups, where mixed tumor subtypes were analyzed [126-128]. 
Additionally, I have observed that tumors linked with worse prognosis (advanced stages T3/T4 and 
HPV negative HNSCC) are characterized with increased blood volume and mean transit time in 
comparison to the surrounding tissue. This could indicate an imaging-based signature of worse 
prognosis however, warrants further investigation and validation. Identification and targeting of tumor 
subtypes is a focus of precision medicine. 
In the era of precision medicine, identification of biomarkers, helping to guide treatment decision, is 
crucial. One of the examples in HNSCC are the results of the DAHANCA 5 study investigating the benefit 
of radiotherapy combined with nimorazole, a hypoxia modifier [129]. Based on the 15 genes signature 
for hypoxia they showed that nimorazole increases the LRC rate only in hypoxic tumors. Moreover, no 
difference in LRC control was observed for HPV positive tumors for two treatment arms irrespective of 
hypoxia level. Another group proposed a gene signature related to tumor intrinsic radiosensitivity  
[130]. Biopsy or blood serum based biomarkers are of high interest as they are a direct measure of 
tumor biology. Medical imaging is another potentially interesting biomarker, although it is mostly only 
a surrogate of tumor biology. However in contrast to biopsy or blood serum based biomarkers, it does 
not show limitations in capturing of the spatial and temporal changes in tumor phenotype [131]. In the 
context of radiation therapy, imaging biomarkers are of high relevance as this treatment option can 
shape the delivered dose according to 3D distribution of radiosensitivity.  
Few clinical trials are currently running, investigating the efficiency of imaging-guided (FDG or FMISO) 
dose redistribution in HNSCC [132, 133]. This year, a first prognostic radiomic signature in HNSCC was 
proposed. This signature was able to identify a group of patients receiving cetuximab with LRC as high 
as in patients receiving cisplatin [134]. However, it requires further validation. I have shown, on the 
example of HNSCC and HPV status, that detection of biological information is feasible even using CT, a 
simple morphologic imaging technique. Additionally, I have observed that a radiomic signature based 
on primary tumor has a higher prognostic power for local tumor control than overall survival. This close 
link to tumor control should be further tested in the context of intrinsic tumor radiosensitivity. In a 
future study, parts of the tumor characterized by higher heterogeneity in CT density could be clustered 
based on a subtumor (regional) radiomics and compared with the location of in field recurrence. If 
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such a correlation could be established, this can lead to a radiomics-based dose painting treatment 
modification. However, radiomics is a top-down approach and therefore extensive validation of risk 
group stratification is required before it will be used in clinical trials either as biomarker for treatment 
intensification or dose redistribution.  
In summary, studies performed as part of this PhD project provided an additional evidence of imaging-
based inter- and intra-tumor heterogeneity. Imaging characteristics, which may be linked with worse 
prognosis were identified: increased blood volume and mean transit time in comparison to 
surrounding tissue, heterogeneity of CT density or aspherical tumors with large subregions of high FDG 
uptake. However, these characteristics should be further validated in external cohort of patients and 
treatment intensification options for worse prognosis groups have to be defined. 
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